paclitaxel has been researched along with Carcinoma, Anaplastic in 599 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 97 (16.19) | 18.2507 |
| 2000's | 236 (39.40) | 29.6817 |
| 2010's | 234 (39.07) | 24.3611 |
| 2020's | 32 (5.34) | 2.80 |
| Authors | Studies |
|---|---|
| Chou, TC; Dong, H; Kakadiya, R; Kapuriya, K; Kapuriya, N; Lee, PC; Lee, TC; Shah, A; Su, TL; Zhang, X | 1 |
| Bai, KK; Chen, FL; Guo, YH; Li, F; Li, WY; Yu, Z | 1 |
| Hikita, K; Honda, M; Iwamoto, H; Kawamoto, B; Morizane, S; Shimizu, R; Takenaka, A; Teraoka, S; Yamaguchi, N; Yumioka, T | 1 |
| Aono, T; Hasegawa, M; Ichikawa, H; Kaneko, K; Maruyama, T; Muto, I; Nakano, M; Naruse, K; Okada, T; Sakata, J; Sato, T; Shimada, Y; Suzuki, S; Takizawa, K; Wakai, T | 1 |
| Asao, T; Dosaka-Akita, H; Fukuhara, T; Harada, T; Honda, R; Kikuchi, E; Kobayashi, K; Kunisaki, M; Morikawa, N; Noro, R; Oizumi, S; Tachihara, M; Takamura, K; Tenma, T; Tsutani, Y; Watanabe, S | 1 |
| Cao, C; Cheng, C; Chu, T; Ding, W; Gao, P; Huang, X; Lin, S; Liu, B; Meng, Y; Peng, T; Wei, J; Wei, Y; Wu, P; Zhi, W | 1 |
| He, ZX; Hu, CB; Li, Q; Nie, L; Song, GB; Tan, J; Wen, F; Xu, CX; Yang, HL; Zhao, X; Zhou, SF; Zhou, ZW; Zi, D | 1 |
| Fushimi, A; Higaki, K; Kono, Y; Ogawara, KI; Yoshizawa, Y | 1 |
| Chen, H; Chu, Y; Guo, Q; Jiang, C; Li, C; Li, X; Liu, P; Sun, T; Wang, Y; Xia, W; Zhang, Y; Zhao, Z | 1 |
| Chen, Y; Gao, J; Jiang, Z; Miao, P; Shang, D; Sun, D | 1 |
| Barber, EL; Chen, S; Hill, EK; Kocherginsky, M; Matei, D; O'Shea, KL; Pineda, MJ; Robertson, SE; Schilder, J; Teoh, D; Zhang, B | 1 |
| Duarte, D; Nunes, M; Ricardo, S; Vale, N | 1 |
| Ishikawa, M; Kataoka, T; Kobayashi, H; Satoh, T; Shibata, T; Takekuma, M; Yaegashi, N | 1 |
| Chang, TC; Huang, SL; Sun, NK | 1 |
| Idei, U; Nagase, S; Ohta, T; Seino, M; Yamatani, H | 1 |
| Cai, J; Cai, Y; Du, Q; Guo, X; Ma, Q; Xu, L; Yuan, Z; Zhong, X | 1 |
| Ernst, A; Kubik, M; Ladekarl, M; Nowicka-Matus, K; Salkus, G; Søkilde Pedersen, I; Sønderkær, M; Takacs-Szabo, Z | 1 |
| Yao, TT; Zhang, B; Zhao, SJ | 1 |
| Balis, FM; Burger, RA; Graul, A; Oved, JH; Reyes, MC; Schwartz, LE | 1 |
| Alcoser, SY; Borgel, S; Bottaro, DP; Chen, AP; Chen, L; Chuaqui, R; Doroshow, JH; Ferry-Galow, KV; Hollingshead, MG; Kinders, RJ; Konaté, MM; Kummar, S; Lawrence, SM; Makhlouf, HR; Miller, SB; Navas, T; Parchment, RE; Rubinstein, L; Srivastava, AK; Subramanian, J; Vilimas, T; Voth, AR; Wilsker, DF | 1 |
| Bohart, R; Goldstein, BH; Micha, JP; Rettenmaier, MA | 1 |
| Jeong, ISD; Moyers, J; Thinn, MM; Thung, I | 1 |
| Hirabayashi, K; Ishida, R; Mizuno, M; Morioka, T; Niikura, N; Okamura, T; Sakaeda, S; Terao, M; Tsuda, B; Watanabe, T; Yokoyama, K | 1 |
| Chen, WY; Hwang, YC; Ke, FY; Kuo, KT; Lin, MC; Wu, HC | 1 |
| Chen, ZP; Jiang, J; Ni, C; Qian, XL; Zhang, M; Zhang, YQ; Zhu, HP; Zuo, Y | 1 |
| Adawi, R; Gopas, J; Khamaisi, H; Koren Carmi, Y; Mahajna, J; Mahmoud, H | 1 |
| Dobleman, T; Hu, S; Liu, J; Xiao, GG; Xiao, KC; Yang, Q | 1 |
| Furuse, J; Ikeda, M; Imaoka, H; Inoue, H; Kawamoto, Y; Kobayashi, S; Maehara, K; Morizane, C; Nagano, H; Okamura, K; Ozaka, M; Sakaguchi, C; Shioji, K; Shirakawa, H; Suzuki, R; Terashima, T; Tsuji, K; Ueno, M; Umemoto, K | 1 |
| Baltezor, M; Campbell, S; diZerega, G; Dorman, P; Iacobucci, M; Marin, A; Maulhardt, H; Verco, J; Verco, S; Wendt, A; Williams, E | 1 |
| Kim, JH; Lee, JH; Lee, KH | 1 |
| Bouvet, M; Han, Q; Higuchi, T; Hoffman, RM; Hozumi, C; Kawaguchi, K; Murata, T; Nishino, H; Sugisawa, N; Tashiro, Y; Unno, M; Yamamoto, J | 1 |
| Elit, L; Ethier, JL; Hirte, H; May, T; Petz, L; Poon, R; Speakman, J; Yao, X | 1 |
| Abednezhad, A; Arasteh, J; Esfandiari, B; Esrafili, A; Faraji, N; Naghizadeh, M | 1 |
| Wang, W; Xu, C; Yu, W; Zhou, N | 1 |
| Hao, S; Wang, Q; Zhang, W | 1 |
| Hu, X; Jing, X; Li, Y; Liu, S; Pei, Q; Xie, Z | 1 |
| Duran, GE; Francisco, EB; Moisan, F; Sikic, BI; Wang, YC | 1 |
| Fong, KW; Hussain, A; Ong, WS; Sommat, K; Soong, YL; Tan, T; Wee, J | 1 |
| Abitbol, J; Amajoud, Z; Eisenberg, N; Fatnassi, A; Gotlieb, WH; Kessous, R; Kogan, L; Laskov, I; Lau, S; Octeau, D; Salvador, S; Yasmeen, A | 1 |
| Fernandes Junior, HJ; Graziani, SR; Kalil Filho, R; Maranhão, RC; Morikawa, AT; Van Eyll, BM; Vital, CG | 1 |
| Chang, TC; Chao, CC; Huang, SL; Sun, NK | 1 |
| Huang, CZ; Jiang, JH; Liu, YX; Ma, F; Peng, YM; Wang, QD; Wang, YF; Zhang, Y | 1 |
| Fujii, K; Ishizuka, S; Saeki, S; Sakata, S; Sasaki, J; Sato, R | 1 |
| Barrios, P; Cascales-Campos, P; Esteve-Pérez, N; Morales-Soriano, R; Segura-Sampedro, JJ | 1 |
| Choi, YS; Jo, DY; Kim, JM; Ko, YB; Lee, HJ; Ryu, H; Song, IC; Yun, HJ | 1 |
| Fuksiewicz, M; Gmyrek, L; Jonska-Gmyrek, J; Kotowicz, B; Kowalska, M; Kucharz, J; Michalski, W; Poniatowska, G; Wiechno, P; Zolciak-Siwinska, A | 1 |
| Bae, WK; Cherukula, K; Lee, JH; Park, IK | 1 |
| Hamamoto, S; Kageyama, K; Miki, Y; Murai, K; Okuma, T; Ueki, A | 1 |
| Xia, X; Zhou, X | 1 |
| Fu, T; Gao, J; Shao, Z; Yan, M; Yan, Y; Zhang, L | 1 |
| Kruitwagen, RF; Lalisang, RI; Sonke, GS; Timmermans, M; Van de Vijver, KK; van der Aa, MA; Witteveen, PO | 1 |
| Bongiorno, C; Dahm, P; Gartlehner, G; Hwang, EC; Jung, JH; Kahlmeyer, A; Kunath, F; Narayan, V; Patel, N; Risk, MC; Skoetz, N | 1 |
| Aoki, R; Asai, H; Kamei, Y; Komatsu, S; Kusakabe, E; Mizuno, Y; Murakami, A; Nishiyama, K; Sugimori, W; Taguchi, K; Takada, Y; Yamasawa, H; Yamashita, M | 1 |
| Fan, J; Fan, Y; He, X; Li, L; Mu, J; Ren, G; Sun, X; Tao, Q; Xiang, Q; Xiang, T; Yang, Y; Zhang, Y; Zhou, D | 1 |
| Carlesimo, M; Caro, G; Cortesi, E; D'Arino, A; Fortuna, CM; Grifalchi, F; Pigliacelli, F; Rossi, A; Zancla, S | 1 |
| Gong, Y; Hao, S; Jiang, YZ; Jin, X; Ren, YX; Shao, ZM; Ye, FG | 1 |
| Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E | 1 |
| Chen, IC; Lu, YS; Yang, MH | 1 |
| Armstrong, DK; Bender, DP; Bookman, MA; Burger, RA; Copeland, LJ; Friedlander, ML; Geller, MA; Guntupalli, SR; Hamilton, CA; Java, JJ; Lee, RB; Markman, M; Method, MW; Muggia, FM; Mutch, DG; Rose, PG; Salani, R; Secord, AA; Tewari, KS; Van Le, L; Wenham, RM | 1 |
| Li, Q; Liang, N; Sun, S; Yan, C; Yan, P | 1 |
| Hara, M; Ishida, T; Miki, Y; Sasano, H; Sato, A; Suzuki, T; Takagi, K; Yoshimura, A | 1 |
| Cheng, X; Cong, C; Gao, D; He, Y; Li, A; Li, X; Yang, M; Zhao, S; Zhu, R | 1 |
| Aoki, D; Iwamori, M; Kiguchi, K; Mikami, M; Tanaka, K | 1 |
| Ishibashi, T; Ishikawa, M; Ishikawa, N; Kurioka, H; Kyo, S; Minamoto, T; Nakamura, K; Nakayama, K; Nakayama, S; Ono, R; Onuma, H; Otsuki, Y; Razia, S; Yamashita, H | 1 |
| Ata, O; Celik, C; Dogan, NU; Yavas, C; Yavas, G; Yılmaz, SA | 1 |
| Shao, Z; Wen, Q; Yang, Z | 1 |
| Chen, Y; Li, X; Lu, W; Lu, Y; Xie, X | 1 |
| Aitini, E; Bighin, C; Bisagni, G; Clavarezza, M; De Placido, S; Del Mastro, L; Durando, A; Galli, A; Garrone, O; Levaggi, A; Restuccia, E; Saracchini, S; Scalamogna, R; Turazza, M | 1 |
| Guntinas-Lichius, O; Hartmann, M; Himmel, M | 1 |
| Abaid, LN; Brown, JV; Goldstein, BH; Lopez, KL; Mendivil, AA; Micha, JP; Rettenmaier, MA | 1 |
| Alva, A; Daignault-Newton, S; Grivas, PD; Hafez, K; Hollenbeck, B; Hussain, M; Lee, CT; Montgomery, JS; Montie, JE; Smith, DC; Weizer, A; Wood, D | 1 |
| Bellmunt, J; Galsky, MD; Sonpavde, G | 1 |
| Canil, CM; Eisen, A; Elser, C; Ko, YJ; Mukherjee, SD; Reaume, MN; Sridhar, SS; Winquist, E; Zhang, L | 1 |
| Agustoni, F; Celio, L; Damian, S; De Benedictis, E; De Braud, F; Mariani, P; Ricchini, F | 1 |
| Payton, S | 1 |
| Hashimoto, Y; Itoh, A; Kameda, Y; Kamoshida, S; Kato, H; Nishino, S; Ogane, N; Yasuda, M; Yokose, T | 1 |
| Cervantes, GM; Faoro, L; Ferguson, BD; Ferguson, MK; Gill, PS; Hasina, R; Hseu, RD; Husain, AN; Iafrate, AJ; Kanteti, R; Karrison, T; Krasnoperov, V; Liu, R; Rolle, CE; Salgia, R; Tan, YH; Tretiakova, MS; Vokes, EE | 1 |
| Chan, AT; Cheng, SH; Cheung, CS; Ho, K; Hui, CW; Hui, EP; Lau, CP; Lui, VW; Ma, BB; Ng, MH; Tsang, CM; Tsao, SW; Wong, CH | 1 |
| He, MF; Li, JS; Qu, JW; Wang, JH; Wang, NN; Wu, LN; Zhao, LJ; Zhao, WZ; Zhao, YB | 1 |
| Fujisawa, M; Inoue, T; Miyake, H; Miyazaki, A; Tanaka, H; Terakawa, T; Yokoyama, N | 1 |
| Cantillo, E; Robinson, W | 1 |
| Atxner, J; Buchwald, D; Happe, A; Kröz, M; Matthes, H; Popp, S; Schad, F | 1 |
| Enomoto, T; Habiro, T; Hatate, K; Hayashi, K; Oshida, S; Sengoku, N; Watanabe, M | 1 |
| Goto, Y; Kato, H; Matano, Y; Nishino, A; Tsukayama, S; Yoshimitsu, M | 1 |
| Al Mutairi, NJ; Le, T | 1 |
| Chen, XG; He, YX; Li, R; Wang, XY; Yang, WY; Yang, X; Zhang, Q | 1 |
| Hulshoff, JB; Plukker, JT; Smit, JK; van der Jagt, EJ | 1 |
| Bergman, JJ; Geijsen, D; Haj Mohammad, N; Hulshof, MC; van Berge Henegouwen, MI; van Laarhoven, HW; Wilmink, JW | 1 |
| Barni, S; Coinu, A; Lorusso, D; Petrelli, F; Raspagliesi, F | 1 |
| Hu, X; Jia, Z; Liu, G; Lu, Y; Lv, F; Qiu, L; Shao, Z; Sun, S; Tang, L; Wang, B; Wang, L; Wang, Z; Zhang, J; Zhang, Q; Zheng, C | 1 |
| Bellmunt, J; Chang, SL; Choueiri, TK; Fay, AP; Leow, JJ; Martin-Doyle, W | 1 |
| Au-Yeung, G; Bressel, M; DeFazio, A; Fereday, S; Mileshkin, L; Webb, PM | 1 |
| Anwar, MF; Asif, M; Beg, MN; Garg, V; Gaur, S; Kardam, H; Suri, S; Yadav, D | 1 |
| Cheewakriangkrai, C; Khunamornpong, S; Kietpeerakool, C; Phongsaranantakul, S; Sribanditmongkol, N; Srisomboon, J | 1 |
| Chen, L; Huang, MJ; Lu, Y; Song, LL; Wang, YS; Xiong, WJ; Xue, JX; Zhang, XX | 1 |
| Carlson, DM; Horai, T; Horiike, A; Horinouchi, H; Kaneda, H; McKee, MD; Nakagawa, K; Nishio, M; Nokihara, H; Ohyanagi, F; Okabe, T; Tamura, T; Terashima, M; Xiong, H; Yamamoto, N | 1 |
| Hamburger, T; Nechushtan, H; Peretz, T; Salmon, AY; Stainberg, H; Vainer, G | 1 |
| Ercoli, A; Fagotti, A; Margariti, PA; Pedone Anchora, L; Petrillo, M; Salutari, V; Scambia, G; Tortorella, L; Zannoni, GF | 1 |
| Fujita, S; Hata, A; Katakami, N; Takayama, K | 1 |
| Meng, H; Xu, Y | 1 |
| Li, H; Yin, D; Zhang, J | 1 |
| Fujiwara, K; Hanaoka, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T | 1 |
| Isohashi, F; Kawano, M; Kimura, T; Kuroda, H; Mabuchi, S; Sasano, T | 1 |
| Chen, X; Mou, J; Pan, X; Peng, G; Zou, Z | 1 |
| Li, G; Liu, Y; Qiu, Y; Ren, S; Su, Z; Tan, P; Tian, Y; Wang, Y; Zhang, X | 1 |
| Liao, Y; Lin, X; Liu, S; Su, L; Xie, J; Zou, H | 1 |
| Cao, K; Cao, P; Han, S; He, D; Li, W; Li, Z; Peng, X; Tan, G; Yu, F; Yu, J; Zhou, J | 1 |
| Limtrakul, P; Naiki, T; Pitchakarn, P; Punfa, W; Suzuki, S; Takahashi, S; Yodkeeree, S | 1 |
| Ansaloni, L; Ballerini, A; Bertoli, P; Busci, LM; Cambria, F; Ceresoli, M; Coccolini, F; D'Incalci, M; Frigerio, L; Grosso, G; Lotti, M; Morosi, L; Pisano, M; Rossetti, D; Zucchetti, M | 1 |
| Aquino, JB; Malvicini, M; Mazzolini, G | 1 |
| Cao, Y; Gao, J; Huang, J; Liu, M; Sun, L; Tang, M; Wang, X; Weng, X; Yang, L; Yi, W; Zeng, W; Zhou, M | 1 |
| Allouache, D; Büschenfelde, CM; Daugaard, G; Fizazi, KS; Greco, FA; Hainsworth, JD; Hübner, G; Knoblauch, P; Lesimple, T; Penel, N; Stahl, MJ | 1 |
| Avgoustakis, K; Bikiaris, D; Karavelidis, V | 1 |
| Huang, HQ; Landrum, LM; Leitao, MM; Long, HJ; Method, M; Michael, H; Monk, BJ; Oaknin, A; Penson, RT; Ramondetta, LM; Reid, TJ; Stockman, S; Tewari, KS; Wenzel, LB | 1 |
| Cao, K; Cao, P; Han, S; He, D; Li, J; Li, W; Li, Z; Peng, X; Tan, G; Yu, F; Yu, J; Zhou, J | 1 |
| Debeb, BG; Larson, R; Li, L; Smith, DL; Woodward, WA; Xu, W | 1 |
| Ang, MK; Cheah, SL; Fong, KW; Lim, WT; Ng, QS; Ong, WS; Quah, D; Soo, KC; Soong, YL; Tan, D; Tan, SH; Tan, T; Wee, J; Yip, C | 1 |
| Ding, N; Feng, D; Liu, Q; Sun, LQ; Tan, G; Wang, X; Xie, B; Yang, X; Zhang, J; Zhang, L; Zhou, Z | 1 |
| Hou, C; Tan, T; Yang, N; Zhu, L | 1 |
| Hidaka, T; Ishiguro, Y; Kameda, T; Kamiunten, A; Kawabata, T; Kitanaka, A; Kubuki, Y; Miyaushiro, S; Sekine, M; Shide, K; Shimoda, K; Umekita, Y | 1 |
| Fukushima, T; Hanamura, T; Ito, K; Koizumi, T; Sasaki, S; Uehara, T | 1 |
| Agoston, AT; Agoston, ES; Brugge, JS; Buchwald, P; Chen, K; Cohick, E; Crum, CP; Foster, R; Gao, S; Hale, KS; Harrell, JC; Ince, TA; Jones, MA; Kozhekbaeva, Z; Krohn, M; Liu, W; Merritt, MA; Mills, GB; Rueda, BR; Selfors, LM; Sergent, P; Sousa, AD; Wang, B; Witt, A; Yong, M | 1 |
| Cheng, X; Dong, R; Du, Y; Huang, L; Wang, B; Xu, Z; Yang, L; Yu, P; Zhou, Y | 1 |
| Blundell, C; Choi, Y; Huh, D; Hyun, E; Kim, HC; Lee, E; Lee, SH; Moon, A; Moon, WK; Seo, J | 1 |
| Brachmann, C; Carleton, M; Chen, N; Chopra, R; Dey, J; Hou, S; Kerwin, WS; Klinghoffer, RA; Li, Y; Liu, X; Palmisano, M; Pierce, DW; Zhou, S | 1 |
| Franciosi, AI; Guérios, SD; Pezzini, PC; Silva, DM | 1 |
| Liu, C; Ran, X; Xiao, L; Yang, J; Zhang, K; Zhou, P | 1 |
| Albers, P; Bellmunt, J; Buonerba, C; Choueiri, TK; Di Lorenzo, G; Kitamura, H; Kume, H; Lee, JL; Matsumoto, K; Mullane, S; Necchi, A; Niegisch, G; Pond, GR; Rozzi, A; Sonpavde, G | 1 |
| Chang, TC; Chao, CC; Huang, SL; Lu, HP; Sun, NK | 1 |
| Burger, RA; Cohn, DE; Duska, LR; Java, JJ | 1 |
| Ajgal, Z; Alexandre, J; Boudou-Rouquette, P; Cessot, A; Chapuis, N; Emile, G; Fontenay, M; Goldwasser, F; Huillard, O; Tigaud, JM | 1 |
| Lan, XW; Mao, YP; OuYang, PY; Su, Z; Tang, J; Xie, FY | 1 |
| Baba, T; Kato, T; Oda, T; Ogura, T; Okudela, K; Sekine, A | 1 |
| Anders, CK; Barry, WT; Berry, DA; Carey, LA; Cheang, MC; Cirrincione, CT; Harris, LN; Henry, NL; Hoadley, KA; Hudis, CA; Iglesia, M; Krop, IE; Ollila, DW; Perou, CM; Pitcher, BN; Singh, B; Weckstein, DJ; Winer, EP | 1 |
| Bidziński, M; Bjørge, L; Colombo, N; de Gregorio, N; Del Campo, JM; Denison, U; du Bois, A; Harter, P; Heubner, M; Hilpert, F; Kristensen, G; Lortholary, A; Malander, S; Meier, W; Merger, M; Minarik, T; Mirza, MR; Nicoletto, MO; Ottevanger, P; Pfisterer, J; Pignata, S; Ray-Coquard, I; Reuss, A; Sailer, MO; Scambia, G; Sevin, E; Vergote, I | 1 |
| Arjona-Sánchez, Á; Briceño, FJ; Casado-Adam, Á; Medina-Fernández, FJ; Muñoz-Casares, FC; Muñoz-Villanueva, MC; Ortega-Salas, R; Rubio, MJ; Rufián-Peña, S; Sánchez-Hidalgo, JM | 1 |
| Cabanillas, ME; Habra, MA | 1 |
| Li, W; Peng, X; Qin, J; Song, Y; Tan, G; Xiang, H; You, Y; Zhang, X | 1 |
| Emoto, S; Hata, K; Ishigami, H; Ishihara, S; Kawai, K; Kazama, S; Kitayama, J; Kiyomatsu, T; Nishikawa, T; Nozawa, H; Sunami, E; Tanaka, J; Tanaka, T; Watanabe, T; Yamaguchi, H | 1 |
| Chekerov, R; Ismaeel, F; Richter, R; Roots, I; Sehouli, J; Siepmann, T; Woopen, H | 1 |
| Colby, AH; Colson, YL; Grinstaff, MW; Herrera, VL; Moran, AM; O'Brien, MJ; Ruiz-Opazo, N; Tan, GA | 1 |
| Li, T | 1 |
| Fukushima, H; Kawabata, K; Mitani, H; Nakano, K; Sasaki, T; Sato, Y; Shimbashi, W; Takahashi, S; Yonekawa, H | 1 |
| Li, G; Liu, C; Liu, Y; Qiu, Y; Ren, S; Su, Z; Tian, Y | 1 |
| Akkar, OB; Karadayi, K; Karakus, S; Kurt, A; Ugurlu, GP; Yanik, A; Yildiz, C | 1 |
| Cosio, S; Fanucchi, A; Gadducci, A; Lanfredini, N; Menichetti, A; Notarnicola, M | 1 |
| Cheng, Y; Li, N; Liang, JY; Liu, R; Qiu, YY; Wang, XZ; Wen, HM; Wu, H; Yang, XL | 1 |
| Chen, S; Chen, X; Liao, Y; Lin, X; Long, D; Shen, F; Yu, T; Zhang, L | 1 |
| Hegde, HV; Hoti, SL; Karthikeyan, S; Nazeer, Y | 1 |
| Jiang, YX; Li, YH; Liang, Y; Luo, HY; Wang, DS; Wang, FH; Wang, Y; Wang, ZQ | 1 |
| Huang, Y; Liang, W; Wu, X; Yang, Y; Zhang, L; Zhang, Y; Zhao, H; Zhao, L; Zhao, Y | 1 |
| Fujiwara, Y; Hashimoto, J; Hirakawa, A; Kodaira, M; Koizumi, F; Komori, O; Nakatochi, M; Okuma, HS; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K; Yunokawa, M | 1 |
| Chang, WC; Chu, YY; Hour, TC; Li, CF; Wang, JM; Wang, WJ; Wang, YH; Yen, CJ | 1 |
| Gupta, S; Kumar, L | 1 |
| Cai, T; Li, G; Liu, C; Liu, Y; Qiu, Y; Ren, S; She, L; Su, Z; Tian, Y; Wang, Y; Wei, M; Zhang, X | 1 |
| Barillot, I; Charra Brunaud, C; Haie-Méder, C; Kerr, C; Peignaux, K; Thomas, L | 1 |
| Hou, J; Hu, Y; Li, F; Lu, Q; Wang, H; Wang, L; Xiang, W; Yu, X; Zeng, W; Zhang, Z | 1 |
| Alvarez, MJ; Ambesi-Impiombato, A; Andrews, SJ; Califano, A; Dela Cruz, FS; Diolaiti, D; Forouhar, F; Glade Bender, JL; Kung, AL; Mansukhani, MM; Marks, LJ; Mitchell, CM; Modzelewski, B; Nagy, PL; Rainey, AR; Turk, AT; Yamashiro, DJ | 1 |
| Chan, DY; Chee, CE; Nga, ME; Phua, JN; Shabbir, A; So, JB; Soh, TI; Syn, NL; Yap, R; Yong, WP | 1 |
| Aghajanian, C; Bell-McGuinn, KM; Brady, WE; Carter, JS; Cohn, DE; Di Silvestro, PA; Dizon, DS; Duan, W; Fracasso, PM; Jelovac, D; Lankes, HA; Mannel, RS; Mutch, DG; Resnick, KE; Salani, R; Thaker, PH | 1 |
| Amemiya, K; Hirotsu, Y; Inoue, M; Mochizuki, H; Nakada, H; Nakagomi, H; Omata, M; Oyama, T | 1 |
| Ao, W; Bateman, NW; Blanton, BE; Conrads, KA; Conrads, TP; Darcy, KM; Hamilton, CA; Hood, BL; Litzi, T; Maxwell, GL; McGuire, WP; Oliver, KE; Paz, K; Sidransky, D; Teng, PN; Wang, G | 1 |
| Duan, Y; Fan, X; Gong, Z; Gulina, K; Hou, Y; Jiang, Z; Li, J; Li, X; Li, Z; Liu, Y; Peng, Y; Sun, L; Tan, G; Xie, B; Yin, L; Yu, X; Yuan, B; Zhu, Q | 1 |
| Chung, HH; Kang, SB; Kim, HS; Kim, JW; Park, NH; Song, YS | 2 |
| Beppu, T; Enomoto, M; Katsuda, K; Murayama, M; Nakao, M; Nosaka, S | 1 |
| Aragon-Ching, JB; Dahut, WL; Desai, N; Figg, WD; Gardner, ER; Hawkins, MJ; Jones, J; Scripture, CD; Sparreboom, A | 1 |
| Long, YM; Rong, J; Xie, WR; Ye, S | 1 |
| Radisky, DC | 1 |
| Kovzun, OI; Popadiuk, ID; Pushkarev, VM; Pushkarev, VV; Saenko, VA; Starenki, DV; Tronko, MD; Yamashita, S | 2 |
| Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, G; Catalano, V; Dennetta, D; Fedeli, SL; Giordani, P; Graziano, F; Rossi, D; Ugolini, M | 1 |
| Bamias, A; Dimopoulos, MA; Horti, M; Kastritis, E; Kavantzas, N; Kyriakou, F; Legaki, S; Murray, S; Noni, A; Patsouris, ES; Tamvakis, N | 1 |
| Becker, A; Bolenz, C; Gabriel, U; Herrmann, E; Michel, MS; Steidler, A; Trojan, L; Weiss, C; Wenzel, M | 1 |
| Akeson, M; Brännström, M; Dahllöf, K; Horvath, G; Zetterqvist, BM | 1 |
| Ghaidi, F; Joshi, B; Kojic, LD; Nabi, IR; Nedev, H; Saragovi, HU; Wiseman, SM | 1 |
| Gennatas, K; Gennatas, S; Michalaki, V | 1 |
| Bagnardi, V; Balduzzi, A; Bertolini, F; Cardillo, A; Colleoni, M; Goldhirsch, A; Mancuso, P; Montagna, E; Orlando, L; Scarano, E; Torrisi, R; Veronesi, P; Viale, G | 1 |
| Egoshi, K; Fukasawa, S; Hamano, M; Ichikawa, T; Imamura, Y; Maruoka, M; Miyasaka, K; Nakamura, K; Nihei, N; Sazuka, T; Suyama, T; Ueda, T | 1 |
| Güth, U; Holzgreve, W; Huang, DJ; Kann, SR; Schötzau, A; Wight, E | 1 |
| Agarwala, SS; Bokar, JA; Cooney, MM; Dowlati, A; Flick, SM; Fu, P; Hartman, PH; Lavertu, PN; Mooney, CJ; Nagaiah, G; Ortiz, JD; Remick, SC; Savvides, PS; Wang, D; Wasman, JK | 1 |
| Calvagno, MG; Fresta, M; Pantò, V; Paolino, D; Pignatello, R; Pistară, V; Puglisi, G; Russo, D | 1 |
| Cinçin, A; Değertekin, M; Gemici, G; Oktay, A | 1 |
| Bai, L; Dou, K; Guo, G; Jin, C; Song, W; Wu, H | 1 |
| Kennedy, AM; Nam, KH; Rapoport, NY; Scaife, CL; Shea, JE | 1 |
| Chen, J; Cheng, MJ; Gao, XL; Kang, Y; Liu, JC; Sun, H; Xu, CJ; Zhang, XY; Zheng, YF | 1 |
| Fridrichová, P; Malírová, E; Melichar, B; Tomsová, M | 1 |
| Londhey, VA; Parikh, FS | 1 |
| Ao, Q; Chen, G; Huang, L; Li, F; Lu, Y; Ma, D; Meng, L; Wang, S; Xing, H; Xu, G; Yang, X; Zhang, Q; Zhou, J | 1 |
| Chen, YX; Diao, F; Fu, CC; Li, ZB; Lu, J; Song, LN; Wang, Y; Yang, R | 1 |
| Ozols, RF | 2 |
| Capasso, I; Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; Di Bonito, M; Frasci, G; Iodice, G; Lastoria, S; Montella, M; Oliviero, P; Petrillo, A; Ruffolo, P; Santangelo, M; Siani, C; Vizioli, L | 1 |
| Amant, F; Berteloot, P; Leunen, K; Neven, P; Vandenput, I; Vergote, I | 1 |
| Czystowska, M; Elishaev, E; Mandapathil, M; Nowak-Markwitz, E; Spaczynski, M; Szajnik, M; Szczepanski, MJ; Whiteside, TL | 1 |
| Bai, YX; Li, HH; Pan, CE; Quan, F; Yao, XB; Yu, L; Zhang, SQ | 1 |
| Arbushites, M; Di Leo, A; Finn, RS; Gagnon, R; Koehler, M; Press, MF | 1 |
| Chen, J; Chen, S; Duan, L; Kong, L; Luo, J; Qiu, X; Wang, R | 1 |
| Amant, F; Berteloot, P; Cadron, I; Legius, E; Leunen, K; Neven, P; Van Gorp, T; Vergote, I | 1 |
| Amant, F; Bauknecht, T; Darstein, C; Kania, M; Michel, AL; Musib, L; Oskay-Oezcelik, G; Sehouli, J; Vergote, I | 1 |
| Greco, FA; Hainsworth, JD; Lane, CM; Murphy, PB; Naot, Y; Spigel, DR; Thompson, DS; Waterhouse, DM | 1 |
| Iwakawa, J; Kawamata, Y; Kumamoto, T; Suetsugu, T; Tanoue, A | 1 |
| Li, HZ; Li, JF; Liu, WW; Lu, SM; Wang, HB; Xu, W; Yu, L | 1 |
| Hatake, K; Ishikawa, Y; Kodaira, M; Mishima, Y; Saotome, T; Takahashi, S; Takeuchi, K; Terui, Y; Ueda, K; Yamada, S; Yamamoto, N; Yokoyama, M | 1 |
| Fukushima, M; Higashiyama, T; Hirokawa, M; Ito, Y; Matsuzuka, F; Miya, A; Miyauchi, A; Uruno, T | 1 |
| Kolivas, ED; Smitherman, TA | 1 |
| Li, W; Peng, X; Tan, G | 1 |
| Ara, G; Cohen, J; Kohn, EC; LaRochelle, W; Rasool, N; Zhong, H | 1 |
| Baggerly, K; Coutant, C; Kim, YC; Lee, JK; Pusztai, L; Qi, Y; Rouzier, R; Symmans, WF; Theodorescu, D | 1 |
| Ayers, GD; Bauer, JA; Caprioli, RM; Chakravarthy, AB; De Matos Granja-Ingram, N; Formenti, SC; Johnson, KN; Kelley, MC; Mayer, IA; Means-Powell, JA; Meszoely, IM; Mi, D; Olivares, MG; Pietenpol, JA; Rosenbluth, JM; Sanders, ME; Schneider, RJ; Seeley, EH; Tsai, CJ | 1 |
| Hirai, T; Ichikawa, Y; Kishikawa, H; Kobayashi, Y; Nishimura, K; Soda, T; Yamanaka, K | 1 |
| Beyer, J; Robinson, WR | 1 |
| Arslan, C; Kilickap, S | 1 |
| Cui, X; Giuliano, A; Kuiatse, I; Lee, AV; Pan, J; Wang, J | 1 |
| Amaral, N; de Oliveira, CF; Domingues, AP; Durão, M; Frutuoso, C; Mota, F | 1 |
| Hikichi, T; Ikeda, T; Imamura, H; Irisawa, A; Obara, K; Ohira, H; Sato, A; Sato, M; Shibukawa, G; Suzuki, R; Takagi, T; Takahashi, Y; Terashima, M; Wakatsuki, T | 1 |
| Kostova, I; Stancheva, T; Zaprjanova, P | 1 |
| Brandwein-Gensler, M; Garg, MK; Haigentz, M; Levine, D; Shifteh, K; Smith, RV; Staffenberg, DA; Tlemcani, K | 1 |
| Ambrosio, MR; Crispino, S; Liberatore, C; Mastrogiulio, MG; Mourmouras, V; Onorati, M; Rocca, BJ; Santopietro, R | 1 |
| Armstrong, DK; Cella, D; Gibbons, HE; Gil, KM; Huang, HQ; Monk, BJ; Rose, PG; von Gruenigen, VE; Wenzel, L | 1 |
| Ito, S; Kawai, H; Matsuo, K; Muro, K; Sawaki, A; Shibata, T; Shitara, K; Tajika, M; Takahari, D; Ura, T; Yokota, T | 1 |
| Burstein, HJ; Dhakil, S; Fabian, C; Kozloff, M; Mayer, EL; Parmar, H; Patel, T; Qamar, R; Samant, M; Sundaram, S; Volterra, F | 1 |
| Abaid, LN; Brown, JV; Goldstein, BH; Lopez, KL; Markman, M; Micha, JP; Rettenmaier, MA | 1 |
| Fujimoto, T; Fukuda, J; Konishi, Y; Sato, H; Sato, N; Tanaka, T | 1 |
| Chao, JI; Chen, C; Cheng, CL; Chiu, YC; Liu, KK; Lo, YS; Wang, CC; Zheng, WW | 1 |
| Ferrandina, G; Lorusso, D; Mainenti, S; Scambia, G | 1 |
| Kawana, K; Nakagawa, K; Nakagawa, S; Oda, K; Okuma, K; Yamashita, H | 1 |
| Han, TS; Hur, K; Kim, WH; Kwak, MK; Lee, HJ; Song, SC; Yanagihara, K; Yang, HK; Yu, J | 1 |
| Aoki, D; Hatae, M; Hiura, M; Jobo, T; Katsumata, N; Konishi, I; Nomura, H; Takahashi, F; Watanabe, Y; Yaegashi, N | 1 |
| Choy, E; Duan, Z; Guo, Y; Hornicek, F; Liu, X; Mankin, H; Nemeth, J; O'Brien, C; Susa, M; Zhang, Z | 1 |
| Avall-Lundqvist, E; Burges, A; du Bois, A; Gropp, M; Hardy-Bessard, AC; Harter, P; Herrstedt, J; Huober, J; Jackisch, C; Jelic, S; Joly, F; Kristensen, G; Kurzeder, C; Müller, HH; Pfisterer, J; Pujade-Lauraine, E; Sehouli, J; Staehle, A; Weber, B; Wimberger, P | 1 |
| Brigulová, K; Cervinka, M; Sedláková, I; Tošner, J | 1 |
| Rexer, H | 2 |
| Hammond, PT; Huang, S; Lee, JA; Poon, Z; Prevost, RJ | 1 |
| Adkins, CE; Bohn, KA; Gaasch, JA; Gril, B; Huang, S; Lockman, PR; Mittapalli, RK; Palmieri, D; Roberts, A; Rudraraju, V; Smith, QR; Steeg, PS; Taskar, KS; Thorsheim, HR | 1 |
| Abboud, M; Charafeddine, M; Geara, FB; Khalil, A; Seoud, M; Shamseddine, A | 1 |
| Brotto, L; Casado, A; Cervantes, A; Chen, D; D'Hondt, V; Eisenhauer, EA; Elit, L; Germa, JR; Ghatage, P; Grimshaw, R; Hoskins, P; Katsaros, D; Mendiola, C; Ojeda, B; Oza, A; Poveda, A; Provencher, D; Roy, M; Stuart, G; Sugimoto, A; Tu, D; Vergote, I; Zola, P | 1 |
| Alvarez, PJ; Aranega, A; Burgos, M; Hita, F; Melguizo, C; Ortiz, R; Prados, J; Rama, AR; Ramos, JL; Rodríguez-Serrano, F | 1 |
| Colson, YL; Grinstaff, MW; Griset, AP; Liu, R; Padera, RF; Schulz, MD; Southard, EB; Wade, JE; Zubris, KA | 1 |
| Barriuso, J; de Santiago, J; Hardisson, D; Inglada-Pérez, L; Leandro-García, LJ; Leskelä, S; Martínez-Delgado, B; Mendiola, M; Muñoz, I; Redondo, A; Robledo, M; Rodríguez-Antona, C | 1 |
| Hudis, CA; Morris, PG | 1 |
| Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK | 1 |
| Akatsu, T; Amemiya, T; Fukushima, H; Hasegawa, H; Ishida, T; Kitagawa, Y; Mitsugi, Y; Murai, S; Shimizu, H; Shoji, T; Yabe, N | 1 |
| Choi, MS; Kim, SH; Kuh, HJ | 1 |
| González Martín, A | 1 |
| Cordeiro, P; D'Andrea, G; Dang, C; Dickler, MN; Fornier, M; Gilewski, T; Grothusen, J; Hawks, L; Hudis, CA; Lake, D; Laragh, JH; McArthur, HL; Melisko, M; Merali, C; Moasser, M; Modi, S; Morrow, M; Moynahan, ME; Norton, L; Nulsen, B; Park, J; Patil, S; Paulson, M; Robson, M; Rugo, H; Sealey, JE; Seidman, A; Sklarin, N; Steingart, R; Sugarman, S; Theodoulou, M; Traina, T; Zhou, Q | 1 |
| Cho, IC; Chung, J; Joung, JY; Kim, EK; Kwon, WA; Lee, KH; Park, S; Park, WS; Seo, HK; Yoon, H | 1 |
| Fujita, K; Ishiguro, Y; Kimura, M; Kondo, N; Matsuda, H; Sakakibara, A; Takahashi, H; Tsukuda, M | 1 |
| Pushkarev, VM; Saenko, VO; Starenki, DV; Tronko, MD; Yamashita, S | 1 |
| Aranda, E; Arjona-Sánchez, Á; Casado, Á; Díaz, R; Díaz-Iglesias, CJ; Muñoz-Casares, FC; Muñoz-Villanueva, MC; Muntané, J; Naranjo, Á; Ortega, R; Rubio, MJ; Rufián, S | 1 |
| Aisner, SC; Johnson, DH; Langer, CJ; Lee, JW; Lemma, GL; Loehrer, PJ; Tester, WJ | 1 |
| Higaki, K; Kimura, T; Kono, Y; Ogawara, K; Yoshizawa, Y | 1 |
| Bertotto, I; Carbonaro, LA; Martincich, L; Montemurro, F; Ponzone, R; Regge, D; Sardanelli, F | 1 |
| Athanassiou, H; Bobos, M; Ciuleanu, E; Ciuleanu, T; Dionysopoulos, D; Eleftheraki, AG; Fountzilas, G; Kalogera-Fountzila, A; Karayannopoulou, G; Markou, K; Misailidou, D; Nikolaou, A; Resiga, L; Samantas, E; Skarlos, D; Zaramboukas, T | 1 |
| Oehler, MK; Ricciardelli, C; Ween, MP | 1 |
| Jin, CS; Liu, Y; Wen, LJ; Yang, JP; Yu, D; Zhong, W | 1 |
| Ando, M; Fujiwara, Y; Hirata, T; Katsumata, N; Ono, M; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K | 1 |
| Brufsky, AM; Copur, MS; Davis, J; Generali, D; Gernhardt, D; Giguere, JK; Gressot, L; Huang, X; Kern, KA; Liau, KF; Minton, SE; Paul, D; Richards, PD; Robert, NJ; Saleh, MN; Smith, JW | 1 |
| Chidiac, T; Cosgriff, T; Harker, G; Keaton, M; Min, M; Mirtsching, B | 1 |
| Hoshino, K; Ide, H; Masuda, T; Satou, A; Tasaka, Y; Uchida, Y; Yasumizu, Y | 1 |
| Furugen, M; Horinouchi, H; Kubota, K; Nokihara, H; Sekine, I; Tamura, T; Tsuta, K; Yamamoto, N | 1 |
| Hu, C; Huang, M; Xie, G | 1 |
| Bechstein, WO; Bodoky, G; Cwiertka, K; Fischbach, W; Fölsch, UR; Haas, SL; Jäger, D; Löhr, JM; Lutz, MP; Osinsky, D; Prausova, J; Schmidt, WE | 1 |
| Abiko, K; Baba, T; Hamanishi, J; Konishi, I; Kosaka, K; Mandai, M; Matsumura, N; Yoshioka, Y | 1 |
| Campos, FC; Cecchini, AL; Cecchini, R; Colado Simão, AN; Herrera, AC; Lemos, LG; Panis, C; Pinge-Filho, P; Victorino, VJ | 1 |
| Kilara, NG; Ramarajapalli, ML; Rao, NA; Subramanyam, M | 1 |
| He, G; Li, H; Li, W; Ma, Y; Tan, G | 1 |
| Hoshiai, H; Kotani, Y; Shiota, M; Tobiume, T; Umemoto, M | 1 |
| Bekku, K; Kanbara, T; Kioshimoto, R; Kobayashi, Y; Kumon, H; Nasu, Y; Saika, T | 1 |
| Egawa-Takata, T; Enomoto, T; Fujita, M; Fujiwara, K; Kamiura, S; Kimura, T; Miyatake, T; Ohta, Y; Ueda, Y; Yoshino, K | 1 |
| Chera, B; Hayes, DN; Rosenberg, L; Rosenman, J; Shockley, W; Weissler, M; Zanation, A | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Matsuzaki, S; Miyoshi, Y; Morimoto, A; Ueda, Y; Yokoyama, T; Yoshino, K | 1 |
| Altevogt, P; Dieckmann, C; Kiefel, H; Korniienko, O; Krüger, A; Moldenhauer, G; Salnikov, A; Schäfer, H; Sebens, S | 1 |
| Ando, N; Asahara, F; Harada, H; Hoshimoto, S; Kawaguchi, S; Matsui, J; Ogawa, S; Sato, M; Takayama, S; Ueno, H | 1 |
| Dai, S; Wang, N; Wang, Y; Yang, X; Yao, Q; Zhang, H | 1 |
| Antsaklis, A; Bamia, C; Bamias, A; Dimopoulos, MA; Haidopoulos, D; Karadimou, A; Rodolakis, A; Soupos, N; Thomakos, N; Vlahos, G; Zagouri, F | 1 |
| Cai, XY; Cai, YC; Cao, Y; Jiang, WQ; Jin, Y; Shi, YX; Tan, YT | 1 |
| Alitalo, K; Anttila, M; Hamalainen, K; Heinonen, S; Koponen, JK; Kosma, VM; Laidinen, S; Laurema, A; Sallinen, H; Sopo, M; Tuppurainen, L; Tuunanen, P; Yla-Herttuala, S | 1 |
| Davidson, B; Elstrand, MB; Oksefjell, H; Sandstad, B; Tropé, CG | 1 |
| Kitada, N; Obata, Y; Ohnishi, N; Shin, Y; Takara, K; Yokoyama, T | 1 |
| Li, H; Tong, X; Wang, J; Yang, F | 1 |
| Gong, C; Luo, F; Qian, Z; Wang, C; Wang, Y; Wu, Q; Zhang, D | 1 |
| Bernasconi, S; Bono, F; Broggini, M; Damia, G; Fruscio, R; Ganzinelli, M; Mangioni, C; Perego, P; Ricci, F; Russo, G; Signorelli, M | 1 |
| Bristow, RE; Chang, SJ; Ryu, HS | 1 |
| Fukushima, M; Higashiyama, T; Hirokawa, M; Ito, Y; Kihara, M; Kobayashi, K; Miya, A; Miyauchi, A; Takamura, Y | 1 |
| Cai, XY; Cai, YC; Cao, Y; Hu, WH; Jiang, WQ; Jin, Y; Shi, YX; Xia, XY; Zhang, WD | 1 |
| Celano, P; Crowley, E; Damstrup, L; Dizon, DS; Finkler, NJ; Glasspool, R; Knoblach, P; Lassen, U; Lichenstein, HS; Penson, RT | 1 |
| Bassi, A; Belotti, D; Castiglioni, V; Cesca, M; Decio, A; Giavazzi, R; Oliva, P; Pesenti, E; Scanziani, E | 1 |
| Guo, Y; Huang, D; Li, G; Li, S; Liu, Y; Qiu, Y; Tan, P; Tian, Y; Xiao, J; Zhang, X | 1 |
| Huang, WL; Li, XY; Lin, SL; Lin, W; Lin, WZ; Lin, YC; Wang, HB | 1 |
| He, G; Li, H; Li, W; Ma, Y; Tan, G; Zhang, X | 1 |
| Aichler, M; Baumgart, A; Blechert, B; Bruchertseifer, F; Essler, M; Feuchtinger, A; Gaertner, FC; Gilbertz, KP; Li, Z; Morgenstern, A; Seidl, C; Senekowitsch-Schmidtke, R; Vallon, M; Walch, AK | 1 |
| Bergmann, TK; Brosen, K; Eckhoff, L; Feddersen, S; Gréen, H; Herrstedt, J; Vach, W | 1 |
| Deng, S; Gong, C; Liu, L; Qian, Z; Wang, Y; Wei, Y; Wu, Q; Xiang, M; Xie, Y; Xiong, D | 1 |
| Drage, MG; Haddad, RI; Lichtman, AH; Shah, SM | 1 |
| Aoki, D; Isonishi, S; Iwamori, M; Kiguchi, K; Mikami, M; Takada, H; Tanaka, K | 1 |
| Baker, TE; Griffin, SJ; Hale, TW; Liu, T; Milla, M; Wang, H | 1 |
| Agosti, V; Amato, R; Colao, E; Costanzo, FS; Cuda, G; D'Antona, L; Di Sanzo, M; Faniello, MC; Iuliano, R; Lang, F; Lavia, P; Malatesta, P; Menniti, M; Mileo, AM; Paggi, MG; Perrotti, N; Scumaci, D; Zingone, A | 1 |
| Catalano, PJ; Colson, YL; Gilmore, D; Grinstaff, MW; Liu, R; Padera, RF; Schulz, M; Zubris, KA | 1 |
| An, X; Chen, C; Li, YH; Liang, Y; Luo, HY; Wang, FH; Wang, ZQ; Zhang, L | 1 |
| Chan, AT; Hui, CW; Hui, EP; Lau, CP; Li, Y; Lui, VW; Ma, BB; Ng, MH; Tsao, SW; Wong, CH | 1 |
| Li, Y; Shen, J; Sun, H; Wang, S; Xu, P; Yin, Q; Yu, H; Zhang, Z | 1 |
| Jiang, C; Jiang, Z; Liu, H; Pu, L; Song, L; Zhang, P; Zhao, S | 1 |
| He, CX; Jin, Y; Lin, BC; Shao, L; Ye, X; Zhang, BB; Zhang, YP | 1 |
| Ajani, JA | 2 |
| Fujimoto, S; Hirano, T; Kaneuchi, M; Negishi, H; Nishiya, M; Okamoto, K; Sakuragi, N; Takeda, M; Todo, Y; Yamamoto, R | 1 |
| Beckett, L; DeVere-White, R; Folkins, AK; Gandour-Edwards, R; Lara, PN; LaSalle, JM; Li, Y; Meyers, FJ | 1 |
| Dreicer, R; Levitt, R; Manola, J; See, W; Vaughn, DJ; Wilding, G | 1 |
| Etiz, E; Kabukcuoglu, S; Ozalp, SS; Tanir, M; Yalcin, OT | 1 |
| Engelholm, SA; Gronlund, B; Hansen, HH; Høgdall, C | 1 |
| Bagaméri, A; Lehoczky, O; Pulay, T | 1 |
| Barsoum, J; Brickelmaier, M; Carmillo, A; Goelz, S; Qin, XQ | 1 |
| Ferrara, N; Hamilton, T; Hofmann, J; Hu, L; Jaffe, RB; Zaloudek, C | 1 |
| Andersson, H; Boman, K; Parö, G; Puistola, U; Ridderheim, M; Rosenberg, P; Sorbe, B | 1 |
| Gutierrez, M; Lhomme, C; Pautier, P | 1 |
| André, T; Culine, S; Epaud, C; Gligorov, J | 1 |
| Friess, T; Osl, F; Scheuer, WV; Schneider, T; Stockinger, H | 1 |
| Chapman, W; Davis, AJ; Hedley, DW; Oza, AM; Tannock, IF | 1 |
| Brady, MF; Schilder, RJ; Shea, T; Spriggs, D | 1 |
| Balachandran, R; Curran, DP; Day, BW; Giuliano, KA; Madiraju, C; Minguez, JM | 1 |
| Begley, CG; Boyd, J; Cook, W; Grant, SL; Kurek, J; O'Flaherty, E | 1 |
| Karaveli, S; Pesterelli, E; Simsek, M; Simsek, T; Trak, B | 1 |
| Beijnen, JH; de Bree, E; Georgoulias, V; Michalakis, J; Romanos, J; Rosing, H; Tsiftsis, DD | 1 |
| Matsumura, K; Naganuma, T; Nakatani, T; Sugimura, K; Uchida, J | 1 |
| Ain, KB; Dziba, JM; Marcinek, R; Robinson, JA; Venkataraman, G | 1 |
| Ando, M; Katsumata, N; Mukai, H; Watanabe, T | 1 |
| Zhou, HB; Zhu, JR | 1 |
| Fields, AL; Runowicz, CD | 1 |
| Bombardelli, E; Cassinelli, G; D'Incalci, M; Frapolli, R; Laccabue, D; Lanzi, C; Morazzoni, P; Pratesi, G; Riva, A; Supino, R; Zucchetti, M; Zunino, F | 1 |
| Allen, M; Bomphray, CC; Gore, ME; Hess, V; Vaughan, MM; Verrill, MW | 1 |
| Benedetti Panici, P; Borsellino, N; Citarrella, P; Di Marco, P; Fallica, G; Gebbia, N; Gebbia, V; Tirrito, ML; Valenza, R; Valerio, MR | 1 |
| Aston, D; Brewster, AE; Crosby, TD; Minett, M; Mukherjee, S | 1 |
| Araki, T; Doi, D; Konishi, H; Ota, Y; Yoneyama, K | 1 |
| Ishihara, A; Nagao, K; Tanaka, H; Toyoda, N; Umekawa, T | 1 |
| Mayer, A; Pete, I; Pulay, T; Szánthó, A; Thurzó, L | 1 |
| Chuang, TC; Kao, MC; Law, SL; Lee, YJ; Li, JW; Lin, YS; Liu, JY; Wang, V | 1 |
| Lehoczky, O; Pulay, T | 2 |
| Lim, JT; Masuda, M; Suzui, M; Weinstein, IB | 1 |
| Bratengeier, K; Flentje, M; Hagen, R; Helms, J; Hoppe, F; Pfreundner, L; Preisler, V; Willner, J | 1 |
| Bottone, MG; Brison, O; Ciomei, M; Gorrini, C; Lazzè, MC; Pellicciari, C; Scovassi, AI; Soldani, C; Tognon, G | 1 |
| De Maria, R; Di Gaudio, F; Di Gesù, G; Di Liberto, D; Florena, A; Patti, M; Ricci-Vitiani, L; Stassi, G; Todaro, M; Zerilli, M | 1 |
| Ernstoff, MS; Fisher, J; Lewis, LD; Tretter, CP; Waugh, MG | 1 |
| Hayman, JA; Ianettonni, M; Orringer, MB; Satoru, H; Urba, SG | 1 |
| Blumenschein, G; Clayman, G; Diaz, EM; Garden, AS; Gillenwater, A; Ginsberg, LE; Glisson, BS; Goepfert, H; Hong, WK; Kies, MS; Lippman, SM; Liu, DD; Morrison, WH; Papadimitrakopoulou, VA; Schommer, D | 1 |
| Boggess, JF; Boruta, DM; Fowler, WC; Gehrig, PA; Van Le, L; Walton, LA | 1 |
| Dilek, TU; Guner, H; Oktem, M | 1 |
| Balachandran, R; Day, BW; Welsh, MJ | 1 |
| Bains, MS; Brenner, B; Gonen, M; Ilson, DH; Kelsen, DP; Minsky, BD; Tong, W | 1 |
| Imazu, H; Matsubara, T; Nakamura, Y; Ochiai, M; Sakai, W; Sakurai, Y; Tonomura, S; Yoshida, I | 1 |
| Engelholm, SA; Gronlund, B; Hansen, HH; Høgdall, C; Høgdall, EV | 1 |
| Brown, AW; Harker, WG; Huh, S; Kabbinavar, F; Miller, L; Rinaldi, D; Vaughn, DJ | 1 |
| du Bois, A; Hilpert, F; Meier, W; Pfisterer, J; Wagner, U | 1 |
| Bhan, V; Hoskin, DW; Mader, JS | 1 |
| Buda, A; Colombo, N; Conte, PF; Floriani, I; Fossati, R; Mangioni, C; Ravaioli, A; Rossi, R; Torri, V | 1 |
| Adams, D; Anderson, E; Chao, NJ; DeCastro, C; Foster, T; Gasparetto, C; Gockerman, JP; Long, GD; McGaughey, D; Moore, JO; Niedzwiecki, D; Rizzieri, DA; Sand, GJ; Toaso, B; Vredenburgh, JJ | 1 |
| Daraï, E; Dormont, D; Madelenat, P; Zylberberg, B | 1 |
| Bikram, M; Furgeson, DY; Janát-Amsbury, MM; Kern, S; Kim, SW; Lee, M; Yockman, JW | 1 |
| Eralp, Y; Lachman, LB; Maughan, MF; Polo, JM; Wang, JP; Wang, X | 1 |
| A'Hern, R; Cole, C; Everard, M; Gibbens, I; Gore, M; Hall, G; Harries, M; Jenkins, A; Kaye, S; Moss, C; Perren, T; Pizzada, O; Shah, R | 1 |
| Broglio, KR; Buzdar, AU; Esteva, FJ; Gonzalez-Angulo, AM; Hortobagyi, GN; Krishnamurthy, S; Pusztai, L; Yamamura, Y | 1 |
| Agnes Pradelli, B; Battaini, A; Capretti, G; Capretti, PG; Lovotti, D; Rosato, S; Simonetti, A; Zeppieri, MC | 1 |
| Sulkes, A | 1 |
| Bentley, RC; Filiaci, VL; Fleming, GF; Gallion, H; Herzog, T; Sorosky, J; Vaccarello, L | 1 |
| Dilek, TU; Guner, H; Oktem, M; Tiras, MB | 1 |
| Dvorák, J; Filip, S; Melichar, B; Odrázka, K; Petera, J; Zoul, Z | 1 |
| Bacon, M; Bezjak, A; Eisenhauer, E; Osoba, D; Piccart, M; Roy, JA; Stuart, G; Tu, D; Zee, B | 1 |
| Asmar, L; Dakhil, S; Friedland, DM; Gregurich, MA; Hollen, C | 1 |
| Cai, SM; Huang, X; Li, ZT; Tang, J; Zang, RY | 1 |
| Atkinson, R; Coleman, R; Gabra, H; Gordon, A; Hay, A; Jayson, GC; Kaye, SB; Parkin, D; Paul, J; Vasey, PA | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hermann, R; Litchy, S; Morrissey, LH; Rodriguez, GI; Shaffer, DW; Yardley, DA | 1 |
| Thigpen, T | 1 |
| González-Martín, AJ | 1 |
| Foo, KF; Leong, SS; Lim, WT; Tan, EH; Tan, SB; Tan, T; Tay, MH; Thng, CH; Toh, CK; Wee, J | 1 |
| Bekele, BN; Doan, D; El-Naggar, AK; Holsinger, FC; Jasser, SA; Kim, S; Mandal, M; McMurphy, AB; Myers, JN; Schiff, BA; Sherman, SI; Yeung, SC; Yigitbasi, OG; Younes, MN; Zhou, G | 1 |
| Haddad, R; Mahadevan, A; Posner, MR; Sullivan, C | 1 |
| Cathomas, R; Gregory, K; Lowndes, S; Rogerson, M | 1 |
| Fang, B; Huang, H; Pan, J; Sun, L; Yeung, SC | 1 |
| Chen, SZ; Jiang, M; Zhen, YS | 1 |
| Bekele, BN; Doan, D; Jasser, SA; Kim, S; Mandal, M; Myers, JN; Schiff, BA; Yigitbasi, OG | 1 |
| Conte, PF; Cosio, S; Gadducci, A; Genazzani, AR | 1 |
| Chin, K; Hatake, K; Inamura, K; Ito, Y; Kobayashi, T; Mishima, Y; Mizunuma, N; Nagasaki, E; Nishimori, H; Shinozaki, E; Takahashi, S; Terui, Y; Yokoyama, M | 1 |
| Iwabuchi, S; Kashiwagi, H; Takahashi, N; Yamazaki, Y; Yanaga, K | 1 |
| Chao, DY; Fu, J; Shi, XY; Tian, HM; Wang, JW; Wu, LY; Zhang, K; Zhang, W | 1 |
| Avril, N; Bader, M; Dose Schwarz, J; Hemminger, G; Jänicke, F; Jenicke, L | 1 |
| Bidart, JM; Duvillard, P; Lacroix, L; Motté, N; Pautier, P; Saulnier, P; Soria, JC | 1 |
| Deutsch, M; Werner, R | 1 |
| Belinson, JL; Michener, CM | 1 |
| Androulakis, N; Christofilakis, C; Georgoulias, V; Kouroussis, C; Latoufis, C; Papakotoulas, P; Polyzos, A; Potamianou, A; Toufexi, H; Xenidis, N | 1 |
| Bewig, B; Keussen, C; Lins, M; Schrader, C; von Freier, A | 1 |
| Alvero, AB; Brown, D; Chen, W; Garg, M; Kelly, G; Mor, G; O'Malley, D; Rutherford, T | 1 |
| Armstrong, DK; Baergen, R; Bundy, B; Burger, RA; Copeland, LJ; Huang, HQ; Lele, S; Walker, JL; Wenzel, L | 1 |
| Albone, EF; Berger, MA; Masters, GR | 1 |
| Aguiar Bujanda, D; Aguiar Morales, J; Bohn Sarmiento, U; Cabrera Suárez, MA; Limeres González, MA; Pavcovich Ruiz, M | 1 |
| Boccardo, F; Boni, L; Bruzzone, M; Centurioni, MG; Cosso, M; Ferrarini, M; Franzone, P; Miglietta, L; Tacchini, L | 1 |
| Bandobashi, K; Kodama, H; Miyoshi, I; Ohtsuki, Y; Saito, T; Taguchi, H | 1 |
| Butler, J; Farrell, FX; Gechtman, Z; Hall, C; LaMontagne, KR; Marshall, DJ; Meshaw, A; Tullai, J | 1 |
| Cooper, DL; Higgins, SA; Kluger, HM; Murren, JR; Noronha, V | 1 |
| Altura, RA; Boyer, MW; Caldas, H; Hammond, S; Jaynes, FO | 1 |
| Alvarez, RD; Barnes, MN; Huh, WK; Kilgore, LC; Leath, CA; Partridge, EE; Rocconi, RP; Straughn, JM | 1 |
| Boellaard, R; Crezee, H; Hoekstra, OS; Hulshof, MC; Omloo, JM; Sloof, GW; ten Kate, FJ; van Lanschot, JJ; Vervenne, WL; Westerterp, M | 1 |
| Altundag, OB; Gungor, T; Mollamahmutoglu, L; Ustunyurt, E | 1 |
| Beck, JF; Belau, A; Gänge, J; Lorenz, G; Ohlinger, R; Pilz, S; Sonnemann, J; Stötzer, C | 1 |
| Bell, J; Brady, MF; Lage, J; Look, KY; Rose, GS; Spirtos, NM; Walker, JL; Young, RC | 1 |
| Gregoire, V; Machiels, JP; Pierard, S; Weynand, B | 1 |
| Altundag, K; Bulut, N; Dizdar, O; Harputluoglu, H | 1 |
| Carrasquillo, JA; Hassan, R; Ho, M; Jang, BS; Le, N; Paik, CH; Pastan, I; Xiang, L; Zhang, Y | 1 |
| Braunstein, GD; Hershman, JM; Koeffler, HP; Luong, QT; O'Kelly, J | 1 |
| Comella, G; Danova, M; Ferraú, F; Lorusso, V; Massidda, B; Nortilli, R; Palmeri, L; Palmeri, S; Porta, C; Vaglica, M | 1 |
| Kajiki, M; Kobayashi, TR; Kuriyama, H; Sugahara, S | 1 |
| Ahmad, SA; Firdaus, I; Howington, JA; James, L; Jazieh, AR; Lowy, AM; Redmond, K; Reed, MF; Rose, P; Roychowdhury, D; Safa, M; Sussman, JJ | 1 |
| Pectasides, D; Pectasides, E | 1 |
| Ino, K; Kajiyama, H; Kikkawa, F; Mizutani, S; Nawa, A; Shibata, K; Terauchi, M; Yamashita, M | 1 |
| Baki, M; Bodoky, G; Cseh, J; Csejtei, A; Csömör, S; Dank, M; Erfán, J; Esik, O; Faluhelyi, Z; Hernádi, Z; Izsó, J; Kammerer, K; Kásler, M; Magyar, T; Mayer, A; Megyery, E; Moskovits, K; Pécsi, L; Pikó, B; Pintér, T; Pulay, T; Ruzsa, A; Szánthó, A; Szántó, I; Szántó, J; Szucs, M; Tálos, Z; Thurzó, L | 1 |
| Alvarez, J; Campaña, O; Lamas, M; Lorenzo, D; Pérez, J; Rodríguez, MJ; Veiras, S | 1 |
| Berta, L; Boccuzzi, G; Bosco, O; Catalano, MG; Costantino, L; Fortunati, N; Frairia, R; Pugliese, M | 1 |
| Asmar, L; Berry, W; Elkordy, M; Khan, M; O'Rourke, M | 1 |
| Berchuck, A; Carney, ME; Clarke-Pearson, DL; Havrilesky, LJ; Rodriguez, GC; Secord, AA; Soper, JT | 1 |
| Cuccuru, G; Favini, E; Scovassi, AI; Supino, R; Zunino, F | 1 |
| Asai, G; Fukuoka, M; Kurata, T; Nakagawa, K; Tamura, K; Uejima, H; Yamamoto, N | 1 |
| Chen, JW; Meng, QG; Tang, Y; Wang, ZR; Xie, D | 1 |
| Aikou, T; Arigami, T; Hokita, S; Ishigami, S; Matsumoto, M; Nakajo, A; Natsugoe, S; Okumura, H; Setoyama, T; Uchikado, Y; Uenosono, Y | 1 |
| Chaplin, D; Pan, J; She, M; Sun, L; Yang, H; Yeung, SC | 1 |
| Chen, A; Ding, F; Liu, Z; Luo, A; Ren, S; Yu, Z; Zhang, L; Zhang, S | 1 |
| Ino, K; Kajiyama, H; Kikkawa, F; Nawa, A; Shibata, K; Terauchi, M; Yamashita, M | 1 |
| Goshima, F; Kasuya, H; Kodera, Y; Nakao, A; Nishiyama, Y; Shimoyama, S; Teshigahara, O | 1 |
| Alberts, DS; Barakat, R; Hess, LM; Ozols, RF; Tian, C | 1 |
| Ando, T; Hirabayashi, N; Kawamura, S; Kobayashi, M; Kojima, H; Kondo, K; Konno, H; Matsuo, K; Miyashita, Y; Morita, S; Musha, N; Nagata, N; Ninomiya, M; Oba, K; Sakamoto, J; Usuki, H | 1 |
| DeMonte, F; El-Naggar, AK; Hanna, EY; Mishra, A | 1 |
| Dong, P; Jiang, AC; Li, L; Wan, Y; Yu, ZW | 1 |
| Boccuzzi, G; Catalano, MG; Fortunati, N; Poli, R; Pugliese, M | 1 |
| Baba, S; Irie, A; Iwamura, M; Matsumoto, K; Okazaki, M; Satoh, T | 1 |
| Alvarez Marcos, CA; de Bock, GH; Gibcus, JH; Hermsen, MA; Kluin, PM; Kok, K; Langendijk, JA; Mastik, MF; Menkema, L; Schuuring, E; Takes, RP; van den Brekel, MW; van der Laan, BF; van der Wal, JE; van Velthuysen, ML | 1 |
| Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N | 1 |
| Balachandran, R; Curran, DP; Day, BW; Fukui, Y; Jung, WH; Madiraju, C; Montgomery, K; Raccor, BS; Shin, Y; Sikorski, RP; Vogt, A | 1 |
| Belani, CP; Gable, PS; LaRocca, RV; Perry, MC; Ramalingam, S; Rinaldi, D; Tester, WJ | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, BS; Kim, TW; Lee, JS; Oh, ST; Ryu, MH; Sohn, HJ; Yook, JH | 1 |
| Barrett, SV; Glasspool, RM; Hay, A; Kaye, SB; Paul, J; Vasey, PA | 1 |
| Economopoulos, T; Fountzilas, G; Gaglia, A; Gouveris, P; Kassanos, D; Koumarianou, A; Panayiotidis, J; Papaxoinis, G; Pectasides, D; Pectasides, E; Psyrri, A; Sykiotis, C; Xiros, N | 1 |
| Allegrini, PR; Brueggen, J; Floersheimer, A; Maira, M; McSheehy, PM; O'Reilly, T; Wartmann, M | 1 |
| Alberts, DS; Alvarez, RD; Bidzinski, M; Bradford, WZ; Clouser, MC; Johnson, G; Kardatzke, DR; Kirn, DH; Loutit, J; Markman, M; Marth, C | 1 |
| Chou, TC; Fong, Y; Gao, SP; Huang, YY; Li, S; Lin, SF; Price, DL; Singh, P; Wong, RJ | 1 |
| Foretová, L; Fridrichová, P; Lukesová, S; Melichar, B; Mergancová, J; Ryska, A; Urminská, H | 1 |
| Adamo, DO; Bicher, A; Christian, M; Davis, P; Kohn, EC; Link, C; Ognibene, FP; Rothenberg, M; Sarosy, G; Steinberg, SM | 1 |
| Holmes, FA | 1 |
| Hatae, M; Maeda, T; Maeda, Y; Nakamura, T; Onishi, Y; Wada, T | 1 |
| Armour, EP; Corry, PM; Lee, YJ; Martinez, AA; Stromberg, JS | 1 |
| Allam, N; Breillout, F; Debal, V; Gourdier, B; Manfait, M; Millot, JM; Morjani, H | 1 |
| Hudes, GR; Smith, CD; Tew, KD; Zhang, X; Zilfou, JT | 1 |
| Bogliun, G; Cavaletti, G; Colombo, N; Marzola, M; Marzorati, L; Tredici, G; Zincone, A | 1 |
| McGuire, WP | 1 |
| Adams, JD; Canetta, R; Christian, MC; Fisherman, JS; Friedman, MA; Hawkins, MJ; Hayn, R; Onetto, N; Trimble, EL; Vena, D | 1 |
| Christen, RD; Howell, SB; Jekunen, AP; Shalinsky, DR | 1 |
| Oriana, S; Orlandi, L; Silvestrini, R; Zaffaroni, N | 1 |
| Bhalla, K; Willingham, MC | 1 |
| Spielmann, M | 1 |
| Hall, EJ; Minarik, L | 1 |
| Steel, GG | 1 |
| Choyke, PL; Cowan, KH; Fisherman, JS; O'Shaughnessy, JA; Pestalozzi, BC; Sotos, GA | 1 |
| Christen, RD; Howell, SB; Jekunen, AP; Jones, JA; Shalinsky, DR; Thiebaut, F | 1 |
| Monden, Y; Prajda, N; Taniki, T; Weber, G | 1 |
| Brady, M; Hoskins, WJ; McGuire, WP; Thigpen, T; Vance, RB | 1 |
| Bissery, MC; Lavelle, F; Vrignaud, P | 1 |
| Chantarawiroj, P; Edwards, CL; Freedman, RS; Gonzalez de Leon, C; Hord, M; Kavanagh, JJ; Kim, EE; Kudelka, AP; Levenback, C; Madden, T; Raber, M; Tresukosol, D; Verschraegen, C; Wallin, B | 1 |
| Averette, HE; Method, MW; Penalver, MA; Rodriguez, M; Serafini, AN; Sevin, BU | 1 |
| Alvarez-Vicent, J; Brandariz, A; Colomer, R; Cortés-Funes, H; Hitt, R; Hornedo, J; Mendiola, C; Sevilla, E | 1 |
| Bernacki, RJ; Ojima, I; Sharma, A; Straubinger, RM | 1 |
| Christian, M; Davis, P; Jacob, J; Kohn, EC; Link, CE; Ognibene, FP; Premkumar, A; Reed, E; Sarosy, GA; Sindelar, WF; Steinberg, SM | 1 |
| Bishop, JF; Linahan, BM; Millward, MJ; Morton, CG; Rischin, D; Toner, GC; Webster, LK; Woollett, AM | 1 |
| Doig, G; Elit, LM; Gafni, A; Levine, MN; Rosen, B; Streiner, DL; Whelan, TJ | 1 |
| Trudeau, ME | 1 |
| Ain, KB; Taylor, KD; Tofiq, S | 1 |
| Hekmat, E | 1 |
| Davidson, NG | 1 |
| Basu, A; Saijo, N; Weixel, K | 1 |
| Bailey, NP; Boddy, AV; Calvert, AH; Lind, MJ; Robson, L; Siddiqui, N; Thomas, HD | 1 |
| Broggini, M; D'Incalci, M; De Feudis, P; Debernardis, D; Parodi, S; Russo, P; Siré, EG; Valenti, M; Vikhanskaya, F | 1 |
| Masanek, U; Stammler, G; Volm, M | 1 |
| Armstrong, D; Carmichael, J; Gordon, A; Malfetano, J; ten Bokkel Huinink, W | 1 |
| Hunter, NR; Milas, L; Milross, CG; Seong, J; Shin, HC | 1 |
| Boyd, JH; Dunleavy, TL; Dunphy, CH; Dunphy, FR; Harrison, BR; Hilton, JG; Kim, HJ; McDonough, EM; Minster, JR; Rodriguez, JJ | 1 |
| Gordon, AN; Matthews, CM; Nemunaitis, J; Stringer, CA; Willis, DL | 1 |
| Delia, D; Di Palma, S; Lavarino, C; Pilotti, S; Zunino, F | 1 |
| Aloe, A; Atlante, G; Calabresi, F; Cognetti, F; De Marco, S; Iacovelli, A; Nardi, M | 1 |
| Khansur, T; Malamud, F; Thigpen, T; Vance, R | 1 |
| Erland, JB; Greco, FA; Hainsworth, JD; Kalman, LA; Schreeder, MT | 1 |
| Bauknecht, T; Bochtler, H; Diergarten, K; du Bois, A; Lück, HJ; Meerpohl, HG; Möbus, V | 1 |
| Collins, JA; Schandi, CA; Vesely, J; Willingham, MC; Young, KK | 1 |
| Fojo, A; Giannakakou, P; Poruchynsky, M; Sackett, DL | 1 |
| Bates, S; Fojo, T; Hose, C; Monks, A; Scala, S; Zhan, Z | 1 |
| Atkinson, EN | 1 |
| Boljesikova, E; Chorvath, B; Chorvath, M; Hunakova, L; Novotny, L; Sedlak, J; Sevcikova, L | 1 |
| Kristensen, G; Tropé, C | 1 |
| Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K | 2 |
| Curé, H; Diéras, V; Guastalla, JP; Jacquin, JP; Leduc, B; Mignot, L; Mousseau, M; Orfeuvre, H; Paraïso, D; Pujade-Lauraine, E; Tubiana-Mathieu, N; Viens, P; Vincent, P; Weber, B | 1 |
| de Swart, C; Engelholm, SA; Hansen, M; Hansen, SW; Hirsch, F; Lund, B; Neijt, JP; Sessa, C; Sørensen, PG; Tuxen, MK; van Houwelingen, HC; Witteveen, PO | 1 |
| Edwards, RP; Hart, LA; Kelley, JL; Kunschner, AJ; Price, FV | 1 |
| Nogaret, JM; Piccart, MJ | 1 |
| Capri, G; Cavina, R; Fulfaro, F; Gianni, L; Grandi, C; Licitra, L; Tarenzi, E | 1 |
| Dimery, I; Garcia, AA; Jeffers, S; Muggia, FM; Parimoo, D; Rogers, M | 1 |
| Greco, FA; Hainsworth, JD | 2 |
| Bachelot, T; Biron, P; Blay, JY; Catimel, G; Chauvin, F; Droz, JP; Guastalla, JP; Merrouche, Y; Ray-Coquard, I | 1 |
| Blumenson, LE; Eltabbakh, GH; Hempling, RE; Piver, MS; Recio, FO | 1 |
| Benjamin, I; Rubin, SC | 1 |
| Birk, CL; Brown, JV; Culkin, K; Dillman, RA; Micha, JP; Rettenmaier, MA | 1 |
| Pronchik, DJ; Sexton, J | 1 |
| Arts, HJ; de Vries, EG; Tinga, DJ; van der Zee, AG; Willemse, PH | 1 |
| Ang, PT; Au, E; Tan, EH | 1 |
| Di Nunno, L; Herrington, JD; Rinehart, JJ | 1 |
| Adachi, KI; Akutsu, M; Kano, Y; Mori, K; Suzuki, K; Tsunoda, S | 1 |
| Cannistra, SA; Lee, S; Niloff, E; Strobel, T; Tai, YT; Weisman, C | 1 |
| Brady, MF; Hanjani, P; Markman, M; Rubin, SC; Spirtos, NM | 1 |
| Ain, KB | 1 |
| Bissery, MC; Fellous, A; Martinez, C; Veitia, R | 1 |
| Akbulut, S; Atahan, IL; Kiratli, H; Ozyar, E; Uzal, D | 1 |
| Bolis, G; Bookman, MA; Fields, SZ; Gordon, A; Krebs, JB; Lissoni, A; Malmström, H | 1 |
| Grinblatt, DL; Malloy, R; Williams, SF; Zimmerman, TM | 1 |
| Baker, TR; Blumenson, LE; Eltabbakh, GH; Hempling, RE; Lele, SB; Marchetti, DL; Piver, MS; Recio, FO | 1 |
| Baker, V; Fletcher, B; Hu, C; Liu, JR; Nunez, G; Page, C | 1 |
| Bergerat, JP; Deplanque, G; Duclos, B; Dufour, P; Eichler, F; Giron, C; Herbrecht, R; Kurtz, JE; Limacher, JM; Maloisel, F; Oberling, F | 1 |
| Benjapibal, M; Edwards, CL; Kavanagh, JJ; Kudelka, AP; Vadhan-Raj, S; Valero, V; Vasuratna, A; Verschraegen, CF | 1 |
| Chikazawa, H; Fujimoto, S | 1 |
| Kerkhofs, L; Kok, TC; Siersema, PD; Splinter, TA; Tilanus, HW; van der Gaast, A | 1 |
| Carbone, R; Chen, Z; Fadiel, A; Jia, JF; Naftolin, F; Sakamoto, H | 1 |
| Mays, D; Pietenpol, JA; Stewart, ZA | 1 |
| Beijnen, JH; de Wit, R; Lieverst, J; Nannan Panday, VR; Rosing, H; Schellens, JH; Schornagel, JH; Schot, M; ten Bokkel Huinink, WW | 1 |
| Hamaguchi, Y; Hasegawa, S; Hisatomi, H; Ichikawa, Y; Ishikawa, T; Kamiyama, M; Momiyama, N; Narita, T; Shimada, H | 1 |
| Chi, CW; Lin, HL; Liu, TY; Wu, CW | 1 |
| Engblom, P; Grènman, S; Kulmala, J; Rantanen, V | 1 |
| Neijt, JP | 1 |
| Atkinson, EN; Burke, TW; Gershenson, DM; Lee, JJ; Levenback, C; Morris, M; Silva, EG; Thall, PF; Wharton, JT; Wolf, J | 1 |
| de Mulder, PH; de Wit, R; Louwerens, M; Rodenhuis, S; Schornagel, J; Verweij, J | 1 |
| Im, DD; Knox, SN; Logan, L; Robinson, JB; Rosenshein, NB | 1 |
| Le Cesne, A; Llombart, A; Rixe, O; Spielmann, M; Sverdlin, R; Zelek, L | 1 |
| Olszewski, W | 1 |
| Bamiagis, A; Christgen, M; Pan, J; Xu, G; Yeung, SC | 1 |
| A'Hern, RP; Barton, D; Blake, P; Gore, ME; Gregory, RK; Hill, ME; Johnston, SR; Moore, J; Shephard, J | 1 |
| Ames, FC; Buzdar, AU; Feig, BW; Hunt, KK; Lenert, JT; Mirza, NQ; Ross, MI; Singletary, SE; Vlastos, G | 1 |
| Kikuchi, Y; Kudoh, K; Nagata, I; Yamamoto, K | 1 |
| Cree, IA; Crohns, C; Felber, M; Hepp, H; Konecny, G; Kurbacher, C; Lude, S; Pegram, M; Untch, M | 1 |
| Berkowitz, R; Cannistra, SA; Kim, Y; Matulonis, U; Niloff, J; Quartulli, M; Seiden, M; Tung, N | 1 |
| Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E | 1 |
| Antila, KJ; Ekholm, EM; Huikuri, HV; Jalonen, J; Rantanen, VT; Salmi, TA; Salminen, EK | 1 |
| Aikins, JA; Paulson, J; Rocereto, TF; Saul, HM | 1 |
| Baek, HS; Yoo, WH | 1 |
| Brun, G; Brun, JL; Chêne, G; Feyler, A; Hocké, C; Saurel, J | 1 |
| Atkinson, EN; Guedes, Ed; Kavanagh, JJ; Kudelka, AP; Nelson-Taylor, T; Rogers, R; Sittisomwong, T; Steger, M; Verschraegen, CF; Vincent, M | 1 |
| Fluellen, L; Fusco, N; Gordon, NH; Hoppel, CL; Ingalls, ST; Rodriguez, M; Rose, PG | 1 |
| Ain, KB; DeSimone, PA; Egorin, MJ | 1 |
| de Swart, CA; Engelholm, SA; Hansen, M; Hirsch, FR; Lund, B; Neijt, JP; Sessa, C; Sorensen, PG; Tuxen, MK; van Houwelingen, HC | 1 |
| Bafaloukos, D; Briasoulis, E; Christodoulou, C; Fountzilas, G; Kalofonos, H; Kosmidis, P; Pavlidis, N; Samantas, E; Skarlos, D; Xiros, N | 1 |
| Atkins, CD | 1 |
| Horwitz, SB; Yang, CP | 1 |
| Bevers, M; Freedman, R; Kavanagh, JJ; Kudelka, AP; Moon, C; Verschraegen, CF | 1 |
| Gharib, H; Giuffrida, D | 1 |
| Belinson, JL; Kennedy, AW; Markman, M; Webster, KD; Zanotti, KM | 1 |
| Arnold, D; Esser, M; Huhn, D; Oettle, H; Riess, H | 1 |
| Bolis, G; Bresciani, G; Fagotti, A; Ferrandina, G; Gatti, L; Lavarino, C; Lucchini, V; Mangioni, C; Oggionni, M; Perego, P; Pierotti, MA; Pilotti, S; Scambia, G; Scarfone, G; Vecchione, F; Zunino, F | 1 |
| Dowell, JE; Garrett, AM; Hande, KR; Johnson, DH; Shyr, Y | 1 |
| Hirabayashi, K; Hoshiai, H; Katsumata, N; Kohno, I; Noda, K; Ogita, S; Taguchi, T; Tanaka, K; Terashima, Y; Tsunematsu, R; Yakushiji, M | 1 |
| Linasmita, V; Termrungruanglert, W; Tresukosol, D; Wilailak, S | 1 |
| Alvarez, RD; Blessing, JA; Curtin, JP; Fowler, WC; Malfetano, JH; Mayer, AR; Rose, PG; Webster, KD | 1 |
| Piedbois, Y; Thirion, P | 1 |
| Martin, C; Pan, J; Xu, G; Yeung, SC | 1 |
| Kanzawa, F; Koh, Y; Nakamura, T; Nishio, K; Saijo, N; Tamura, T | 1 |
| Bacus, SS; Gudkov, AV; Keyomarsi, K; Komarov, AP; Lowe, M; Lyass, L; Seger, R; Yarden, Y; Yung, Y | 1 |
| Bednar, M; Chachoua, A; Ferrari, AC; Mandeli, J; Muggia, F; Rosenthal, M; Singh, H; Taneja, S | 1 |
| Brady, MF; Fracasso, PM; Grogan, TM; Letvak, L; McGuire, WP; Moore, DH; Rose, PG; Walker, JL | 1 |
| Blackburn, A; Buchanan, A; Cunningham, C; Edelman, G; Kirn, D; Maples, P; Nemunaitis, J; Netto, G; Olson, S; Randlev, B; Tong, A | 1 |
| Gitelman, I; Horwitz, SB; Sagi, O; Seidman, R; Wolfson, M | 1 |
| Crystal, RG; Hogan, SM; Leopold, PL; Seidman, MA; Wendland, RL; Worgall, S | 1 |
| Hiramatsu, H; Kikuchi, Y; Kita, T; Seto, H | 1 |
| Bookman, MA | 1 |
| Hirayama, Y; Koyama, R; Nagai, T; Ohta, H; Saito, S; Yonesaka, A | 1 |
| Blohmer, JU; Caputo, A; Costa, SD; du Bois, A; Eidtmann, H; Gademann, G; Gerber, B; Graf, E; Hilfrich, J; Jackisch, C; Kaufmann, M; Lampe, D; Merkle, E; Raab, G; Schütte, M; Sinn, HP; Tulusan, AH; von Minckwitz, G | 1 |
| Bastert, G; Beldermann, F; Geberth, M; Goerner, R; Lenz, F; Schneeweiss, A; Solomayer, E | 1 |
| Horowitz, J | 1 |
| Biswas, RS; Cha, HJ; Hardwick, JM; Srivastava, RK | 1 |
| Hazama, K; Kagisaki, K; Matsuda, H; Miyoshi, S; Ohta, M; Shintani, Y | 1 |
| Appert, H; Howard, J; Iwamura, T; Liu, B; Staren, E | 2 |
| Broome, CM; Gutheil, JC; Hussain, M; Markowitz, AB; Vaughn, DJ | 1 |
| Barton, JH; Bradof, JE; Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Litchy, S; Morrissey, LH; Richards, P; Scullin, DC | 1 |
| Busson, P; Feng, WH; Israel, B; Kenney, SC; Raab-Traub, N | 1 |
| Kelly, WK; Kenneson, K; Morris, MJ; Osman, I; Reuter, VE; Scher, HI; Slovin, SF; Verbel, D | 1 |
| Allen, M; Gibbs, DD; Gore, ME; Johnston, SR; Pyle, L; Vaughan, M; Webb, A | 1 |
| Abratt, RP; Chasen, MR; Cronje, N; Fourie, L; Hacking, D; McMichael, G; Rapoport, BL; Vorobiof, DA | 1 |
| Avigan, D; Elias, AD; Frei, E; Ibrahim, J; Joyce, R; McCauley, M; Reich, E; Richardson, P; Wheeler, C | 1 |
| Fusco, A; Portella, G; Scala, S; Vecchio, G; Vitagliano, D | 1 |
| Domon, H; Fujimoto, S; Fujimoto, T; Fujino, T; Hareyama, H; Ishizaki, Y; Kaneuchi, M; Kawaguchi, I; Minobe, S; Sakuragi, N; Sato, C; Yamaguchi, T; Yamamoto, R; Yoshiaki, K | 1 |
| Barone, L; Speicher, LA; Tew, KD | 1 |
| Collins, JL; Mutch, DG; Williams, S; Xu, L | 1 |
| Adamo, DO; Cunnion, RE; Jacob, J; Kohn, E; Ognibene, FP; Reed, E; Rothenberg, M; Sarosy, G; Stone, DA | 1 |
| Cui, Q; Shen, M; Shu, Q; Wang, B; Zhou, X; Zhu, L | 1 |
44 review(s) available for paclitaxel and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Comparison of one-week versus three-week paclitaxel for advanced pan-carcinomas: systematic review and meta-analysis.
Topics: Carcinoma; Humans; Paclitaxel; Progression-Free Survival | 2022 |
Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies.
Topics: Carcinoma; Carcinoma, Non-Small-Cell Lung; Humans; Immunotherapy; Lung Neoplasms; Male; Paclitaxel | 2021 |
Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2021 |
Serous Carcinoma of the Uterine Cervix, an Extremely Rare Aggressive Entity: A Literature Review.
Topics: Adult; Antineoplastic Agents; Carboplatin; Carcinoma; Chemoradiotherapy; Combined Modality Therapy; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Risk Factors; Treatment Outcome; Uterine Cervical Neoplasms | 2018 |
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Docetaxel; Humans; Paclitaxel; Quality of Life; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2018 |
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nomograms; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Retrospective Studies; United States | 2019 |
A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome; Uterine Cervical Neoplasms | 2014 |
A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Humans; Kidney Neoplasms; Neoadjuvant Therapy; Paclitaxel; Survival Rate; Ureteral Neoplasms; Urothelium | 2014 |
First two cases of primary carcinoma of the vagina successfully treated with concurrent weekly carboplatin plus paclitaxel, external beam radiotherapy and high-dose-rate interstitial brachytherapy: a case report and published work review.
Topics: Adult; Antineoplastic Agents; Brachytherapy; Carboplatin; Carcinoma; Female; Humans; Middle Aged; Paclitaxel; Vaginal Neoplasms | 2015 |
Combined therapy for gastrointestinal carcinomas: exploiting synergies between gene therapy and classical chemo-radiotherapy.
Topics: Antineoplastic Agents; Carcinoma; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Gastrointestinal Neoplasms; Gemcitabine; Genetic Therapy; Humans; Immunotherapy; Paclitaxel | 2015 |
Chemosensitivity in Carcinoma Showing Thymus-Like Differentiation: A Case Report and Review of the Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cell Differentiation; Cisplatin; Cyclophosphamide; Doxorubicin; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Positron-Emission Tomography; Thyroid Neoplasms; Tomography, X-Ray Computed; Vincristine | 2015 |
Promising effect of chemotherapy with bevacizumab for patients with pulmonary pleomorphic carcinoma: Two case reports and a literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Female; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Vascular Endothelial Growth Factor A | 2015 |
Lenvatinib: Role in thyroid cancer and other solid tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Everolimus; Humans; Infant; Iodine Radioisotopes; Mice; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Receptors, Growth Factor; Signal Transduction; Thyroid Neoplasms; Thyroidectomy; Xenograft Model Antitumor Assays | 2016 |
The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polypharmacy; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Withholding Treatment; Young Adult | 2016 |
Integrating Chemotherapy in the Management of Cervical Cancer: A Critical Appraisal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Palliative Care; Uterine Cervical Neoplasms | 2016 |
Counterpoint: Intraperitoneal chemotherapy: an investigational treatment in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Female; Humans; Infusions, Parenteral; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Therapies, Investigational | 2004 |
Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.
Topics: Antineoplastic Agents; Carcinoma; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Versicans | 2011 |
Docetaxel for gastric and esophageal carcinomas.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Clinical Trials as Topic; Docetaxel; Esophageal Neoplasms; Humans; Paclitaxel; Stomach Neoplasms; Taxoids | 2002 |
[Gemicitabine in the treatment of epithelial ovarian cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematologic Diseases; Humans; Multicenter Studies as Topic; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prodrugs; Remission Induction; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Current therapies in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Doxorubicin; Drug Approval; Female; Forecasting; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Multicenter Studies as Topic; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Topotecan; Treatment Outcome; United States; United States Food and Drug Administration | 2003 |
[Advances in the treatment of ovarian carcinoma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2004 |
Chemotherapy in gastric cancer: a brief chronicle with emphasis on recent developments.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Docetaxel; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pyrimidines; Stomach Neoplasms; Taxoids | 2004 |
First-line therapy for ovarian carcinoma: what's next?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Combined Modality Therapy; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Risk Factors | 2004 |
Medical treatment of epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis | 2004 |
Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Female; Humans; Ovarian Neoplasms; Paclitaxel; Remission Induction; Taxoids | 2005 |
Angiosarcoma of the breast with delay in diagnosis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Biopsy; Breast Neoplasms; Carcinoma; Diagnosis, Differential; Early Diagnosis; False Negative Reactions; Fatal Outcome; Female; Hemangiosarcoma; Humans; Lymph Node Excision; Mastectomy, Segmental; Middle Aged; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Paclitaxel; Pigmentation Disorders; Radiodermatitis; Radiotherapy, Adjuvant; Telangiectasis | 2004 |
Maintenance or consolidation therapy in advanced ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carcinoma; Chemotherapy, Adjuvant; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Analysis; Treatment Outcome | 2006 |
[Consensus and new development in epithelial ovarian cancer chemotherapy in 1995].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clinical Trials as Topic; Consensus Development Conferences as Topic; Cyclophosphamide; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Ovarian Neoplasms; Paclitaxel | 1995 |
Taxol: a new drug with significant activity as a salvage therapy in advanced epithelial ovarian carcinoma.
Topics: Carcinoma; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Injections, Intraperitoneal; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy | 1993 |
The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Female; Humans; Ovarian Neoplasms; Paclitaxel; Salvage Therapy | 1995 |
Docetaxel: a review of its pharmacology and clinical activity.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Division; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Eruptions; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Microtubules; Neutropenia; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Taxoids; Tubulin | 1996 |
Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Multicenter Studies as Topic; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Remission Induction; Safety; Survival Rate; Topoisomerase I Inhibitors; Topotecan | 1997 |
The role of chemotherapy in the management of celomic epithelial carcinoma of the ovary.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel | 1997 |
Current status of chemotherapy in gynecologic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Uterine Cervical Neoplasms | 1997 |
[Optimal therapeutic strategies in ovarian epithelial cancer in 1997].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Female; Humans; Ovarian Neoplasms; Paclitaxel; Survival Analysis | 1997 |
Treatment of patients with upper gastrointestinal carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Therapy, Combination; Esophageal Neoplasms; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Stomach Neoplasms | 1997 |
Modern treatment options in epithelial ovarian carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Dose-Response Relationship, Drug; Female; Humans; Injections, Intraperitoneal; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 1998 |
Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Humans; Paclitaxel; Radiotherapy, Adjuvant; Thyroid Neoplasms | 1998 |
[Cytostatic treatment of ovarian carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Hydroxamic Acids; Ovarian Neoplasms; Paclitaxel; Protease Inhibitors; Trastuzumab | 1999 |
Anaplastic thyroid carcinoma: current diagnosis and treatment.
Topics: Age of Onset; Antineoplastic Agents, Phytogenic; Biopsy, Needle; Carcinoma; Combined Modality Therapy; Female; Humans; Middle Aged; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Thyroid Neoplasms; Thyroidectomy; Treatment Outcome | 2000 |
Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; DNA Adducts; Female; Gemcitabine; Humans; Immunologic Factors; Liposomes; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Topoisomerase I Inhibitors; Topotecan | 2001 |
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Female; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Taxoids; Treatment Outcome | 2001 |
Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Genes, p53; Genetic Therapy; Genetic Vectors; Glioblastoma; Head and Neck Neoplasms; Humans; Injections; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasms; Ovarian Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Recombinant Fusion Proteins; Salvage Therapy; Signal Transduction; Treatment Outcome; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 1999 |
Thymic carcinoma successfully resected with superior vena cava after chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Pericardial Effusion; Pleural Effusion, Malignant; Taxoids; Thymus Neoplasms; Vena Cava, Superior | 2001 |
153 trial(s) available for paclitaxel and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Phase II study of carboplatin-paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Humans; Lung Neoplasms; Paclitaxel; Prospective Studies | 2022 |
Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Endometrial Neoplasms; Female; Humans; Lung Neoplasms; Paclitaxel | 2022 |
Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (J
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms | 2023 |
Thyroid V40 Predicts Primary Hypothyroidism After Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Hypothyroidism; Incidence; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Pituitary Gland; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Regression Analysis; Thyroid Gland; Time Factors | 2017 |
Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Lipids; Nanoparticles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols | 2017 |
Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Consolidation Chemotherapy; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Intention to Treat Analysis; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Severity of Illness Index; Survival Analysis | 2013 |
A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Paclitaxel; Thrombocytopenia; Urinary Bladder Neoplasms | 2013 |
Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Canada; Carcinoma; Chemistry, Pharmaceutical; Disease-Free Survival; Drug Administration Schedule; Drug Carriers; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Nanoparticles; Paclitaxel; Proportional Hazards Models; Time Factors; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urothelium | 2013 |
Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Constipation; Dexamethasone; Doxorubicin; Female; Headache; Humans; Isoquinolines; Middle Aged; Nausea; Paclitaxel; Palonosetron; Quinuclidines; Serotonin Antagonists; Time Factors; Treatment Outcome; Vomiting; Young Adult | 2013 |
Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Middle Aged; Nanocapsules; Paclitaxel; Treatment Outcome | 2014 |
A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Chemotherapy-Induced Febrile Neutropenia; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Japan; Leukopenia; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index; Thrombocytopenia; Tumor Burden | 2014 |
A phase 1/2 of a combination of cetuximab and taxane for "triple negative" breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cetuximab; Docetaxel; ErbB Receptors; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Skin Neoplasms; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Risk Assessment; Risk Factors; Thrombocytopenia; Treatment Outcome | 2014 |
Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease-Free Survival; Drug Administration Schedule; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Sulfonamides; Treatment Failure | 2015 |
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Europe; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Quality of Life; Risk Factors; Surveys and Questionnaires; Time Factors; Topotecan; Treatment Outcome; United States; Uterine Cervical Neoplasms | 2015 |
Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Patient Compliance; Quality of Life; Radiation-Sensitizing Agents | 2015 |
Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Bevacizumab; Body Mass Index; CA-125 Antigen; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Obesity; Ovarian Neoplasms; Paclitaxel; Patient Readmission; Peritoneal Neoplasms; Risk Factors; Time Factors | 2015 |
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Estrogen Receptor alpha; Female; Gene Expression; Humans; Immunoglobulin G; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Trastuzumab; Treatment Outcome; Tumor Microenvironment; Tumor Suppressor Protein p53; Young Adult | 2016 |
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cytoreduction Surgical Procedures; Diarrhea; Disease Progression; Disease-Free Survival; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Indoles; Intention to Treat Analysis; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Response Evaluation Criteria in Solid Tumors; Thrombocytopenia; Young Adult | 2016 |
Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma.
Topics: Adult; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Male; Maximum Tolerated Dose; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Osteonectin; Paclitaxel; Treatment Outcome | 2016 |
Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Taxoids; Tissue Array Analysis; Transcriptome; Trastuzumab; Treatment Outcome; Young Adult | 2016 |
A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).
Topics: Adult; Aged; Benzimidazoles; Carcinoma; Cisplatin; Disease-Free Survival; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Uterine Cervical Neoplasms | 2017 |
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Cross-Over Studies; Fallopian Tube Neoplasms; Female; Humans; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Solvents | 2008 |
Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Brain Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Paclitaxel; Prognosis; Salvage Therapy; Survival Rate | 2008 |
In vivo evaluation of intravesical paclitaxel and combined bcl-xL antisense oligodeoxynucleotide treatment for orthotopic urothelial carcinoma.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents, Phytogenic; bcl-X Protein; Carcinoma; Combined Modality Therapy; Disease Models, Animal; Humans; Kidney; Oligonucleotides, Antisense; Paclitaxel; Rats; Rats, Nude; Urinary Bladder Neoplasms; Urologic Neoplasms | 2009 |
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2009 |
Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Eruptions; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Survival Rate; Thrombocytopenia; Urinary Bladder Neoplasms | 2009 |
A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Carboplatin; Carcinoma; CD56 Antigen; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neural Cell Adhesion Molecules; Organophosphorus Compounds; Paclitaxel; Stilbenes; Survivors; Thyroid Neoplasms; Treatment Outcome; Young Adult | 2009 |
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Italy; Middle Aged; Paclitaxel; Preoperative Care; Taxoids | 2010 |
Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Dosage Forms; Dose-Response Relationship, Drug; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Recurrence; Remission Induction; Survival Analysis | 2009 |
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Probability; Prognosis; Proportional Hazards Models; Quinazolines; Survival Analysis; Treatment Outcome | 2009 |
Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study.
Topics: Administration, Oral; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Drug Interactions; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2009 |
Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Quinazolines; Survival Rate; Young Adult | 2009 |
Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Thyroid Neoplasms; Time Factors; Tumor Burden | 2010 |
A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Health Status; Humans; Ovarian Neoplasms; Paclitaxel; Patient Selection; Quality of Life; Social Support; Surveys and Questionnaires; Treatment Outcome | 2010 |
SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Feasibility Studies; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Docetaxel; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2011 |
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Prospective Studies; Quality of Life; Time Factors; Treatment Outcome; Young Adult | 2010 |
[Second line AUO study AB35/09 of metastasized urothelial cell carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Everolimus; Humans; Paclitaxel; Sirolimus; Treatment Outcome; Urinary Bladder Neoplasms | 2010 |
A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy; Uterine Cervical Neoplasms | 2010 |
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Staging; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Failure | 2010 |
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Nanoparticles; Paclitaxel; Ventricular Function, Left | 2011 |
Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease-Free Survival; Female; Humans; Male; Middle Aged; Paclitaxel; Thymoma; Thymus Neoplasms | 2011 |
Variation of breast vascular maps on dynamic contrast-enhanced MRI after primary chemotherapy of locally advanced breast cancer.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cohort Studies; Contrast Media; Doxorubicin; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Predictive Value of Tests; Treatment Outcome | 2011 |
Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeC
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Chemoradiotherapy; Cisplatin; Epirubicin; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Ki-67 Antigen; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Tumor Suppressor Protein p53; Young Adult | 2012 |
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pyrroles; Sunitinib; Survival Analysis | 2011 |
A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Drug Administration Schedule; Female; Humans; Middle Aged; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Trastuzumab | 2011 |
Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cations; Deoxycytidine; Disease Progression; Dosage Forms; Female; Gemcitabine; Humans; Liposomes; Male; Middle Aged; Models, Biological; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2012 |
Immunological effects of taxol and adryamicin in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cytokines; Doxorubicin; Female; Humans; Immunomodulation; Middle Aged; Nitric Oxide; Oxidative Stress; Paclitaxel | 2012 |
[Second line AUO (Working Group Urological Oncology) study AB 35/09 on metastasized urothelial carcinoma. Phase II study with RAD001 in combination with paclitaxel for patients with metastasized urothelial carcinoma of the urinary bladder after failure of
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Everolimus; Humans; Paclitaxel; Sirolimus; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Female; Humans; Hydroxamic Acids; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Sulfonamides | 2012 |
Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Prognosis | 2013 |
Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2002 |
Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Female; Humans; Infusions, Intravenous; Kidney Diseases; Male; Middle Aged; Paclitaxel; Prognosis; Survival Analysis; Urinary Bladder Neoplasms | 2002 |
Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cimetidine; Clemastine; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Hypersensitivity; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Injections, Intravenous; Life Tables; Middle Aged; Muscular Diseases; Nervous System Diseases; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Premedication; Salvage Therapy; Survival Analysis; Treatment Outcome | 2002 |
Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epithelial Cells; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Melphalan; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Recombinant Proteins | 2003 |
Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System; Treatment Outcome | 2003 |
Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I-II study.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antiemetics; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Survival Analysis | 2003 |
[Early results of first-line chemotherapy with paclitaxel and carboplatin in patients with epithelial ovarian carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2003 |
Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis | 2003 |
Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Eye Enucleation; Female; Humans; Ifosfamide; Infusions, Intra-Arterial; Infusions, Intravenous; Male; Middle Aged; Orbit; Paclitaxel; Paranasal Sinus Neoplasms; Radiotherapy, Adjuvant; Treatment Outcome | 2003 |
Weekly paclitaxel infusion as salvage therapy in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Treatment Outcome | 2003 |
Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Combined Modality Therapy; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Treatment Outcome | 2004 |
Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carcinoma; Cisplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Reference Values; Topotecan; Treatment Outcome; World Health Organization | 2004 |
Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Administration Schedule; Estramustine; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Survival Analysis; Treatment Outcome | 2004 |
Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute,
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome | 2004 |
Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Female; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Microcirculation; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Salvage Therapy | 2004 |
First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; France; Humans; Ifosfamide; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome | 2004 |
A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lung; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2004 |
Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Recombinant Proteins; Treatment Outcome | 2004 |
Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Appetite; Carcinoma; Cisplatin; Cyclophosphamide; Emotions; Female; Health Status; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Quality of Life; Sleep; Social Support; Survival Analysis | 2004 |
A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carboplatin; Carcinoma; Combined Modality Therapy; Dexamethasone; Diphenhydramine; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hyperglycemia; Life Tables; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Premedication; Survival Analysis; Treatment Outcome; Urologic Neoplasms; Urothelium | 2004 |
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Confidence Intervals; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neutropenia; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Proportional Hazards Models; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Treatment Outcome | 2004 |
Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neutropenia; Paclitaxel; Severity of Illness Index; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2005 |
Phase I study of a weekly schedule of fixed-dose paclitaxel and escalating doses of cisplatin for recurrent or unresectable gastric cancer in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Feasibility Studies; Female; Gastrectomy; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Japan; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Treatment Outcome | 2005 |
Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Treatment Outcome | 2005 |
Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Ovarian Neoplasms; Paclitaxel; Quinazolines; Treatment Outcome | 2006 |
Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Doxorubicin; Drug Administration Schedule; Female; Humans; Liposomes; Middle Aged; Neoplasm Staging; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2005 |
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Survival Analysis | 2006 |
Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intravenous; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome | 2006 |
A phase II trial with cisplatin-paclitaxel cytotoxic treatment and concurrent external and endocavitary radiation therapy in locally advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Treatment Outcome; Uterine Cervical Neoplasms | 2006 |
Paclitaxel and carboplatin therapy in stage I fallopian tube carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Second-Look Surgery | 2006 |
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Survival Analysis | 2006 |
Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intravenous; Italy; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Vinblastine; Vinorelbine | 2006 |
A phase II study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Survival Analysis; Treatment Outcome | 2006 |
Results of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: a reasonable regimen for the community-based clinic?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Disease-Free Survival; Female; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2007 |
Phase I and pharmacokinetic study of combination chemotherapy using irinotecan and paclitaxel in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2006 |
Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2007 |
Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Paclitaxel; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2007 |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Paclitaxel; Peripheral Nervous System Diseases; Tamoxifen | 2008 |
Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Epidermal Cyst; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2008 |
A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2008 |
Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Humans; Middle Aged; Obesity; Ovarian Neoplasms; Overweight; Paclitaxel; Survival Analysis; Taxoids; Thinness | 2008 |
Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of prog
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease-Free Survival; Female; Humans; Interferon-gamma; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recombinant Proteins; Treatment Outcome | 2008 |
Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer.
Topics: Adult; Aged; Bone Marrow Diseases; Carcinoma; Drug Administration Schedule; Drug Resistance; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prospective Studies; Survival Analysis; Treatment Outcome | 1994 |
Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Care Facilities; Carcinoma; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Texas | 1995 |
Peripheral neurotoxicity of taxol in patients previously treated with cisplatin.
Topics: Adult; Carcinoma; Cisplatin; Drug Synergism; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nerves; Peripheral Nervous System Diseases | 1995 |
Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Drug Resistance; Female; Humans; Infusions, Intravenous; Life Tables; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Analysis | 1993 |
Taxol (paclitaxel) in patients with metastatic breast carcinoma who have failed prior chemotherapy: interim results of a multinational study.
Topics: Breast Neoplasms; Canada; Carcinoma; Drug Administration Schedule; Female; France; Germany; Humans; Infusions, Intravenous; Italy; Middle Aged; Paclitaxel; Treatment Failure; Treatment Outcome | 1994 |
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan | 1996 |
The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. A preliminary report.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Cisplatin; Combined Modality Therapy; Female; Humans; Image Processing, Computer-Assisted; Indium Radioisotopes; Laparotomy; Mice; Middle Aged; Neoplasm, Residual; Oligopeptides; Ovarian Neoplasms; Paclitaxel; Pentetic Acid; Predictive Value of Tests; Prospective Studies; Radioimmunodetection; Remission Induction; Sensitivity and Specificity; Single-Blind Method; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 1996 |
A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carcinoma; Cisplatin; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Paresthesia; Remission Induction; Treatment Outcome | 1995 |
A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Analysis; Treatment Outcome | 1996 |
Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Vehicles; Polyethylene Glycols; Time Factors | 1996 |
A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Female; Hematopoiesis; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 1997 |
A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Cohort Studies; Combined Modality Therapy; Female; Fever; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Nervous System Diseases; Neutropenia; Paclitaxel; Preoperative Care; Survival Rate; Thrombocytopenia | 1997 |
Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma; Cisplatin; Disease Progression; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Recombinant Proteins | 1997 |
Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cisplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Salvage Therapy; Treatment Failure | 1997 |
Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Etoposide; Female; Humans; Liver Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Survival Analysis | 1997 |
Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Dose-Response Relationship, Drug; Feasibility Studies; Female; Hematologic Diseases; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 1997 |
Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Cisplatin; Confidence Intervals; Disease Progression; Female; France; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Safety; Survival Rate; Thrombocytopenia; Treatment Outcome | 1997 |
Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow; Carboplatin; Carcinoma; Cisplatin; Female; Follow-Up Studies; Hospitalization; Humans; Incidence; Infusions, Intravenous; Middle Aged; Nausea; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Remission Induction; Survival Rate; Vomiting | 1997 |
A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Cause of Death; Chemotherapy, Adjuvant; Disease Progression; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiography; Remission Induction; Risk Factors; Salvage Therapy; Sensation Disorders; Survival Rate; Thrombocytopenia | 1997 |
Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Palliative Care; Treatment Outcome | 1997 |
Tolerance of paclitaxel 3-hour infusion with and without granulocyte colony-stimulating factor on a biweekly schedule.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Treatment Outcome | 1997 |
One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Survival Rate; Treatment Outcome | 1997 |
Prospective sequential trials of induction weekly cisplatin followed by monthly cisplatin, doxorubicin, cyclophosphamide and paclitaxel and cisplatin in optimal (< or = 1 cm) stage III and IV ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 1998 |
Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Survival Rate; Treatment Outcome | 1998 |
Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate | 1998 |
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Cisplatin; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Treatment Outcome | 1998 |
A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Breast Neoplasms; Carcinoma; Cohort Studies; Cyclophosphamide; Diarrhea; Esophagitis; Female; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Incidence; Infusions, Intravenous; Lung Diseases; Middle Aged; Neoplasm Staging; Paclitaxel; Pulmonary Alveoli; Remission Induction; Stomatitis; Survival Rate; Thiotepa; Transplantation, Autologous | 1998 |
Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Leukopenia; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Thrombocytopenia | 1999 |
Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasms; Paclitaxel | 1999 |
A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Melphalan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 1999 |
Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Etoposide; Germinoma; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms, Unknown Primary; Paclitaxel; Prognosis; Testicular Neoplasms | 1999 |
Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neutropenia; Paclitaxel; Taxoids | 1999 |
Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome | 2000 |
Phase II study of mifepristone (RU486) in refractory ovarian cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; CA-125 Antigen; Carcinoma; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hormone Antagonists; Humans; Mifepristone; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2000 |
Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Statistics, Nonparametric; Survival Analysis; Taxoids | 2000 |
A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Lactones; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan | 2000 |
Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group.
Topics: Aged; Aged, 80 and over; Carcinoma; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Survival Rate; Thyroid Neoplasms; Treatment Outcome | 2000 |
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Drug Administration Schedule; Epithelium; Feasibility Studies; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Drug Administration Routes; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel | 2000 |
Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Quality of Life; Salvage Therapy | 2000 |
A randomized Phase II trial in patients with carcinoma of an unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Etoposide; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Treatment Outcome | 2001 |
A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Phase II study of high-dose paclitaxel in platinum-refractory epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome | 2000 |
Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Treatment Outcome; Uterine Cervical Neoplasms | 2001 |
Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2001 |
A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dose-Response Relationship, Drug; Estramustine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prostatic Neoplasms; Treatment Outcome | 2001 |
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma; Cyclosporins; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2001 |
Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenoviridae; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Papillary; Carcinoma, Squamous Cell; Colonic Neoplasms; Feasibility Studies; Female; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Osteosarcoma; Paclitaxel; Thyroid Neoplasms | 2001 |
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Female; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Taxoids; Treatment Outcome | 2001 |
Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2002 |
Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Survival Rate; Treatment Outcome | 2002 |
HER-2 profiling and targeting in prostate carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2002 |
A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Liposomes; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2002 |
Malignant pleural mesothelioma: a phase II trial with docetaxel.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Docetaxel; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Mesothelioma; Middle Aged; Paclitaxel; Pleural Neoplasms; Survival Rate; Taxoids | 2002 |
The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farbe
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Estrogens; Female; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Life Tables; Melphalan; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Progesterone; Prognosis; Proportional Hazards Models; Remission Induction; Survival Analysis; Thiotepa; Time Factors; Treatment Outcome | 2002 |
A phase I/II study of carboplatin and paclitaxel in patients with epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2002 |
Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Carcinoma; Drug Evaluation; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 1992 |
403 other study(ies) available for paclitaxel and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes.
Topics: Animals; Antineoplastic Agents, Alkylating; Aza Compounds; Breast Neoplasms; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Survival; Cross-Linking Reagents; DNA; Female; Humans; Indenes; Mice; Mice, Nude; Neoplasms; Remission Induction; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2009 |
Synthesis and evaluation of ursolic acid derivatives as potent cytotoxic agents.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cytotoxins; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Hydrophobic and Hydrophilic Interactions; Static Electricity; Stomach Neoplasms; Triterpenes; Ursolic Acid | 2012 |
Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2021 |
[A Case of Surgical Resection of Anaplastic Carcinoma of the Pancreas(Pleomorphic Cell Type)with Poor Response to Neoadjuvant Chemotherapy].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2021 |
CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma.
Topics: Carcinoma; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptors, CXCR4; Signal Transduction; TOR Serine-Threonine Kinases | 2022 |
Effects of particle size and release property of paclitaxel-loaded nanoparticles on their peritoneal retention and therapeutic efficacy against mouse malignant ascites.
Topics: Animals; Ascites; Carcinoma; Cell Line, Tumor; Emulsions; Liposomes; Mice; Nanoparticles; Paclitaxel; Particle Size; Peritoneal Neoplasms; Quality of Life | 2022 |
Microenvironment-tailored micelles restrain carcinoma-astrocyte crosstalk for brain metastasis.
Topics: Animals; Astrocytes; Brain Neoplasms; Carcinoma; Cell Line, Tumor; Glutathione; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Peptides, Cyclic; Protocadherins; RNA, Small Interfering; Tumor Microenvironment | 2022 |
MiR-4284 inhibits sensitivity to paclitaxel in human ovarian carcinoma SKOV3ip1 and HeyA8 cells by targeting DMC1.
Topics: Carcinoma; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Ovarian Neoplasms; Paclitaxel | 2022 |
The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cell Line, Tumor; Drug Synergism; Humans; Metformin; Neoplasm Recurrence, Local; Paclitaxel | 2022 |
Curcumin reduces paclitaxel resistance in ovarian carcinoma cells by upregulating SNIP1 and inhibiting NFκB activity.
Topics: Carcinoma; Cell Line, Tumor; Curcumin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; NF-kappa B; Ovarian Neoplasms; Paclitaxel; RNA-Binding Proteins | 2023 |
Mechanism of Cell Death by Combined Treatment with an xCT Inhibitor and Paclitaxel: An Alternative Therapeutic Strategy for Patients with Ovarian Clear Cell Carcinoma.
Topics: Carcinoma; Cell Death; Cell Line, Tumor; Glutathione; Humans; Paclitaxel; Reactive Oxygen Species; Sulfasalazine | 2023 |
Chloroquine Sensitizes Esophageal Carcinoma EC109 Cells to Paclitaxel by Inhibiting Autophagy.
Topics: Apoptosis; Autophagy; Carcinoma; Cell Line, Tumor; Cell Proliferation; Chloroquine; Esophageal Neoplasms; Humans; Paclitaxel; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases | 2023 |
Scrotal Paget's Disease Associated With Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Apocrine Carcinoma With Complete Response to Paclitaxel, Trastuzumab, and Pertuzumab.
Topics: Breast Neoplasms; Carcinoma; Female; Humans; Paclitaxel; Trastuzumab | 2023 |
Clear cell carcinoma arising in an ovarian remnant 19 years after oophoerctomy: case report.
Topics: Carboplatin; Carcinoma; Cesarean Section; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pregnancy; Quality of Life | 2023 |
Exceptional Response to Nivolumab in a 13-Year-Old Female with Metastatic HPV-Negative Cervical Carcinoma.
Topics: Adolescent; Antineoplastic Agents, Immunological; Carboplatin; Carcinoma; Female; Gamma Rays; Humans; Hysterectomy; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Nivolumab; Ovariectomy; Paclitaxel; Papillomaviridae; Salpingectomy; Treatment Outcome; Uterine Cervical Neoplasms | 2019 |
Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Biomarkers, Tumor; Biopsy, Large-Core Needle; Cadherins; Carcinoma; Cell Line, Tumor; Cell Plasticity; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Indazoles; Male; Mice; Neoplastic Stem Cells; Paclitaxel; Pyrimidines; Sulfonamides; Vimentin; Xenograft Model Antitumor Assays | 2020 |
A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma.
Topics: Aged; Antineoplastic Agents; California; Carboplatin; Carcinoma; Cisplatin; Female; Humans; Hyperthermia, Induced; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2020 |
Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma.
Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Humans; Leuprolide; Male; Nitriles; Paclitaxel; Salivary Ducts; Salivary Gland Neoplasms; Tosyl Compounds | 2020 |
A Case of Unknown Primary Cancer with a Tumor Formed in the Retroperitoneum: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Positron-Emission Tomography; Retroperitoneal Neoplasms; Tomography, X-Ray Computed | 2020 |
Novel monoclonal antibody against integrin α3 shows therapeutic potential for ovarian cancer.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Carboplatin; Carcinoma; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Disease Models, Animal; Female; HCT116 Cells; Human Umbilical Vein Endothelial Cells; Humans; Integrin alpha3; Mice; Mice, Inbred BALB C; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2020 |
Responses of metastatic primary fallopian tube carcinoma to pembrolizumab and nab-paclitaxel: A case report.
Topics: Adult; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Fallopian Tube Neoplasms; Female; Humans; Paclitaxel | 2020 |
Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
Topics: 3T3-L1 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; MAP Kinase Signaling System; Mice; Ovarian Neoplasms; Paclitaxel; Platinum; Tumor Microenvironment | 2020 |
Obg-like ATPase 1 inhibited oral carcinoma cell metastasis through TGFβ/SMAD2 axis in vitro.
Topics: Adenosine Triphosphatases; Cadherins; Carcinoma; Cell Line, Tumor; Down-Regulation; GTP-Binding Proteins; Humans; Mouth Neoplasms; Neoplasm Metastasis; Paclitaxel; Signal Transduction; Smad2 Protein; Snail Family Transcription Factors; Transforming Growth Factor beta; Up-Regulation | 2020 |
Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Tegafur; Treatment Outcome | 2020 |
In Silico Inference of Synthetic Cytotoxic Interactions from Paclitaxel Responses.
Topics: Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Computer Simulation; Endometrial Neoplasms; Female; Gene Regulatory Networks; Genes, Tumor Suppressor; Genome, Human; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Mutation; Paclitaxel; Prognosis; Proportional Hazards Models; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2021 |
Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carbon-Sulfur Lyases; Carcinoma; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Heterografts; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Sarcoma, Clear Cell; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Synthesis of pH-sensitive hyaluronic acid nanogels loaded with paclitaxel and interferon gamma: Characterization and effect on the A549 lung carcinoma cell line.
Topics: A549 Cells; Carcinoma; Cell Line, Tumor; Cell Survival; HEK293 Cells; Humans; Hyaluronic Acid; Hydrogen-Ion Concentration; Interferon-gamma; Lung; Lung Neoplasms; Nanogels; Paclitaxel | 2021 |
Circular RNA PLEC acts as a sponge of microRNA-198 to promote gastric carcinoma cell resistance to paclitaxel and tumorigenesis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Carcinogenesis; Carcinoma; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Paclitaxel; RNA, Circular; Stomach; Stomach Neoplasms | 2021 |
LncRNA CCAT1 modulates the sensitivity of paclitaxel in nasopharynx cancers cells via miR-181a/CPEB2 axis.
Topics: Base Sequence; Carcinoma; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; MicroRNAs; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; RNA-Binding Proteins; RNA, Long Noncoding; Signal Transduction; Up-Regulation | 2017 |
Paclitaxel dimers assembling nanomedicines for treatment of cervix carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Cell Survival; Cervix Uteri; Chemistry, Pharmaceutical; Dimerization; Drug Carriers; Drug Liberation; Drug Stability; Female; Humans; Male; Mice, Nude; Micelles; Nanomedicine; Paclitaxel; Particle Size; Polyethylene Glycols; Solubility; Surface Properties; Uterine Cervical Neoplasms | 2017 |
Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
Topics: Antineoplastic Agents, Phytogenic; Cadherins; Carcinoma; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Fibronectins; Gene Expression; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; MicroRNAs; Ovarian Neoplasms; Paclitaxel; Polymerization; Taxoids; Tubulin; Tumor Suppressor Protein p53; Vimentin; Vinblastine | 2017 |
Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease-Free Survival; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Pilot Projects; Proportional Hazards Models; Retrospective Studies; Survival Analysis | 2017 |
TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Binding Sites; Carcinoma; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; NF-kappa B; Ovarian Neoplasms; Paclitaxel; Promoter Regions, Genetic; RNA Interference; Signal Transduction; Sulfonamides; Toll-Like Receptor 4; Transfection; Up-Regulation | 2018 |
Cepharanthine hydrochloride reverses P‑glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzylisoquinolines; Carcinoma; Cell Line, Tumor; Chromones; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Oncogene Protein v-akt; Ovarian Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Signal Transduction | 2017 |
Long-term complete response to carboplatin plus paclitaxel combined with bevacizumab in a patient with metastatic spindle cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Carboplatin; Carcinoma; Drug Administration Schedule; Humans; Lung Neoplasms; Lymphatic Metastasis; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pleural Neoplasms; Proteinuria; Tomography, X-Ray Computed; Treatment Outcome; Withholding Treatment | 2017 |
Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey.
Topics: Antineoplastic Agents; Carcinoma; Cardiac Output; Cisplatin; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Mesothelioma; Mitomycin; Monitoring, Intraoperative; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Practice Patterns, Physicians'; Spain; Stomach Neoplasms; Surveys and Questionnaires | 2018 |
ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma; Cisplatin; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pelvic Neoplasms; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms | 2017 |
Programmed 'triple-mode' anti-tumor therapy: Improving peritoneal retention, tumor penetration and activatable drug release properties for effective inhibition of peritoneal carcinomatosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Drug Carriers; Drug Liberation; Female; Humans; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Peritoneal Neoplasms; Peritoneum | 2018 |
Combination therapy involving radiofrequency ablation and targeted chemotherapy with bevacizumab plus paclitaxel and cisplatin in a rabbit VX2 lung tumor model.
Topics: Animals; Antineoplastic Agents; Bevacizumab; Carcinoma; Catheter Ablation; Cell Line, Tumor; Cisplatin; Combined Modality Therapy; Disease Models, Animal; Drug Therapy, Combination; Female; Lung Neoplasms; Paclitaxel; Rabbits | 2018 |
Knockdown of SIRT1 inhibits proliferation and promotes apoptosis of paclitaxel-resistant human cervical cancer cells.
Topics: Apoptosis; Carcinoma; Cell Cycle; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Paclitaxel; RNA Interference; RNA, Small Interfering; Sirtuin 1; Uterine Cervical Neoplasms | 2018 |
Targeted regulationof STAT3 by miR-29a in mediating Taxol resistance of nasopharyngeal carcinoma cell line CNE-1.
Topics: Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; STAT3 Transcription Factor | 2018 |
Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Fallopian Tube Neoplasms; Female; Humans; Length of Stay; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Postoperative Complications; Survival Rate; Time Factors | 2018 |
[A Case of Microangiopathic Hemolytic Anemia with Bone Marrow Carcinomatosis from Breast Cancer].
Topics: Anemia, Hemolytic; Antineoplastic Agents, Phytogenic; Biopsy; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma; Female; Humans; Middle Aged; Paclitaxel | 2018 |
The new 6q27 tumor suppressor DACT2, frequently silenced by CpG methylation, sensitizes nasopharyngeal cancer cells to paclitaxel and 5-FU toxicity via β-catenin/Cdc25c signaling and G2/M arrest.
Topics: Adaptor Proteins, Signal Transducing; beta Catenin; Carcinoma; Carrier Proteins; cdc25 Phosphatases; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; CpG Islands; DNA Methylation; Down-Regulation; Fluorouracil; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Nasopharyngeal Neoplasms; Neoplasm Proteins; Paclitaxel; Promoter Regions, Genetic; Signal Transduction | 2018 |
Isochemotopic response: the first case on a scar.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cicatrix; Cisplatin; Erythema; Humans; Lung Neoplasms; Male; Neoplasms, Second Primary; Paclitaxel; Thyroid Neoplasms; Thyroidectomy | 2020 |
Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy; Mastectomy, Segmental; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Taxoids; Triple Negative Breast Neoplasms | 2019 |
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Italy; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Liver Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms; Platinum Compounds; Progression-Free Survival; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Treatment Failure | 2019 |
PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study.
Topics: Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Female; Humans; Metaplasia; Morpholines; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Randomized Controlled Trials as Topic; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Biotin and arginine modified hydroxypropyl-β-cyclodextrin nanoparticles as novel drug delivery systems for paclitaxel.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Antineoplastic Agents; Arginine; Biotin; Carcinoma; Drug Carriers; Female; Humans; MCF-7 Cells; Mice; Nanoparticles; Paclitaxel; Particle Size; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Cytochrome c1 as a favorable prognostic marker in estrogen receptor-positive breast carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Breast; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytochromes c1; Disease-Free Survival; Estrogen Receptor alpha; Female; Glycolysis; Humans; Ki-67 Antigen; Lactic Acid; MCF-7 Cells; Middle Aged; Paclitaxel; Phenotype; Prognosis; RNA, Small Interfering; Time Factors | 2019 |
Nano-drug System Based on Hierarchical Drug Release for Deep Localized/Systematic Cascade Tumor Therapy Stimulating Antitumor Immune Responses.
Topics: Animals; Antineoplastic Agents; Carcinoma; Disease Models, Animal; Doxorubicin; Drug Delivery Systems; Drug Liberation; Drug Therapy; Gold; HeLa Cells; Humans; Hyperthermia, Induced; Immunologic Factors; Immunotherapy; Mice; Models, Biological; Nanocomposites; Neoplasm Transplantation; Paclitaxel; Photosensitizing Agents; Phototherapy; Transplantation, Heterologous; Treatment Outcome | 2019 |
Involvement of the MDR1 gene and glycolipids in anticancer drug-resistance of human ovarian carcinoma-derived cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Glycolipids; Humans; Hydrophobic and Hydrophilic Interactions; Ovarian Neoplasms; Paclitaxel | 2019 |
Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).
Topics: Aged; Antibodies, Neutralizing; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma; Carcinoma, Endometrioid; Cisplatin; DNA Mismatch Repair; Doxorubicin; Endometrial Neoplasms; Female; Gene Expression; Humans; Immunophenotyping; Lymphocytes, Tumor-Infiltrating; Microsatellite Instability; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Programmed Cell Death 1 Receptor | 2019 |
Comparison of "sandwich chemo-radiotherapy" and six cycles of chemotherapy followed by adjuvant radiotherapy in patients with stage IIIC endometrial cancer: a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Drug Administration Schedule; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Staging; Ovariectomy; Paclitaxel; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Retrospective Studies; Salpingectomy; Treatment Outcome | 2013 |
Concomitant paclitaxel plus carboplatin and radiotherapy for high-risk or advanced endometrial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; China; Endometrial Neoplasms; Feasibility Studies; Female; Humans; Middle Aged; Paclitaxel; Retrospective Studies | 2013 |
MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; MicroRNAs; Middle Aged; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; rab GTP-Binding Proteins; Real-Time Polymerase Chain Reaction; Up-Regulation | 2013 |
Cost effectiveness of neoadjuvant chemotherapy in locally advanced operable head and neck cancer followed by surgery and postoperative radiotherapy: a Markov model-based decision analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Disease-Free Survival; Fluorouracil; Germany; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Markov Chains; Monte Carlo Method; Neoadjuvant Therapy; Paclitaxel | 2013 |
A new approach to second-line therapy for urothelial cancer?
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Carriers; Female; Humans; Kidney Neoplasms; Male; Nanoparticles; Paclitaxel; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urothelium | 2013 |
Bladder cancer: second-line nab-paclitaxel for advanced urothelial carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Drug Carriers; Female; Humans; Kidney Neoplasms; Male; Nanoparticles; Paclitaxel; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urothelium | 2013 |
Prognostic value of organic anion transporting polypeptide 1B3 and copper transporter 1 expression in endometrial cancer patients treated with paclitaxel and carboplatin.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma; Cation Transport Proteins; Chemotherapy, Adjuvant; Copper Transporter 1; Endometrial Neoplasms; Female; Gene Expression; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Organic Anion Transporters, Sodium-Independent; Paclitaxel; Prognosis; Solute Carrier Organic Anion Transporter Family Member 1B3; Survival Analysis; Treatment Outcome | 2013 |
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
Topics: Animals; Antineoplastic Agents; Autopsy; Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Mice; Paclitaxel; Protein Kinase Inhibitors; Receptor, EphB4; RNA, Small Interfering; Signal Transduction; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Inhibitory Concentration 50; MAP Kinase Signaling System; Mice; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinolines; TOR Serine-Threonine Kinases | 2014 |
Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma; Caveolin 1; Cell Cycle; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Protein Kinase C-alpha; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays | 2013 |
Clinical outcome of paclitaxel and carboplatin as second-line chemotherapy for advanced urothelial carcinoma resistant to first-line therapy with gemcitabine and cisplatin.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2014 |
Debulking surgery and intraperitoneal chemotherapy are associated with decreased morbidity in women receiving neoadjuvant chemotherapy for ovarian cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Critical Care; Female; Hospital Mortality; Humans; Infusions, Parenteral; Length of Stay; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2014 |
Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Endosonography; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Gemcitabine; Humans; Injections, Intralesional; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Phytotherapy; Plant Extracts; Retrospective Studies; Survival Rate; Ultrasonography, Interventional; Viscum album | 2014 |
[A patient with thyroid cancer evaluated according to Response Evaluation Criteria in Solid Tumors during treatment for breast cancer recurrence in hepatic and cervical lymph nodes].
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Carcinoma, Papillary; Diagnosis, Differential; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Neck; Paclitaxel; Recurrence; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2013 |
[A case of peritoneal carcinomatosis due to recurrence of primary adenocarcinoma of the ureter treated with weekly paclitaxel].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Fatal Outcome; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Recurrence; Urologic Neoplasms | 2014 |
Does modality of adjuvant chemotherapy after interval surgical debulking matter in epithelial ovarian cancer?: An exploratory analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2014 |
A targeting drug delivery system for ovarian carcinoma: transferrin modified lipid coated paclitaxel-loaded nanoparticles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Stability; Endocytosis; Female; Human Umbilical Vein Endothelial Cells; Humans; Lactic Acid; Lipids; Liposomes; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Nanomedicine; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solubility; Surface Properties; Technology, Pharmaceutical; Time Factors; Transferrin; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Evaluation of progression prior to surgery after neoadjuvant chemoradiotherapy with computed tomography in esophageal cancer patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Disease Progression; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multidetector Computed Tomography; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Preoperative Care; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2014 |
Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Esophageal Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Odds Ratio; Paclitaxel; Patient Admission; Radiotherapy Dosage; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2014 |
Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
Topics: Aged; Antineoplastic Agents; Body Mass Index; Carboplatin; Carcinoma; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Multivariate Analysis; Obesity; Ovarian Neoplasms; Overweight; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2014 |
Development of polymeric nanopaclitaxel and comparison with free paclitaxel for effects on cell proliferation of MCF-7 and B16F0 carcinoma cells.
Topics: Acrylamides; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Delayed-Action Preparations; Drug Carriers; Humans; MCF-7 Cells; Melanoma, Experimental; Nanoparticles; Paclitaxel; Particle Size; Polymers | 2014 |
Survival and prognostic factors of patients with primary fallopian tube cancer receiving adjuvant paclitaxel and carboplatin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Hospitals, University; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Analysis; Thailand | 2014 |
[Outcomes of treatment of 32 cases of advanced or relapsed post-surgery pulmonary sarcomatoid carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Postoperative Period; Survival Rate | 2014 |
Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Ovarian Epithelial; Cohort Studies; Cytoreduction Surgical Procedures; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prognosis; Remission Induction; Retrospective Studies; Treatment Outcome; Tumor Burden | 2014 |
Bevacizumab for critical brain metastases in a patient with pulmonary pleomorphic carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Edema; Brain Neoplasms; Carcinoma; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2014 |
Paclitaxel-loaded stealth liposomes: Development, characterization, pharmacokinetics, and biodistribution.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Carcinoma; Cell Line, Tumor; Cholesterol; Drug Compounding; Drug Liberation; Half-Life; Humans; Injections, Intravenous; Liposomes; Liver; Lung Neoplasms; Mice; Paclitaxel; Phosphatidylcholines; Phosphatidylethanolamines; Polyethylene Glycols; Rats, Sprague-Dawley; Spleen; Tissue Distribution; Xenograft Model Antitumor Assays | 2016 |
hMSH2 expression is associated with paclitaxel resistance in ovarian carcinoma, and inhibition of hMSH2 expression in vitro restores paclitaxel sensitivity.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Dosage; Humans; In Vitro Techniques; MutS Homolog 2 Protein; Ovarian Neoplasms; Paclitaxel; RNA, Small Interfering | 2014 |
[Preliminary mechanism of paclitaxel enhanced radiation sensitivity for nasopharyngeal carcinoma cells].
Topics: Apoptosis; Carcinoma; Cell Cycle; Cell Line, Tumor; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Radiation Tolerance | 2014 |
Ephrin type‑A receptor 2 regulates sensitivity to paclitaxel in nasopharyngeal carcinoma via the phosphoinositide 3‑kinase/Akt signalling pathway.
Topics: Animals; Apoptosis; Carcinoma; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Rabbits; Receptor, EphA2; Signal Transduction | 2015 |
Op18/stathmin is involved in the resistance of taxol among different epithelial carcinoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; MCF-7 Cells; Paclitaxel; Stathmin; Transfection | 2014 |
MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Mice, Nude; MicroRNAs; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Curcumin-loaded PLGA nanoparticles conjugated with anti- P-glycoprotein antibody to overcome multidrug resistance.
Topics: Animals; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biocompatible Materials; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Curcumin; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Humans; Lactic Acid; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Uterine Cervical Neoplasms | 2014 |
Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Cisplatin; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Peritoneum | 2015 |
Evaluation of a dansyl-based amino acid DNSBA as an imaging probe for apoptosis detection.
Topics: Animals; Annexin A5; Apoptosis; Biological Transport; Carcinoma; Caspases; Cell Line, Tumor; Cell Membrane Permeability; Dansyl Compounds; Gene Expression; Humans; In Situ Nick-End Labeling; Injections, Subcutaneous; Kinetics; Mice; Mice, Inbred BALB C; Molecular Probes; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Optical Imaging; Paclitaxel; Phenylpropionates; Tumor Necrosis Factor-alpha | 2015 |
New thermosensitive nanoparticles prepared by biocompatible pegylated aliphatic polyester block copolymers for local cancer treatment.
Topics: Adipates; Antineoplastic Agents; Biocompatible Materials; Carcinoma; Drug Delivery Systems; Female; Fever; HeLa Cells; Hep G2 Cells; Hepatoblastoma; Hot Temperature; Humans; Liver Neoplasms; Nanocapsules; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Polyesters; Polyethylene Glycols; Polypropylenes; Uterine Cervical Neoplasms | 2015 |
MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mice; MicroRNAs; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2015 |
Differential effect of phosphorylation-defective survivin on radiation response in estrogen receptor-positive and -negative breast cancer.
Topics: Breast Neoplasms; Carcinoma; Cell Line, Tumor; Databases, Nucleic Acid; Female; Gene Expression; Humans; Inhibitor of Apoptosis Proteins; MCF-7 Cells; Neoplasm Staging; Paclitaxel; Phosphorylation; Radiation Tolerance; Receptors, Estrogen; Survivin | 2015 |
FOXC2 promotes chemoresistance in nasopharyngeal carcinomas via induction of epithelial mesenchymal transition.
Topics: Animals; Anoikis; Carcinoma; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Mice; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel | 2015 |
[Study of the relationship among expression of Survivin and MRP and the drug resistance in human nasopharyngeal carcinoma].
Topics: Antineoplastic Agents; Carcinoma; Cisplatin; Drug Resistance, Neoplasm; Fluorouracil; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Lymphatic Metastasis; Multidrug Resistance-Associated Proteins; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Nasopharynx; Paclitaxel; Survivin; Vincristine | 2015 |
Nasopharyngeal carcinoma with bone marrow metastasis: positive response to weekly paclitaxel chemotherapy.
Topics: Bone Marrow Neoplasms; Carcinoma; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Paclitaxel | 2015 |
Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours.
Topics: Carcinoma; Cell Line, Tumor; Cisplatin; Culture Media; Drug Screening Assays, Antitumor; Female; Gene Expression Profiling; Heterografts; Humans; Ovarian Neoplasms; Paclitaxel; Phenotype | 2015 |
PCF Chemotherapy Combined with Surgical Treatment of Late Gastric Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Female; Fluorouracil; Gastrectomy; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prospective Studies; Risk Factors; Stomach Neoplasms; Time Factors; Treatment Outcome | 2014 |
A microengineered pathophysiological model of early-stage breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Cell Culture Techniques; Cell Survival; Cells, Cultured; Extracellular Matrix; Female; Genes, Reporter; Humans; Mammary Glands, Human; Microfluidic Analytical Techniques; Models, Biological; Paclitaxel; Tumor Microenvironment | 2015 |
Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Transport; Capillary Permeability; Carcinoma; Cell Line, Tumor; Cells, Cultured; Drug Delivery Systems; Endosomes; Endothelium, Vascular; Human Umbilical Vein Endothelial Cells; Humans; Infusions, Intravenous; Mice, Nude; Microinjections; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Serum Albumin; Serum Albumin, Human; Tissue Distribution; Tubulin Modulators; Xenograft Model Antitumor Assays | 2015 |
Subcutaneous administration of paclitaxel in dogs with cancer: A preliminary study.
Topics: Animals; Carcinoma; Dog Diseases; Dogs; Female; Injections, Subcutaneous; Lymphoma; Male; Mastocytoma; Paclitaxel; Sarcoma | 2015 |
MiR-218 inhibits HMGB1-mediated autophagy in endometrial carcinoma cells during chemotherapy.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Phytogenic; Autophagy; Binding Sites; Carcinoma; Cell Line, Tumor; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; HMGB1 Protein; Humans; MicroRNAs; Paclitaxel; Signal Transduction; Transfection; Up-Regulation | 2015 |
Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Multivariate Analysis; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Risk Factors; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome; Urologic Neoplasms; Urothelium | 2016 |
Integrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: Analysis of the androgen receptor.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Inhibitory Concentration 50; Male; Oligonucleotide Array Sequence Analysis; Oligonucleotides; Ovarian Neoplasms; Paclitaxel; Phenotype; Polymerase Chain Reaction; Prostatic Neoplasms; Receptors, Androgen; RNA Interference; Transcription Factors; Transcriptome; Up-Regulation | 2015 |
Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Case-Control Studies; Doxorubicin; Female; Hand-Foot Syndrome; Hematologic Diseases; Humans; Leukocyte Count; Male; Middle Aged; Monocytes; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols; Retrospective Studies; Sarcoma; Stomatitis; Thymus Neoplasms; Young Adult | 2015 |
Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Paclitaxel; Prognosis; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome | 2016 |
Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cytoreduction Surgical Procedures; Female; Hospitals, High-Volume; Humans; Hyperthermia, Induced; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult | 2016 |
Amplification of chromosome 8q21-qter associated with the acquired paclitaxel resistance of nasopharyngeal carcinoma cells.
Topics: Angiopoietin-1; Antineoplastic Agents, Phytogenic; Blotting, Western; Carcinoma; Cell Line, Tumor; Chromosomes, Human, Pair 8; Comparative Genomic Hybridization; Drug Resistance, Neoplasm; Gene Amplification; Gene Expression Profiling; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Real-Time Polymerase Chain Reaction; Transcriptome | 2015 |
A patient with gastric cancer with peritoneal carcinomatosis treated with intraperitoneal chemotherapy who survived more than 5 years receiving repeated laparoscopic examinations: a case report.
Topics: Antineoplastic Agents, Phytogenic; Asian People; Carcinoma; Drug Administration Schedule; Female; Gastrectomy; Humans; Injections, Intraperitoneal; Laparoscopy; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Treatment Outcome | 2016 |
Evaluation of expansile nanoparticle tumor localization and efficacy in a cancer stem cell-derived model of pancreatic peritoneal carcinomatosis.
Topics: Animals; Carcinoma; Disease Models, Animal; Drug Delivery Systems; Humans; Nanoparticles; Neoplastic Stem Cells; Paclitaxel; Pancreatic Neoplasms; Peritoneum; Rats; Rhodamines; Xenograft Model Antitumor Assays | 2016 |
[Pacilitaxel induces human nasopharyngeal carcinoma cell line CNE2 apoptosis and growth inhibition by suppressing PI3K/AKT/p53 signaling pathway].
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma; Cell Line, Tumor; Flow Cytometry; Humans; Membrane Potentials; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Suppressor Protein p53 | 2015 |
Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Female; Humans; Male; Middle Aged; Paclitaxel; Retrospective Studies; Salivary Gland Neoplasms; Salivary Glands; Treatment Outcome | 2016 |
Ionizing radiation promotes advanced malignant traits in nasopharyngeal carcinoma via activation of epithelial-mesenchymal transition and the cancer stem cell phenotype.
Topics: Antineoplastic Agents; Cadherins; Carcinoma; Cell Line, Tumor; Cell Movement; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins c-myc; Radiation, Ionizing; Receptors, G-Protein-Coupled; Vimentin | 2016 |
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for gynecological malignancies: a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cohort Studies; Cytoreduction Surgical Procedures; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Sarcoma; Survival Rate; Treatment Outcome; Uterine Neoplasms; Young Adult | 2016 |
Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy?
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Carboplatin; Carcinoma; Carcinoma, Endometrioid; Cohort Studies; Cytoreduction Surgical Procedures; Epirubicin; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies | 2016 |
The natural secolignan peperomin E induces apoptosis of human gastric carcinoma cells via the mitochondrial and PI3K/Akt signaling pathways in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Benzodioxoles; Carcinoma; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mitochondria; Neoplasm Transplantation; Oncogene Protein v-akt; Paclitaxel; Phosphatidylinositol 3-Kinases; Signal Transduction; Stomach Neoplasms | 2016 |
Silencing Op18/stathmin by RNA Interference Promotes the Sensitivity of Nasopharyngeal Carcinoma Cells to Taxol and High-Grade Differentiation of Xenografted Tumours in Nude Mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Combined Modality Therapy; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Grading; Paclitaxel; Random Allocation; RNA Interference; RNAi Therapeutics; Stathmin; Xenograft Model Antitumor Assays | 2016 |
Glaucarubinone sensitizes KB cells to paclitaxel by inhibiting ABC transporters via ROS-dependent and p53-mediated activation of apoptotic signaling pathways.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Transporters; Carcinoma; Cell Cycle; Cell Proliferation; Cell Survival; Chromatin; DNA Fragmentation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glaucarubin; Humans; KB Cells; Lymphocytes; Membrane Potential, Mitochondrial; Molecular Docking Simulation; Mouth Neoplasms; Paclitaxel; Reactive Oxygen Species; Signal Transduction; Tumor Suppressor Protein p53 | 2016 |
A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Cisplatin; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Prognosis; Re-Irradiation; Treatment Outcome | 2016 |
Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.
Topics: Aminosalicylic Acids; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; CCAAT-Enhancer-Binding Protein-delta; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Multidrug Resistance-Associated Protein 2; Paclitaxel; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Urinary Bladder Neoplasms; Urothelium | 2017 |
Next generation deep sequencing identified a novel lncRNA n375709 associated with paclitaxel resistance in nasopharyngeal carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Drug Resistance, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Polymerase Chain Reaction; RNA, Long Noncoding; Transfection | 2016 |
[Radiotherapy of cervix and endometrial carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Dose Fractionation, Radiation; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymphatic Irradiation; Lymphatic Metastasis; Organoplatinum Compounds; Organs at Risk; Paclitaxel; Radiation Injuries; Radiotherapy; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Radiotherapy, Image-Guided; Uterine Cervical Neoplasms | 2016 |
Value of intravoxel incoherent motion and dynamic contrast-enhanced MRI for predicting the early and short-term responses to chemoradiotherapy in nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Chemoradiotherapy; Contrast Media; Diffusion Magnetic Resonance Imaging; Dose Fractionation, Radiation; Female; Gadolinium DTPA; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm, Residual; Organoplatinum Compounds; Paclitaxel; Perfusion; Predictive Value of Tests; ROC Curve; Time Factors; Treatment Outcome | 2016 |
A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; DNA Mutational Analysis; Etoposide; Fatal Outcome; Genomics; Humans; Male; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Paclitaxel; Rare Diseases; Scalp; Xenograft Model Antitumor Assays | 2016 |
Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Infusions, Parenteral; Male; Middle Aged; Oxaloacetates; Paclitaxel; Peritoneal Neoplasms; Peritoneum; Stomach Neoplasms; Survival Rate | 2017 |
Rapid Changes in Circulating Tumor DNA in Serially Sampled Plasma During Treatment of Breast Cancer: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; DNA, Neoplasm; Fatal Outcome; Female; Frameshift Mutation; Genes, p53; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant | 2017 |
Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Discovery; Drug Resistance, Neoplasm; Exome; Female; Gene Expression Profiling; Heterografts; Humans; Mice; Mutation; Neoplasm Staging; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Proteomics; Tumor Suppressor Protein p53 | 2017 |
The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells.
Topics: Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Multidrug Resistance-Associated Proteins; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Paclitaxel; Signal Transduction | 2017 |
Are three additional cycles of chemotherapy useful in patients with advanced-stage epithelial ovarian cancer after a complete response to six cycles of intravenous adjuvant paclitaxel and carboplatin?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Treatment Outcome | 2008 |
[Pleomorphic carcinoma of the lung; report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Fatal Outcome; Female; Humans; Lung Neoplasms; Lymph Node Excision; Paclitaxel; Pneumonectomy; Treatment Outcome | 2008 |
Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Female; Humans; Incidence; Korea; Male; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Reproducibility of Results; Sensitivity and Specificity; Survival Analysis; Survival Rate; Treatment Outcome | 2008 |
Nuclear factor kappa B: a marker of chemotherapy for human stage IV gastric carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Disease-Free Survival; Electrophoretic Mobility Shift Assay; Female; Fluorouracil; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Stomach Neoplasms; Time Factors; Transcription Factor RelA; Treatment Outcome | 2008 |
Fibroblasts act as co-conspirators for chemotherapy resistance.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Death; Cell Line, Tumor; Cell Physiological Phenomena; Cisplatin; Coculture Techniques; Drug Resistance; Fibroblasts; Humans; Lung Neoplasms; Models, Biological; Necrosis; Paclitaxel; Signal Transduction | 2008 |
Differential effects of low and high doses of Taxol in anaplastic thyroid cancer cells: possible implication of the Pin1 prolyl isomerase.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; Humans; Necrosis; NIMA-Interacting Peptidylprolyl Isomerase; Paclitaxel; Peptidylprolyl Isomerase; Phosphorylation; Retinoblastoma Protein; Thyroid Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2008 |
Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication.
Topics: Adenomatous Polyposis Coli Protein; Adult; Aged; Antineoplastic Agents; beta Catenin; Carboplatin; Carcinoma; Cell Nucleus; Chemotherapy, Adjuvant; Female; Humans; Male; Middle Aged; Mutation; Paclitaxel; Urinary Bladder Neoplasms; Urothelium; Wnt Proteins | 2009 |
Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Sweden | 2008 |
Raft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cells.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Carcinoma; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Delivery Systems; Endocytosis; Glucose-6-Phosphate Isomerase; HCT116 Cells; HT29 Cells; Humans; Melanoma; Membrane Microdomains; Mice; Neoplasms; Paclitaxel; Receptors, Autocrine Motility Factor; Receptors, Cytokine; Ubiquitin-Protein Ligases | 2008 |
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Hypertension; Infusions, Intravenous; Letrozole; Mastectomy; Middle Aged; Nitriles; Paclitaxel; Prognosis; Proteinuria; Radiotherapy, Adjuvant; Triazoles | 2009 |
Systemic therapy developments and their effects regarding the current concept of recurrent ovarian carcinoma as a chronic disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chronic Disease; Cohort Studies; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel | 2009 |
Lipoamino acid prodrugs of paclitaxel: synthesis and cytotoxicity evaluation on human anaplastic thyroid carcinoma cells.
Topics: Amino Acids; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromatography, High Pressure Liquid; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Paclitaxel; Prodrugs; Spectroscopy, Fourier Transform Infrared; Thyroid Neoplasms | 2009 |
Effects of low and high concentrations of antitumour drug taxol in anaplastic thyroid cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Caspases; Cell Cycle; Cell Line, Tumor; Humans; Membrane Potential, Mitochondrial; Paclitaxel; Thyroid Neoplasms | 2009 |
Paclitaxel-induced ST-segment elevations.
Topics: Acute Coronary Syndrome; Administration, Sublingual; Angina Pectoris; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Biomarkers; Carcinoma; Coronary Angiography; Coronary Vasospasm; Creatine Kinase, MB Form; Electrocardiography; Female; Humans; Infusions, Intravenous; Middle Aged; Nitroglycerin; Ovarian Neoplasms; Paclitaxel; Stents; Treatment Outcome; Troponin T; Vasodilator Agents | 2009 |
Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Cell Hypoxia; Cell Survival; Drug Carriers; Female; HeLa Cells; Humans; Lactic Acid; Male; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Uterine Cervical Neoplasms | 2009 |
Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles.
Topics: Animals; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Drug Delivery Systems; Emulsions; Female; Humans; Mice; Microbubbles; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Phase Transition; Ultrasonics | 2009 |
Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Delivery Systems; Drug Synergism; Female; Follicle Stimulating Hormone, beta Subunit; Follicle Stimulating Hormone, Human; Humans; Mice; Mice, Inbred BALB C; Middle Aged; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Peptide Fragments; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Young Adult | 2009 |
Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Female; Genes, BRCA1; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Ovarian Neoplasms; Paclitaxel; Platinum Compounds | 2009 |
Paclitaxel-induced myocardial infarction in a case of carcinoma ovary.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Female; Heart Arrest; Humans; Middle Aged; Myocardial Infarction; Ovarian Neoplasms; Paclitaxel | 2009 |
Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Hypoxia; Cell Proliferation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Ovarian Neoplasms; Oxygen Consumption; Paclitaxel; RNA, Small Interfering; Tumor Cells, Cultured | 2010 |
Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Adhesion; Cell Survival; Cisplatin; Dexamethasone; Drug Resistance, Neoplasm; Extracellular Matrix; Female; Gene Expression Regulation, Neoplastic; Humans; Integrin alpha4beta1; Integrin alpha5beta1; Integrin beta1; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Cells, Cultured | 2010 |
TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.
Topics: Carcinoma; Cell Proliferation; Cell Survival; Cytokines; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lipopolysaccharides; Myeloid Differentiation Factor 88; NF-kappa B; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Toll-Like Receptor 4; Tumor Cells, Cultured; Tumor Escape; Up-Regulation | 2009 |
[Resveratrol increases sensitivity of CNE2 cells to chemotherapeutic drugs under hypoxia].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Down-Regulation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Multidrug Resistance-Associated Proteins; Nasopharyngeal Neoplasms; Paclitaxel; Resveratrol; Stilbenes | 2009 |
Inhibition of human gastric carcinoma cell growth in vitro and in vivo by cladosporol isolated from the paclitaxel-producing strain Alternaria alternata var. monosporus.
Topics: Alternaria; Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Naphthalenes; Neoplasms; Paclitaxel; Plant Bark; Stomach Neoplasms; Taxus; Transplantation, Heterologous | 2009 |
Does paclitaxel-carboplatin chemotherapy in a dose-dense regimen enhance survival of BRCA-related ovarian cancer patients?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carboplatin; Carcinoma; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Female; Genetic Predisposition to Disease; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2009 |
[A case of meningeal carcinomatosis of lung adenocarcinoma well controlled by re-treatment with gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Drug Resistance, Neoplasm; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Meningeal Neoplasms; Mutation; Paclitaxel; Quinazolines | 2009 |
Alteration in TWIST expression: possible role in paclitaxel-induced apoptosis in human laryngeal carcinoma Hep-2 cell line.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma; Cell Line, Tumor; Flow Cytometry; Gene Expression; Humans; Laryngeal Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Twist-Related Protein 1 | 2009 |
Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma; Cohort Studies; Female; Health Status; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Prognosis; Retrospective Studies; Survival Analysis; Task Performance and Analysis | 2010 |
Resolution of menstrually related migraine following aggressive treatment for breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Estrogens; Female; Humans; Menstrual Cycle; Menstruation Disturbances; Migraine Disorders; Paclitaxel; Radiotherapy; Selective Estrogen Receptor Modulators; Tamoxifen | 2010 |
Reversal of taxol resistance by cisplatin in nasopharyngeal carcinoma by upregulating thromspondin-1 expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Humans; Nasopharyngeal Neoplasms; Paclitaxel; Repressor Proteins; Signal Transduction; Thrombospondin 1; Up-Regulation | 2010 |
Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Proliferation; Cell Survival; Drug Antagonism; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Ovarian Neoplasms; Paclitaxel; Secretory Leukocyte Peptidase Inhibitor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Breast Neoplasms; Carcinoma; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Sensitivity and Specificity | 2010 |
Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.
Topics: Biomarkers, Pharmacological; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Metabolome; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Paclitaxel; Proteomics; Taxoids; Tumor Cells, Cultured | 2010 |
[Combination chemotherapy with gemcitabine and paclitaxel in a hemodialysis patient with metastatic urothelial carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Gemcitabine; Humans; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Renal Dialysis; Urinary Bladder Neoplasms | 2010 |
Factors affecting the completion of intraperitoneal chemotherapy in women with ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Humans; Injections, Intraperitoneal; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Randomized Controlled Trials as Topic; Risk Factors; Withholding Treatment | 2010 |
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis: how much is it true?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Etoposide; Female; Humans; Paclitaxel; Preoperative Care; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2010 |
Sustained c-Jun-NH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Dedifferentiation; Cell Lineage; Cell Movement; Cell Survival; Cell Transformation, Neoplastic; Enzyme Activation; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Insulin Receptor Substrate Proteins; JNK Mitogen-Activated Protein Kinases; Mesoderm; Mice; Neoplasm Invasiveness; Paclitaxel; Proto-Oncogene Proteins c-fos; Transcription Factor AP-1; Up-Regulation | 2010 |
Neoadjuvant chemotherapy in advanced vulvar cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bleomycin; Carcinoma; Cisplatin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Portugal; Retrospective Studies; Survival Rate; Treatment Outcome; Vulvar Neoplasms | 2010 |
Complete response of anaplastic pancreatic carcinoma to paclitaxel treatment selected by chemosensitivity testing.
Topics: Adenosine Triphosphate; Biopsy, Needle; Carcinoma; Cell Survival; Drug Screening Assays, Antitumor; Endosonography; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Tubulin Modulators | 2010 |
[Clinical experience in the treatment of ovarian carcinoma and the role of the nurse during the hemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Nurse-Patient Relations; Ovarian Neoplasms; Paclitaxel; Young Adult | 2009 |
Metastatic apocrine carcinoma of the scalp: prolonged response to systemic chemotherapy.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Drug Administration Schedule; Fatal Outcome; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Paclitaxel; Scalp; Sweat Gland Neoplasms; Young Adult | 2010 |
Lymphoepithelioma-like carcinoma of the ovary.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Female; Humans; Lymphocytes; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2011 |
Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Analysis | 2010 |
The prognostic significance of optimal debulking in the setting of a complete clinical response for advanced ovarian carcinoma patients receiving maintenance chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma; Disease-Free Survival; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2011 |
Scleroderma-like cutaneous lesions induced by paclitaxel and carboplatin for ovarian carcinoma, not a single course of carboplatin, but re-induced and worsened by previously administrated paclitaxel.
Topics: Aged; Carboplatin; Carcinoma; Female; Humans; Ovarian Neoplasms; Paclitaxel; Scleroderma, Localized | 2010 |
Covalent linkage of nanodiamond-paclitaxel for drug delivery and cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carbon; Carcinoma; Cell Line, Tumor; Cell Survival; Humans; Lung Neoplasms; Mice; Mice, SCID; Nanoparticles; Paclitaxel | 2010 |
Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Female; Humans; Multicenter Studies as Topic; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Quality of Life; Risk Factors; Treatment Outcome | 2010 |
Advanced age is a significant determinant of poor prognosis in patients treated with surgery plus postoperative radiotherapy for endometrial cancer.
Topics: Age Factors; Aged; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Hysterectomy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Treatment Outcome | 2010 |
The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal carcinomatosis model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Carriers; Female; Humans; Hydrogels; Luciferases, Firefly; Luminescent Measurements; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Peritoneal Neoplasms; Polymers; Stomach Neoplasms; Temperature; Time Factors; Transfection; Xenograft Model Antitumor Assays | 2012 |
Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Signal Transduction; STAT3 Transcription Factor; Validation Studies as Topic; Xenograft Model Antitumor Assays | 2010 |
Chemoresistance testing of human ovarian cancer cells and its in vitro model.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Gemcitabine; Humans; Models, Biological; Ovarian Neoplasms; Paclitaxel; Topotecan | 2010 |
Highly stable, ligand-clustered "patchy" micelle nanocarriers for systemic tumor targeting.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Drug Carriers; Drug Stability; Humans; Injections, Intravenous; Ligands; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Nanomedicine; Nanoparticles; Paclitaxel; Xenograft Model Antitumor Assays | 2011 |
Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Doxorubicin; Female; Humans; Mice; Mice, Nude; Paclitaxel; Permeability; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
E phage gene transfection enhances sensitivity of lung and colon cancer cells to chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Carcinoma; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genetic Therapy; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Paclitaxel; Transfection; Viral Proteins | 2010 |
The performance of expansile nanoparticles in a murine model of peritoneal carcinomatosis.
Topics: Albumins; Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Survival; Female; Humans; Mesothelioma; Mice; Mice, Nude; Microscopy, Confocal; Microscopy, Electron, Scanning; Paclitaxel; Peritoneal Neoplasms | 2011 |
The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma; Disease-Free Survival; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Multigene Family; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Tubulin | 2011 |
Optimizing dose-dense regimens for early-stage breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Erythropoietin; Female; Humans; Mastectomy; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Recombinant Proteins; Survival Analysis | 2010 |
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
[A case of advanced gastric cancer resistant to S-1 successfully treated with weekly administration of paclitaxel].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2010 |
Penetration of paclitaxel and 5-fluorouracil in multicellular layers of human colorectal cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fluorouracil; HT29 Cells; Humans; Models, Biological; Paclitaxel; Transcytosis | 2011 |
Early-stage ovarian cancer management: still a challenge.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Combined Modality Therapy; Female; Gynecologic Surgical Procedures; Humans; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Recurrence; Treatment Outcome | 2011 |
Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; Doxorubicin; Female; Gentamicins; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Paclitaxel; Retrospective Studies; Treatment Failure; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urothelium; Vinblastine | 2011 |
Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines.
Topics: Adenoviridae Infections; Adenovirus E1A Proteins; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bacterial Proteins; Carcinoma; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Coxsackie and Adenovirus Receptor-Like Membrane Protein; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, myc; Head and Neck Neoplasms; Humans; Neoplasms, Squamous Cell; Oncolytic Virotherapy; Oncolytic Viruses; Paclitaxel; Receptors, Virus; RNA, Messenger; S Phase; Squamous Cell Carcinoma of Head and Neck; Streptolysins; Telomerase | 2011 |
Effects of Paclitaxel and combination of the drug with radiation therapy in an in vivo model of anaplastic thyroid carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Prospective Studies; Treatment Outcome | 2011 |
PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Drug Carriers; Drug Compounding; Emulsions; Inhibitory Concentration 50; Liposomes; Male; Mice; Mice, Inbred BALB C; Nanospheres; Paclitaxel; Polyethylene Glycols; Rats; Rats, Wistar; Survival Analysis; Tissue Distribution; Tumor Burden | 2011 |
Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Carcinoma; Cell Line, Tumor; Cisplatin; Flow Cytometry; Fluorouracil; Glycoproteins; Humans; Laryngeal Neoplasms; Neoplasm Proteins; Neoplastic Stem Cells; Paclitaxel; Peptides; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Second-line chemotherapy in patients with primary unknown cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Failure; Treatment Outcome | 2011 |
Successful management of metastatic urothelial carcinoma with gemcitabine and Paclitaxel chemotherapy in a hemodialysis patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Renal Dialysis; Time Factors; Tomography, X-Ray Computed; Urinary Bladder Neoplasms; Urothelium | 2011 |
Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Retrospective Studies; Therapeutics; Thymus Neoplasms | 2011 |
[Methylation status of RASSF1A and clinical efficacy of neoadjuvant therapy in patients with advanced epithelial ovarian cancer].
Topics: Adult; Aged; Carcinoma; Cisplatin; DNA Methylation; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Promoter Regions, Genetic; Tumor Suppressor Proteins; Young Adult | 2011 |
The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclooxygenase 1; Cyclooxygenase 2; Female; Humans; Immunologic Factors; Lymphocytes, Tumor-Infiltrating; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis | 2011 |
Technique of intraperitoneal chemotherapy using veress needle in patients with ovarian cancer.
Topics: Antineoplastic Agents; Carcinoma; Cisplatin; Female; Humans; Infusions, Parenteral; Needles; Ovarian Neoplasms; Paclitaxel | 2011 |
Inhibition of α folate receptor resulting in a reversal of taxol resistance in nasopharyngeal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Resistance, Neoplasm; Folate Receptor 1; Folic Acid; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2012 |
Incidental detection of breast apocrine carcinoma via endometrial cytology.
Topics: Apocrine Glands; Breast Neoplasms; Carcinoma; Endometrium; Female; Humans; Laparotomy; Lymph Node Excision; Mastectomy, Modified Radical; Middle Aged; Paclitaxel; Uterine Neoplasms | 2011 |
Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma?
Topics: Adult; Aged; Carcinoma; Cisplatin; Disease-Free Survival; Drug Therapy; Female; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Treatment Outcome; Urothelium | 2013 |
Investigating the relative efficacies of combination chemotherapy of paclitaxel/carboplatin, with or without anthracycline, for endometrial carcinoma.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Japan; Middle Aged; Paclitaxel; Recurrence; Remission Induction; Retrospective Studies | 2012 |
Concurrent chemoradiotherapy for locoregionally advanced salivary gland malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Retrospective Studies; Salivary Gland Neoplasms | 2012 |
Salvage chemotherapy for ovarian carcinoma recurring during or after consolidation chemotherapy with paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Salvage Therapy; Time Factors; Treatment Outcome | 2011 |
Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytostatic Agents; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Mice; Mice, SCID; Neural Cell Adhesion Molecule L1; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms | 2012 |
[A case of bone marrow carcinomatosis from breast cancer treated with weekly Paclitaxel].
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma; Female; Humans; Paclitaxel | 2012 |
TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer.
Topics: Adult; Aged; Carcinoma; Cell Line, Tumor; DNA Methylation; DNA, Neoplasm; Drug Resistance, Neoplasm; Epigenesis, Genetic; Extracellular Matrix Proteins; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Promoter Regions, Genetic; Transforming Growth Factor beta | 2012 |
A risk-adapted strategy of adjuvant paclitaxel/carboplatin in early-stage ovarian cancer: time-dependent effect of 4 versus 6 cycles on outcome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Risk Factors; Treatment Outcome; Young Adult | 2011 |
Radiofrequency ablation combined with systemic chemotherapy in nasopharyngeal carcinoma liver metastases improves response to treatment and survival outcomes.
Topics: Carcinoma; Catheter Ablation; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies | 2012 |
Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma.
Topics: Animals; Carcinoma; Cell Line, Tumor; Combined Modality Therapy; Female; Genetic Therapy; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays | 2012 |
Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Chi-Square Distribution; Female; Gynecologic Surgical Procedures; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Norway; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Proportional Hazards Models; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2012 |
Effects of Agaricus blazei Murill extract on sensitivity to chemotherapeutic agents in HeLa cells and its resistant sublines.
Topics: Agaricus; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Products; Carcinoma; Cell Proliferation; Cisplatin; Dietary Supplements; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; HeLa Cells; Humans; Paclitaxel; Uterine Cervical Neoplasms | 2008 |
Prognosis of primary peritoneal carcinoma: effect of cytoreductive surgery combined with neoadjuvant chemotherapy after laparoscopic diagnosis and evaluation: a multi-center trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Hysterectomy; Kaplan-Meier Estimate; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Ovariectomy; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Salpingectomy | 2012 |
Efficient inhibition of colorectal peritoneal carcinomatosis by drug loaded micelles in thermosensitive hydrogel composites.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Drug Carriers; Erythrocytes; Fluorouracil; Hydrogel, Polyethylene Glycol Dimethacrylate; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Peritoneal Neoplasms; Polyesters; Polyethylene Glycols; Rabbits; Temperature | 2012 |
Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma; Cell Differentiation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Etoposide; Female; Fluorescent Antibody Technique, Indirect; Humans; Mesenchymal Stem Cells; Neoplasm Proteins; Neoplastic Stem Cells; Organic Chemicals; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2012 |
Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Pelvis; Peritoneal Neoplasms; Proportional Hazards Models; Retrospective Studies | 2012 |
Clinical trial of weekly paclitaxel chemotherapy for papillary thyroid carcinoma with squamous cell carcinoma component.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma; Carcinoma, Papillary; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Paclitaxel; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2012 |
Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Retrospective Studies | 2012 |
Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Disease Progression; Female; Humans; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Vascular Endothelial Growth Factor A | 2012 |
[Synergistic interactions of TRAIL and paclitaxel on the nasopharyngeal carcinoma cell lines in vitro].
Topics: Apoptosis; Carcinoma; Cell Line, Tumor; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2012 |
[Study of sequence-dependent in vitro effects of zoledronic acid and paclitaxel upon human nasopharyngeal carcinoma cell line HNE1].
Topics: Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Humans; Imidazoles; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Zoledronic Acid | 2012 |
Genomic methylation profiling combined with gene expression microarray reveals the aberrant methylation mechanism involved in nasopharyngeal carcinoma taxol resistance.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Azacitidine; Carcinoma; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Gene Expression Profiling; Genomics; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel | 2012 |
Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Division; Cell Line, Tumor; Chemoradiotherapy; G2 Phase Cell Cycle Checkpoints; HEK293 Cells; HMGN2 Protein; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Organometallic Compounds; Paclitaxel; Peritoneal Neoplasms; Protein Structure, Tertiary; Radiopharmaceuticals; Treatment Outcome | 2012 |
GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Extracellular Matrix Proteins; Female; Genetic Predisposition to Disease; Genome-Wide Association Study; GPI-Linked Proteins; Humans; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Reproducibility of Results; Retrospective Studies; Scandinavian and Nordic Countries; Validation Studies as Topic | 2013 |
Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Carriers; Fluorescein-5-isothiocyanate; Injections, Intravenous; Injections, Subcutaneous; Lung Neoplasms; Mice; Mice, Inbred C57BL; Micelles; Paclitaxel; Polyesters; Polyethylene Glycols; Tissue Distribution; Zebrafish | 2012 |
Metastatic human papillomavirus-positive nasopharyngeal carcinoma with an unusual pattern of aggressive hematogenous spread.
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biomarkers, Tumor; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Diagnosis, Differential; Drug Administration Schedule; Fatal Outcome; Fluorodeoxyglucose F18; Fluorouracil; Heart Failure; Humans; Hypertension, Pulmonary; Hypoxia; Immunohistochemistry; Laryngoscopy; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Papillomavirus Infections; Positron-Emission Tomography; Pulmonary Artery; Radiopharmaceuticals; Radiotherapy, Intensity-Modulated; Randomized Controlled Trials as Topic; Thrombophilia; Tomography, X-Ray Computed; Vascular Neoplasms | 2012 |
Possible involvement of glycolipids in anticancer drug resistance of human ovarian serous carcinoma-derived cells.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Cell Survival; Cholesterol; Cisplatin; Drug Resistance, Neoplasm; Female; Glycolipids; Glycosyltransferases; Humans; Inhibitory Concentration 50; Morpholines; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; Paclitaxel; Phospholipids; Sialyltransferases | 2012 |
Transfer of carboplatin and paclitaxel into breast milk.
Topics: Adult; Antineoplastic Agents; Carboplatin; Carcinoma; Carcinoma, Papillary; Chromatography, High Pressure Liquid; Female; Humans; Lactation; Milk, Human; Paclitaxel; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2012 |
Sgk1 enhances RANBP1 transcript levels and decreases taxol sensitivity in RKO colon carcinoma cells.
Topics: Apoptosis; Carcinoma; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Immediate-Early Proteins; Nuclear Proteins; Paclitaxel; Phosphorylation; Protein Serine-Threonine Kinases; Proteomics; RNA Interference; Sp1 Transcription Factor; Transcription, Genetic | 2013 |
Cytoreductive surgery and intraoperative administration of paclitaxel-loaded expansile nanoparticles delay tumor recurrence in ovarian carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Cell Membrane Permeability; Cell Survival; Drug Carriers; Ethanol; Female; Humans; Mice; Mice, Nude; Nanoparticles; Neoplasm Recurrence, Local; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Vehicles; Polyethylene Glycols | 2013 |
Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines.
Topics: Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cisplatin; Heterocyclic Compounds, 3-Ring; Humans; Mitogen-Activated Protein Kinases; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases | 2013 |
Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Drug Combinations; Female; Genetic Therapy; Imines; Mice; Mice, Inbred BALB C; Mice, Nude; Nanocapsules; Paclitaxel; Poloxalene; Polyethylene Glycols; Polyethylenes; RNA, Small Interfering; Transfection; Treatment Outcome; Vitamin E | 2013 |
[Effect of low-molecular-weight heparin combined with paclitaxel on the invasiveness and migration of nasopharyngeal carcinoma cells in vitro].
Topics: Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Glucuronidase; Heparin Lyase; Heparin, Low-Molecular-Weight; Humans; Matrix Metalloproteinase 9; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Tissue Inhibitor of Metalloproteinase-1 | 2012 |
Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; Cisplatin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Outcome Assessment, Health Care; Paclitaxel; Palliative Care; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Young Adult | 2013 |
Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prognosis; Receptor, ErbB-2; Survival Analysis; Urinary Bladder Neoplasms | 2002 |
Multidrug resistance gene-1 (Pgp) expression in epithelial ovarian malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Second-Look Surgery; Survival Analysis; Turkey | 2002 |
Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome | 2002 |
[Reinduction of paclitaxel therapy after a successfully treated hypersensitivity reaction].
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Eruptions; Drug Hypersensitivity; Female; Humans; Ovarian Neoplasms; Paclitaxel | 2002 |
Cytotoxicity of combinations of IFN-beta and chemotherapeutic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Division; Cisplatin; Deoxycytidine; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Interferon-beta; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |
Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Ascites; Carcinoma; Cell Division; Combined Modality Therapy; Endothelial Growth Factors; Female; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Mice, Nude; Neutralization Tests; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
[Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Mitomycins; Multicenter Studies as Topic; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Radiotherapy; Remission Induction; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 2002 |
Quantification of human Alu sequences by real-time PCR--an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants.
Topics: Alu Elements; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Colonic Neoplasms; DNA, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, SCID; Neoplasms; Paclitaxel; Pancreatic Neoplasms; Piperazines; Polymerase Chain Reaction; Pyrimidines; Sensitivity and Specificity; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: pilot study.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma; Cell Division; Cell Nucleus; Clone Cells; Drug Resistance, Neoplasm; Female; Humans; Ki-67 Antigen; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pilot Projects | 2003 |
Synthesis and high content cell-based profiling of simplified analogues of the microtubule stabilizer (+)-discodermolide.
Topics: Alkanes; Antineoplastic Agents; Binding Sites; Carbamates; Carbon; Carcinoma; Cell Division; Dose-Response Relationship, Drug; Gene Library; HeLa Cells; Humans; Lactones; Microtubules; Models, Chemical; Paclitaxel; Phosphorylation; Pyrones; Signal Transduction; Spindle Apparatus; Tubulin; Tumor Cells, Cultured | 2002 |
Cytotoxicity of paclitaxel or cisplatin on carcinoma cell lines is not inhibited by leukemia inhibitory factor (LIF).
Topics: Antigens, CD; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Differentiation; Cell Division; Cisplatin; Cytokine Receptor gp130; Dose-Response Relationship, Drug; Growth Inhibitors; Humans; Interleukin-6; Leukemia Inhibitory Factor; Leukemia Inhibitory Factor Receptor alpha Subunit; Lymphokines; Membrane Glycoproteins; Paclitaxel; Receptors, Cytokine; Receptors, OSM-LIF; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tumor Cells, Cultured | 2002 |
The effect of platinum-based combination chemotherapy on the lymph nodes in advanced-stage epithelial ovarian cancer: does it decrease the incidence of lymph node involvement?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2002 |
Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Carcinoma; Combined Modality Therapy; Docetaxel; Female; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Intraoperative Care; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids; Tissue Distribution | 2003 |
Advanced ureteral cancer with complete remission achieved by taxan containing systemic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Tomography, X-Ray Computed; Treatment Outcome; Ureteral Neoplasms; Vinblastine | 2003 |
Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Division; Dose-Response Relationship, Drug; Humans; Male; Mice; Mice, Nude; Paclitaxel; Stilbenes; Thyroid Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Unknown primary carcinoma: a feasibility assessment of combination chemotherapy with cisplatin and docetaxel.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Diarrhea; Docetaxel; Drug Hypersensitivity; Feasibility Studies; Female; Humans; Male; Middle Aged; Nausea; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel; Patient Compliance; Prospective Studies; Severity of Illness Index; Taxoids; Treatment Outcome; Vomiting | 2003 |
Paclitaxel induces apoptosis in human gastric carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Carcinoma; Humans; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms; Tumor Cells, Cultured | 2003 |
IDN 5390: an oral taxane candidate for protracted treatment schedules.
Topics: Administration, Oral; Animals; Brain Neoplasms; Bridged-Ring Compounds; Carcinoma; Colonic Neoplasms; Drug Administration Schedule; Female; Glioblastoma; Humans; Injections, Subcutaneous; Mice; Mice, Nude; Neoplasms, Experimental; Ovarian Neoplasms; Paclitaxel; Taxoids; Transplantation, Heterologous | 2003 |
The significance of cardiac doses received during chemoradiation of oesophageal and gastro-oesophageal junctional cancers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Heart; Humans; Male; Middle Aged; Paclitaxel; Radiation Injuries; Radiotherapy, Conformal; Retrospective Studies; Stroke Volume | 2003 |
Evaluation of the neurotoxicity of paclitaxel and carboplatin by current perception threshold in ovarian cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Sensory Thresholds | 2003 |
Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in platinum- and paclitaxel-resistant epithelial ovarian cancer: case reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Mitomycin; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Salvage Therapy; Sampling Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
[Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Administration Schedule; Erythropoietin; Female; Humans; Hungary; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Registries; Retrospective Studies; Survival Analysis; Treatment Outcome | 2003 |
EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Carcinoma; DNA Topoisomerases, Type II; DNA-Binding Proteins; Down-Regulation; Doxorubicin; Drug Delivery Systems; Drug Therapy, Combination; Epstein-Barr Virus Nuclear Antigens; Etoposide; Female; G2 Phase; Genetic Therapy; Humans; Kinetics; Mitosis; Ovarian Neoplasms; Paclitaxel; Receptor, ErbB-2; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2003 |
Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Carcinoma; Catechin; Cell Division; Cell Line, Tumor; Cyclin D1; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Genes, Reporter; Head and Neck Neoplasms; Humans; Immunoblotting; Luciferases; Paclitaxel; Phosphorylation; Prognosis; Promoter Regions, Genetic; Proto-Oncogene Proteins c-fos; Receptor, ErbB-2; Signal Transduction; Time Factors | 2003 |
Induction chemotherapy with paclitaxel and cisplatin and CT-based 3D radiotherapy in patients with advanced laryngeal and hypopharyngeal carcinomas--a possibility for organ preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Female; Humans; Hypopharyngeal Neoplasms; Imaging, Three-Dimensional; Laryngeal Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Radiation Injuries; Tomography, X-Ray Computed | 2003 |
Multiple effects of paclitaxel are modulated by a high c-myc amplification level.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Compartmentation; Cell Division; Cell Nucleus; Colonic Neoplasms; Eukaryotic Cells; Gene Amplification; Gene Dosage; Genes, myc; Humans; Neoplasms; Paclitaxel; Phosphorylation; Tumor Cells, Cultured; Up-Regulation | 2003 |
Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10.
Topics: Aged; Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma; Carcinoma, Papillary; Cell Death; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Humans; Interleukin-10; Interleukin-4; Middle Aged; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Thyroid Gland; Thyroid Neoplasms | 2003 |
Taxanes synergize with the bispecific antibody MDXH447 to enhance antibody-dependent cell-mediated cytotoxicity.
Topics: Antibodies, Bispecific; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Interactions; ErbB Receptors; Paclitaxel; Receptors, IgG; Skin Neoplasms; Taxoids; Tumor Cells, Cultured | 2003 |
Granulocyte-macrophage colony stimulating factor prior to chemotherapy for advanced epithelial ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Probability; Prognosis; Prospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2003 |
Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Microtubule Proteins; Ovarian Neoplasms; Paclitaxel; Phosphoproteins; Stathmin | 2003 |
Weekly administration of paclitaxel attenuated rectal stenosis caused by multiple peritoneal recurrence 8 years after the resection of gastric carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Constriction, Pathologic; Drug Administration Schedule; Female; Gastrectomy; Humans; Paclitaxel; Peritoneal Neoplasms; Rectal Diseases; Recurrence; Stomach Neoplasms; Time Factors; Treatment Outcome | 2003 |
In vitro exposure to paclitaxel modulates integrin expression by human T lymphocytes and inhibits T cell adhesion to breast carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Cell Adhesion; Cell Line, Tumor; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Integrins; Jurkat Cells; Paclitaxel; T-Lymphocytes | 2004 |
Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Combined Modality Therapy; Female; Genetic Therapy; Glycerol; Interleukin-12; Lipids; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Paclitaxel; Plasmids; Polyethyleneimine | 2004 |
Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Breast Neoplasms; Cancer Vaccines; Carcinoma; Cell Line; Combined Modality Therapy; Disease Models, Animal; Doxorubicin; Drug Administration Schedule; Epitopes; Female; Humans; Interferon-gamma; Lymphocyte Activation; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Paclitaxel; Receptor, ErbB-2; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; Vaccines, DNA | 2004 |
Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Gene Amplification; Genes, erbB-2; Humans; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
[Radical peritonectomy in 37 patients with stage II and III ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Female; Humans; Infusions, Parenteral; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneum; Retrospective Studies; Second-Look Surgery; Treatment Outcome | 2004 |
The effect of recombinant GM-CSF on IL-6 and TNF-alpha levels in epithelial ovarian cancer patients who received paclitaxel and cisplatinum: preliminary results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-6; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Probability; Prognosis; Prospective Studies; Recombinant Proteins; Sensitivity and Specificity; Statistics, Nonparametric; Treatment Outcome; Tumor Necrosis Factor-alpha | 2004 |
Weekly paclitaxel combined with local hyperthermia in the therapy of breast cancer locally recurrent after mastectomy--a pilot experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Carcinoma, Ductal; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyperthermia, Induced; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Palliative Care; Treatment Outcome | 2004 |
[Multidisciplinary treatment of recurrent epithelial ovarian carcinoma and prognostic analysis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2004 |
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Carcinoma, Papillary; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Quinazolines; Thyroid Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2004 |
Long term survival with adjuvant carboplatin, paclitaxel, and radiation therapy in anaplastic thyroid cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Combined Modality Therapy; Humans; Male; Paclitaxel; Thyroid Neoplasms; Thyroidectomy | 2005 |
Primary peritoneal carcinoma with acute renal failure: successful treatment with chemotherapy.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Female; Humans; Paclitaxel; Paraneoplastic Syndromes; Peritoneal Neoplasms; Renal Dialysis; Treatment Outcome | 2005 |
Bcl-2-associated X protein is the main mediator of manumycin a-induced apoptosis in anaplastic thyroid cancer cells.
Topics: Animals; Apoptosis; bcl-X Protein; Carcinoma; Cell Line, Tumor; Enzyme Inhibitors; Humans; Mice; Mice, Nude; Mitochondria; Paclitaxel; Polyenes; Polyunsaturated Alkamides; Proto-Oncogene Proteins c-bcl-2; Thyroid Neoplasms; Transplantation, Heterologous | 2005 |
HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Biomarkers; Breast Neoplasms; Camptothecin; Carcinoma; Colonic Neoplasms; Coloring Agents; Drug Interactions; Drug Resistance, Neoplasm; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Gene Expression Profiling; Humans; Lung Neoplasms; Paclitaxel; Potassium Channels, Voltage-Gated; Tetrazolium Salts; Thiazoles; Transfection; Vincristine | 2005 |
Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma; Cell Death; Cell Proliferation; Dose-Response Relationship, Drug; Endothelium, Vascular; ErbB Receptors; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Microcirculation; Microscopy, Fluorescence; Neoplasm Transplantation; Paclitaxel; Phosphorylation; Purines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms; Time Factors | 2005 |
[An autopsied case of metastatic endocrine carcinoma of the pancreas with primary site difficult to identify].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Male; Neoplasm Metastasis; Neoplasms, Unknown Primary; Paclitaxel; Pancreatic Neoplasms; Taxoids | 2005 |
[Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Luminescent Measurements; Middle Aged; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Sensitivity and Specificity | 2005 |
Modern management of recurrent ovarian carcinoma. A systematic approach to a chronic disease.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chronic Disease; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Secondary Prevention; Topotecan | 2005 |
Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma.
Topics: Acute Disease; Angina Pectoris; Anticoagulants; Antineoplastic Agents, Phytogenic; Bradycardia; Carcinoma; Electrocardiography; Female; Follow-Up Studies; Heparin; Humans; Middle Aged; Myocardial Ischemia; Nausea; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2005 |
Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carboplatin; Carcinoma; Caspase 2; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Interactions; Enzyme Activation; Female; Gemcitabine; Humans; Isoflavones; Mice; Ovarian Neoplasms; Paclitaxel; Proteasome Endopeptidase Complex; Transplantation, Heterologous | 2006 |
Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts.
Topics: Animals; Antibodies, Monoclonal; CA-125 Antigen; Carcinoma; Female; Humans; Immunoconjugates; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radioimmunotherapy; Transplantation, Heterologous; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2006 |
Papuloerythematous rash due to intralymphatic cutaneous metastasis of cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma; Head and Neck Neoplasms; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Lymphatic Metastasis; Lymphedema; Male; Middle Aged; Paclitaxel; Prednisolone; Respiratory Insufficiency; Skin; Skin Neoplasms; Thyroid Neoplasms | 2006 |
Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cell Hypoxia; Cell Movement; Cell Proliferation; Erythropoietin; Female; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Paclitaxel; Proto-Oncogene Proteins c-akt; Receptors, Erythropoietin; Recombinant Proteins; Xenograft Model Antitumor Assays | 2006 |
Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Female; Humans; Lymphatic Metastasis; Myoepithelioma; Paclitaxel; Treatment Outcome; Vulvar Neoplasms | 2006 |
Survivin and Granzyme B-induced apoptosis, a novel anticancer therapy.
Topics: Animals; Apoptosis; Artificial Gene Fusion; Carcinoma; Cell Proliferation; Combined Modality Therapy; Female; Genetic Therapy; Granzymes; Humans; Inhibitor of Apoptosis Proteins; Mice; Microtubule-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Promoter Regions, Genetic; Serine Endopeptidases; Survivin; Transfection | 2006 |
Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Polyethylene Glycols; Time Factors | 2006 |
Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Hyperthermia, Induced; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Prospective Studies; Radiotherapy; Sensitivity and Specificity; Treatment Outcome | 2006 |
Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Topics: Acetylation; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Caspase 3; Caspases; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Protein Processing, Post-Translational; Tumor Cells, Cultured; Vorinostat | 2006 |
Epithelial-myoepithelial carcinoma of the submandibular gland with symptomatic lung metastases treated with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Fatal Outcome; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Myoepithelioma; Neoplasms, Glandular and Epithelial; Paclitaxel; Radiotherapy Dosage; Submandibular Gland Neoplasms | 2006 |
Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: association between caveolin-1 expression and ABI-007.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Caveolin 1; Female; Humans; Paclitaxel; Patient Selection; Prognosis; Treatment Outcome | 2006 |
Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Humans; Injections, Intraperitoneal; Injections, Subcutaneous; Mesothelin; Mice; Mice, Nude; Paclitaxel; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2006 |
Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Carboplatin; Carcinoma; Cell Cycle Proteins; Cell Proliferation; Cell Survival; Doxorubicin; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Paclitaxel; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; Thyroid Neoplasms; Treatment Outcome; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vorinostat; Xenograft Model Antitumor Assays | 2006 |
Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992).
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carbohydrate Sequence; Carcinoma; Cell Line, Tumor; Chromatography, High Pressure Liquid; Colonic Neoplasms; Dextrans; Dose-Response Relationship, Drug; Humans; Injections, Intravenous; Male; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Molecular Weight; Neoplasm Transplantation; Paclitaxel; Tissue Distribution | 2007 |
Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; CD13 Antigens; Cell Line, Tumor; Female; Humans; Leucine; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Paclitaxel; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2007 |
[The results of ovarian cancer therapy in the Hungarian Centers in 2002-2003].
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brenner Tumor; Carboplatin; Carcinoma; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Humans; Hungary; Middle Aged; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Retrospective Studies; Treatment Outcome | 2006 |
[Anesthetic management for scheduled peritonectomy and hyperthermic intraperitoneal chemotherapy in 20 patients].
Topics: Adult; Aged; Analgesia, Epidural; Anesthesia, General; Anesthesia, Inhalation; Anesthesia, Intravenous; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colloids; Combined Modality Therapy; Crystalloid Solutions; Diuretics; Erythrocyte Transfusion; Female; Fever; Fluid Therapy; Fluorouracil; Humans; Hyperthermia, Induced; Hypotension; Intraoperative Complications; Isotonic Solutions; Male; Middle Aged; Mitomycin; Monitoring, Intraoperative; Paclitaxel; Peritoneal Neoplasms; Peritoneum; Plasma; Postoperative Complications; Prospective Studies; Vasoconstrictor Agents | 2006 |
High energy shock waves activate 5'-aminolevulinic Acid and increase permeability to Paclitaxel: antitumor effects of a new combined treatment on anaplastic thyroid cancer cells.
Topics: Aminolevulinic Acid; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Membrane Permeability; Cell Survival; Combined Modality Therapy; High-Energy Shock Waves; Humans; Paclitaxel; Photochemotherapy; Thyroid Neoplasms | 2007 |
Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinosarcoma; Disease-Free Survival; Dose-Response Relationship, Drug; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; North Carolina; Paclitaxel; Pilot Projects; Treatment Outcome; Utah; Uterine Cervical Neoplasms | 2007 |
Effect of paclitaxel on intracellular localization of c-Myc and P-c-Myc in prostate carcinoma cell lines.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Line, Tumor; Humans; Intracellular Fluid; Male; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Mas; Proto-Oncogene Proteins c-myc | 2007 |
[A case report of paclitaxel combined with carboplatin for poorly differentiated prostate cancer with renal failure].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Humans; Male; Paclitaxel; Prostatic Neoplasms; Renal Dialysis; Renal Insufficiency | 2007 |
[Clinical efficacy of biweekly paclitaxel and S-1 regimen for 14 gastric cancer patients with liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Rate; Tegafur | 2007 |
Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Carboplatin; Carcinoma; Cell Line, Tumor; Cell Shape; Endothelial Cells; Humans; Immunohistochemistry; Mice; Mice, Nude; Microscopy, Electron, Transmission; Neoplasm Transplantation; Paclitaxel; Polyenes; Polyunsaturated Alkamides; Stilbenes; Thyroid Neoplasms; Transplantation, Heterologous | 2007 |
XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cisplatin; Esophageal Neoplasms; Etoposide; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Paclitaxel; RNA Interference; X-Linked Inhibitor of Apoptosis Protein | 2007 |
Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelium; Female; Humans; Mesoderm; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel | 2007 |
Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Colonic Neoplasms; Combined Modality Therapy; Genetic Vectors; Mice; Mice, Inbred BALB C; Oncolytic Virotherapy; Paclitaxel; Peritoneal Neoplasms; Simplexvirus | 2007 |
Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Weight; Carboplatin; Carcinoma; Cisplatin; Clinical Trials, Phase III as Topic; Cystadenocarcinoma, Serous; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; United States; Weight Gain; Weight Loss | 2007 |
Endodermal sinus tumor of the paranasal sinuses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Endodermal Sinus Tumor; Humans; Ifosfamide; Magnetic Resonance Imaging; Male; Middle Aged; Nasal Obstruction; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Paclitaxel; Paranasal Sinus Neoplasms; Radiotherapy, Adjuvant; Skull Base | 2008 |
The characteristics of Hep-2 cell with multiple drug resistance induced by Taxol.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma; Cell Cycle; Cell Line, Tumor; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Dyes; Fluorouracil; Gemcitabine; Humans; Laryngeal Neoplasms; Multidrug Resistance-Associated Proteins; Paclitaxel; Rhodamine 123 | 2007 |
Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines.
Topics: Acetylation; Acetyltransferases; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Enzyme Inhibitors; Humans; Paclitaxel; Thyroid Neoplasms; Tubulin; Valproic Acid | 2007 |
Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Cell Cycle; Chromosome Aberrations; Chromosome Mapping; Chromosomes, Human, Pair 11; Fas-Associated Death Domain Protein; Gene Expression Profiling; Humans; Laryngeal Neoplasms; Nucleic Acid Hybridization; Paclitaxel; Pharyngeal Neoplasms; Phosphorylation; Time Factors | 2007 |
[Evaluation of second-line chemotherapies most often used in recurrent epithelial ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan; Treatment Outcome | 2007 |
Cell-based and biochemical structure-activity analyses of analogs of the microtubule stabilizer dictyostatin.
Topics: Alkanes; Animals; Benzimidazoles; Binding Sites; Brain Chemistry; Carbamates; Carcinoma; Cattle; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Epothilones; Female; Fluorescein-5-isothiocyanate; Fluorescent Antibody Technique, Indirect; Fluorescent Dyes; G2 Phase; HeLa Cells; Histones; Humans; Kinetics; Lactones; Macrolides; Microtubules; Molecular Structure; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Protein Binding; Pyrones; Quantitative Structure-Activity Relationship; Radioligand Assay; Tubulin; Tubulin Modulators | 2008 |
Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2008 |
Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epothilones; Female; Glioma; Magnetic Resonance Imaging; Mice; Mice, Nude; Microtubules; Neoplasm Proteins; Paclitaxel; Pancreatic Neoplasms; Rats; Rats, Inbred Lew; Tissue Distribution; Xenograft Model Antitumor Assays | 2008 |
Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer.
Topics: Acetylation; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma; Cell Survival; Combined Modality Therapy; Doxorubicin; Female; Fluorescent Antibody Technique; Humans; Mice; Mice, Nude; Mitosis; Oncolytic Virotherapy; Oncolytic Viruses; Paclitaxel; Simplexvirus; Thyroid Neoplasms; Virus Replication | 2008 |
Pathological complete response after primary chemotherapy in a mother and daughter with hereditary breast carcinoma: two case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Doxorubicin; Exons; Female; Gene Deletion; Genetic Predisposition to Disease; Humans; Mothers; Mutation; Nuclear Family; Paclitaxel; Ubiquitin-Protein Ligases | 2008 |
Lack of radiosensitization after paclitaxel treatment of three human carcinoma cell lines.
Topics: Breast Neoplasms; Carcinoma; Cell Cycle; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Flow Cytometry; G2 Phase; Humans; Male; Mitosis; Paclitaxel; Prostatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tumor Cells, Cultured | 1995 |
[Characterization of the mechanism of cross-resistance to vinca alkaloids and taxoids in the human J82 bladder tumor cell line].
Topics: Antineoplastic Agents; Carcinoma; Colchicine; Doxorubicin; Drug Resistance, Multiple; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Phenotype; Podophyllotoxin; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 1994 |
Modulation of P-glycoprotein activity by estramustine is limited by binding to plasma proteins.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Proteins; Breast Neoplasms; Carcinoma; Dialysis; Drug Resistance, Multiple; Estramustine; Gene Expression Regulation, Neoplastic; Humans; Orosomucoid; Paclitaxel; Protein Binding; Serum Albumin; Tritium; Tumor Cells, Cultured; Verapamil; Vinblastine | 1995 |
Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro.
Topics: Carcinoma; Cell Cycle; Cell Survival; Cisplatin; Drug Resistance; Drug Synergism; Female; Glutathione; Humans; Microtubules; Ovarian Neoplasms; Paclitaxel; Time Factors; Tumor Cells, Cultured | 1994 |
In vitro cytotoxic activity of Taxol and Taxotere on primary cultures and established cell lines of human ovarian cancer.
Topics: Carcinoma; Cell Death; Cisplatin; Docetaxel; Drug Resistance; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1993 |
Transient mitotic phase localization of bcl-2 oncoprotein in human carcinoma cells and its possible role in prevention of apoptosis.
Topics: Antibodies, Monoclonal; Antibodies, Neoplasm; Apoptosis; Carcinoma; Cell Compartmentation; Cell Division; Fluorescent Antibody Technique; G2 Phase; Humans; Mitosis; Models, Biological; Paclitaxel; Prophase; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2 | 1994 |
[Epithelial cancer of the ovary: current data].
Topics: Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Female; Humans; Injections, Intraperitoneal; Melphalan; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Risk Factors; Survival Analysis | 1993 |
Taxol in combination with acute and low dose rate irradiation.
Topics: Animals; Carcinoma; Cell Death; Cell Line; Cell Survival; Cesium Radioisotopes; Combined Modality Therapy; Female; G2 Phase; Gamma Rays; Humans; Mice; Mice, Inbred C3H; Mitosis; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1994 |
Cell synchronization unfortunately may not benefit cancer therapy.
Topics: Animals; Carcinoma; Cell Cycle; Cell Death; Cell Survival; Cytological Techniques; Female; Humans; Paclitaxel; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1994 |
Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Intraductal, Noninfiltrating; Cecal Diseases; Doxorubicin; Female; Humans; Inflammation; Lymphatic Metastasis; Middle Aged; Paclitaxel | 1993 |
In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules.
Topics: Amino Acid Sequence; Biological Transport; Carcinoma; Cisplatin; Colchicine; Colforsin; Drug Resistance; Female; Humans; In Vitro Techniques; Microtubule-Associated Proteins; Microtubules; Molecular Sequence Data; Ovarian Neoplasms; Paclitaxel; Phosphoproteins; Phosphorylation; Protein Kinases; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1993 |
Synergistic action of taxol and tiazofurin in human ovarian, pancreatic and lung carcinoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Carcinoma, Adenosquamous; Cell Division; Drug Screening Assays, Antitumor; Drug Synergism; Female; Guanosine Diphosphate; Guanosine Triphosphate; Humans; Liver Neoplasms, Experimental; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Rats; Ribavirin; Spindle Apparatus; Tumor Cells, Cultured | 1993 |
Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Docetaxel; Female; Humans; Leukemia P388; Male; Mammary Neoplasms, Experimental; Melanoma, Experimental; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Paclitaxel; Taxoids | 1995 |
Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Docetaxel; Drug Carriers; Female; Humans; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Taxoids | 1995 |
Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Decision Making; Female; Humans; Middle Aged; Ontario; Ovarian Neoplasms; Paclitaxel; Patient Participation; Patient Satisfaction; Physician-Patient Relations; Prognosis; Quality of Life; Surveys and Questionnaires; Survival Rate | 1996 |
Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo.
Topics: Animals; Carcinoma; Cell Count; Cell Division; Dose-Response Relationship, Drug; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Thyroid Neoplasms; Tumor Cells, Cultured | 1996 |
Fatal myocardial infarction potentially induced by paclitaxel.
Topics: Aged; Breast Neoplasms; Carcinoma; Fatal Outcome; Female; Humans; Myocardial Infarction; Neoplasm Staging; Paclitaxel | 1996 |
Single-agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Female; Humans; Infusions, Intravenous; Middle Aged; Neuritis; Paclitaxel; Premenopause; Radiotherapy, Adjuvant; Remission Induction; Survival Rate; United Kingdom | 1996 |
Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells.
Topics: Antineoplastic Agents; Bleomycin; Bryostatins; Carcinoma; Carcinoma, Small Cell; Cisplatin; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Female; Head and Neck Neoplasms; Herpes Simplex Virus Protein Vmw65; Humans; Lactones; Lung Neoplasms; Macrolides; Ovarian Neoplasms; Paclitaxel; Phorbol 12,13-Dibutyrate; Protein Kinase C; Signal Transduction; Tumor Cells, Cultured | 1996 |
p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel.
Topics: Apoptosis; bcl-2-Associated X Protein; Carcinoma; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Fragmentation; Dose-Response Relationship, Drug; Female; GADD45 Proteins; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Intracellular Signaling Peptides and Proteins; Ovarian Neoplasms; Paclitaxel; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1997 |
Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Southern; Carcinoma; Cisplatin; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Glutathione Peroxidase; Glutathione Transferase; Humans; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Phenotype; Protein Kinase C; RNA, Messenger; Thymidylate Synthase; Tumor Cells, Cultured | 1997 |
Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-alpha.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Carcinoma, Hepatocellular; Drug Synergism; Female; Liver Neoplasms; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mitosis; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1997 |
p53 in drug resistance in ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; DNA Damage; Drug Resistance, Neoplasm; Female; Genes, p53; Humans; Mutation; Ovarian Neoplasms; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Remission Induction | 1997 |
Major DNA fragmentation is a late event in apoptosis.
Topics: Apoptosis; Carcinoma; Cell Membrane; DNA Fragmentation; DNA, Neoplasm; Female; Humans; Microscopy, Video; Models, Biological; Necrosis; Paclitaxel; Ricin; Time Factors; Tumor Cells, Cultured | 1997 |
Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain; Carcinoma; Drug Resistance, Neoplasm; Female; Humans; Microtubules; Ovarian Neoplasms; Paclitaxel; Polymers; Rats; Rats, Sprague-Dawley; Tubulin; Tumor Cells, Cultured | 1997 |
Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Carcinoma; Cell Death; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1997 |
A bayesian strategy for evaluating treatments applicable only to a subset of patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma; Cisplatin; Drug Evaluation; Female; Genital Neoplasms, Female; Humans; Paclitaxel; Pilot Projects; Prognosis; Randomized Controlled Trials as Topic; Research Design; Selection Bias | 1997 |
Non-immunosuppressive cyclosporine derivative PSC 833 abolishes resistance of human multidrug-resistant ovarian carcinoma cells in vitro to paclitaxel and paclitaxel-induced radiosensitization.
Topics: Carcinoma; Cell Survival; Cyclosporins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1997 |
Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Carcinoma; Cause of Death; Drug Hypersensitivity; Endometrial Neoplasms; Female; Fever; Genital Neoplasms, Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Remission Induction; Retrospective Studies; Sepsis; Thrombocytopenia; Treatment Outcome | 1997 |
Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carcinoma; Cisplatin; Confidence Intervals; Disease Progression; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Remission Induction; Risk Factors; Survival Rate; Thrombocytopenia; Treatment Failure; Vinblastine; Vinorelbine | 1998 |
Three-hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 1998 |
Emergency department presentation of an unusual pleural effusion.
Topics: Aged; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Catheterization, Central Venous; Catheters, Indwelling; Chest Pain; Diagnosis, Differential; Emergency Service, Hospital; Female; Humans; Infusions, Intravenous; Ovarian Neoplasms; Paclitaxel; Pleural Effusion; Thorax | 1998 |
Laparoscopic placement of PAP catheters for intraperitoneal chemotherapy in ovarian carcinoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Catheterization; Catheters, Indwelling; Cisplatin; Cyclophosphamide; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Intraoperative Complications; Laparoscopy; Middle Aged; Ovarian Neoplasms; Paclitaxel; Tissue Adhesions | 1998 |
Lack of CNS penetration of docetaxel in a patient with leptomeningeal carcinomatosis.
Topics: Adult; Antineoplastic Agents, Phytogenic; Arachnoid; Blood-Brain Barrier; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Meningeal Neoplasms; Paclitaxel; Taxoids | 1998 |
In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cell Division; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Irinotecan; Paclitaxel; Tumor Cells, Cultured | 1998 |
BAX protein expression and clinical outcome in epithelial ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carcinoma; Disease-Free Survival; DNA, Complementary; Female; Humans; Immunohistochemistry; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Sequence Analysis, DNA | 1998 |
Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Immunoblotting; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Proteins; Paclitaxel; Pancreatic Neoplasms; Polymerase Chain Reaction; RNA, Messenger; tau Proteins; Taxoids; Tubulin | 1998 |
Choroid metastasis of undifferentiated nasopharyngeal carcinoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Choroid Neoplasms; Combined Modality Therapy; Fatal Outcome; Humans; Male; Nasopharyngeal Neoplasms; Paclitaxel; Radiotherapy, High-Energy | 1998 |
Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Prospective Studies; Sensitivity and Specificity; Treatment Outcome | 1998 |
Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Biomarkers, Tumor; Blotting, Western; Carcinoma; Cisplatin; Female; Flow Cytometry; Humans; In Vitro Techniques; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1998 |
Paclitaxel-anthracycline combination chemotherapy in relapsing advanced ovarian cancer after platinum-based chemotherapy: a pilot study.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Platinum Compounds; Recurrence; Salvage Therapy; Treatment Outcome | 1998 |
Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma; Cyclophosphamide; Cystadenocarcinoma, Papillary; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids | 1998 |
Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Injections, Intravenous; Lung Neoplasms; Male; Methotrexate; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Nitrosourea Compounds; Paclitaxel; Vinblastine | 1998 |
Induction of apoptosis and suppression of clonogenicity of ovarian carcinoma cells with estrogen mustard.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Carcinoma; Estramustine; Female; Humans; In Situ Nick-End Labeling; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |
Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; CDC2 Protein Kinase; Colonic Neoplasms; Cyclin B; Cyclin B1; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Ecdysterone; Female; G1 Phase; Mice; Mice, Nude; Microtubules; Neoplasm Proteins; Neoplasm Transplantation; Paclitaxel; S Phase; Tumor Cells, Cultured; Vincristine | 1999 |
Telomerase enzyme activity and RNA expression in adriamycin-resistant human breast carcinoma MCF-7 cells.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Carcinoma; Cell Count; Cell Division; Cell Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Electrophoresis, Agar Gel; Female; Fluorouracil; Gene Expression; Humans; Paclitaxel; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Taxoids; Telomerase; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1999 |
Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel.
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Berberine; Carcinoma; Cell Cycle; Colonic Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorescent Dyes; Genes, MDR; Growth Inhibitors; Humans; Mice; Mouth Neoplasms; Paclitaxel; Rhodamine 123; Stomach Neoplasms; Tumor Cells, Cultured | 1999 |
Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Colony-Forming Units Assay; Docetaxel; Female; Humans; Linear Models; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1999 |
The use of paclitaxel and cisplatin in a patient with epithelial ovarian cancer and human immunodeficiency virus.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female; HIV Infections; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema.
Topics: Anthropometry; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capillary Permeability; Carcinoma; Docetaxel; Double-Blind Method; Edema; Electronics, Medical; Female; Flavonoids; Humans; Leg; Lymphedema; Mastectomy; Optics and Photonics; Ovarian Neoplasms; Paclitaxel; Placebos; Randomized Controlled Trials as Topic; Taxoids; Venous Insufficiency; Weight Loss | 2000 |
Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cisplatin; Doxorubicin; Drug Synergism; Enzyme Inhibitors; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Polyenes; Polyunsaturated Alkamides; Thyroid Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Doxorubicin; Epirubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Treatment Outcome | 2000 |
The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chi-Square Distribution; Cyclophosphamide; Doxorubicin; Feasibility Studies; Female; Fluorouracil; Humans; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Remission Induction | 2000 |
Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cisplatin; Drug Resistance, Neoplasm; Female; Genes, MDR; Humans; Immunohistochemistry; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2000 |
Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Cyclophosphamide; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epirubicin; Female; Humans; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Regression Analysis; Sensitivity and Specificity; Survival Analysis; Tumor Cells, Cultured | 2000 |
[A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; Humans; Injections, Intra-Arterial; Leucovorin; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Skin Neoplasms; Taxoids | 2000 |
Impairment of heart rate variability during paclitaxel therapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Autonomic Nervous System; Breast Neoplasms; Carcinoma; Circadian Rhythm; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Heart Conduction System; Heart Rate; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Risk Factors; Signal Processing, Computer-Assisted | 2000 |
Management of patients with cancer of unknown primary site.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma; Etoposide; Evaluation Studies as Topic; Female; Humans; Male; Neoplasms, Unknown Primary; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2000 |
Remission of rheumatoid arthritis with taxol in a patient with breast carcinoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Arthritis, Rheumatoid; Breast Neoplasms; Carcinoma; Female; Humans; Paclitaxel; Remission Induction | 2000 |
Long-term results and prognostic factors in patients with epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Risk Assessment; Survival Analysis | 2000 |
Re: randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; Female; Humans; Multicenter Studies as Topic; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 2000 |
Taxol mediates serine phosphorylation of the 66-kDa Shc isoform.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Antineoplastic Agents, Phytogenic; Carcinoma; Cyanogen Bromide; Cycloheximide; Drug Interactions; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Enzyme Inhibitors; Flavonoids; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Microtubules; Paclitaxel; Peptide Fragments; Phosphorylation; Protein Isoforms; Protein Structure, Tertiary; Protein Synthesis Inhibitors; Proteins; Proto-Oncogene Proteins c-raf; Serine; Shc Signaling Adaptor Proteins; Src Homology 2 Domain-Containing, Transforming Protein 1; Tumor Cells, Cultured; Tyrosine | 2000 |
Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma; Cimetidine; Cystadenocarcinoma; Dexamethasone; Diphenhydramine; Docetaxel; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids | 2000 |
Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2000 |
p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; Carcinoma; Cisplatin; DNA Repair; Female; Genes, p53; Humans; Microsatellite Repeats; Middle Aged; Multivariate Analysis; Mutation, Missense; Ovarian Neoplasms; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Remission Induction; Retrospective Studies | 2000 |
Preoperative chemoradiotherapy using taxanes for locally advanced esophageal carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Esophageal Neoplasms; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Reproducibility of Results; Treatment Outcome | 2001 |
Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Division; Cell Hypoxia; Cell Movement; Cell Survival; Drug Synergism; Endothelial Growth Factors; Endothelium, Vascular; Humans; Lymphokines; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Polyenes; Polyunsaturated Alkamides; Thyroid Neoplasms; Transplantation, Heterologous; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Northern; Carcinoma; DNA, Complementary; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Microtubule Proteins; Paclitaxel; Phosphoproteins; RNA, Messenger; Stathmin; Transfection; Tumor Cells, Cultured; Vincristine; Vindesine | 2001 |
Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Carcinoma; CDC2-CDC28 Kinases; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Enzyme Inhibitors; Female; Flavonoids; G2 Phase; Humans; Imidazoles; MAP Kinase Kinase Kinase 1; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Mitosis; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Protein Serine-Threonine Kinases; Pyridines; Rats; Receptor, ErbB-2; Retinoblastoma Protein; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells.
Topics: Apoptosis; Carcinoma; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Female; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Signal Transduction | 2001 |
Variation in adenovirus receptor expression and adenovirus vector-mediated transgene expression at defined stages of the cell cycle.
Topics: Adenoviridae; Antigens, CD; Aphidicolin; Capsid; Carcinoma; Cell Cycle; Coxsackie and Adenovirus Receptor-Like Membrane Protein; Cyclin B; Cyclin B1; Gene Expression; Gene Transfer Techniques; Genetic Vectors; Integrin alphaV; Lung Neoplasms; Nocodazole; Paclitaxel; Receptors, Virus; Transgenes; Tumor Cells, Cultured | 2001 |
A rare case of advanced ovarian carcinoma who developed difficulty walking 25 days after treatment with weekly paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Female; Humans; Leg; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pain; Peripheral Nervous System Diseases; Proprioception | 2001 |
Meningeal carcinomatosis from an ovarian primary with complete response to adjuvant chemotherapy after cranial irradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Magnetic Resonance Imaging; Meningeal Neoplasms; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2001 |
[Taxane-based palliative chemotherapy for metastatic breast cancer: matched pair analysis to compare the efficacy and safety of docetaxel and paclitaxel].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Disease-Free Survival; Docetaxel; Female; Humans; Matched-Pair Analysis; Middle Aged; Paclitaxel; Palliative Care; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Inhibition of drug-induced Fas ligand transcription and apoptosis by Bcl-XL.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Breast Neoplasms; Calcineurin; Carcinoma; Caspases; DNA-Binding Proteins; Dose-Response Relationship, Drug; Fas Ligand Protein; fas Receptor; Humans; Jurkat Cells; Ligands; Membrane Glycoproteins; NFATC Transcription Factors; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Transcription Factors; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 2001 |
Effects of Taxotere on invasive potential and multidrug resistance phenotype in pancreatic carcinoma cell line SUIT-2.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biocompatible Materials; Carcinoma; Collagen; Docetaxel; Drug Combinations; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorescent Dyes; Humans; In Vitro Techniques; Laminin; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Phenotype; Proteoglycans; Rhodamine 123; RNA, Neoplasm; Taxoids; Tumor Cells, Cultured | 2001 |
Taxotere resistance in SUIT Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Docetaxel; Drug Resistance, Neoplasm; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids; Tumor Cells, Cultured | 2001 |
Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carcinoma; Cisplatin; Drug Synergism; Epithelial Cells; Epstein-Barr Virus Infections; Female; Fluorouracil; Ganciclovir; Herpesvirus 4, Human; Humans; MAP Kinase Signaling System; Mice; Mice, Nude; Paclitaxel; Stomach Neoplasms; Virus Replication; Xenograft Model Antitumor Assays | 2002 |
ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines.
Topics: Adenocarcinoma, Follicular; Adenovirus E1B Proteins; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinogenicity Tests; Carcinoma; Carcinoma, Papillary; Cell Death; Defective Viruses; Doxorubicin; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Rats; Thyroid Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Cycle; Drug Screening Assays, Antitumor; Estramustine; Flow Cytometry; Humans; Male; Micronucleus Tests; Microtubules; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1992 |
Divergent effects of taxol on tumor necrosis factor-alpha-mediated cytolysis of ovarian carcinoma cells.
Topics: Carcinoma; Cytotoxins; Drug Synergism; Emetine; Female; Humans; Ovarian Neoplasms; Paclitaxel; Protein Biosynthesis; Proteins; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1992 |
Report from ASCO on taxol as second-line therapy for ovarian Ca.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Carcinoma; Female; Humans; Ovarian Neoplasms; Paclitaxel | 1990 |
Aqueous extract of Taxus chinensis (Pilger) Rehd inhibits lung carcinoma A549 cells through the epidermal growth factor receptor/mitogen-activated protein kinase pathway in vitro and in vivo.
Topics: Animals; Carcinoma; Cell Line, Tumor; Down-Regulation; Drugs, Chinese Herbal; ErbB Receptors; Humans; Lung Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Rabbits; Taxus | 2014 |